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Abstract 	  
Inflammation is critical for clearing microbial infections, however, excessive or 
pro-longed inflammation is an underlying component of many disease states, 
including atherosclerosis. Macrophages recognise sterile or microbial ligands 
via receptors such as Toll Like Receptors (TLRs). Activation of macrophages 
by TLR ligands leads to inflammation, mediated by cytokines and 
chemokines, which amplify the immune response. Elevated levels of High 
Density Lipoprotein (HDL) are inversely correlated with cardiovascular 
disease (CVD) risk and atherosclerosis progression. The protective effect of 
HDL in CVD is mainly attributed to its ability to remove excess cholesterol 
from peripheral tissues. In addition, HDL has anti-inflammatory properties, 
and fittingly, is also protective against inflammatory disorders such as sepsis. 
However, the molecular mechanisms by which HDL mediates these anti-
inflammatory effects remain poorly characterised. Considering the key role 
that macrophages, TLRs and pro-inflammatory cytokines play in inflammation, 
the effect of HDL on TLR-mediated macrophage activation was investigated. 
Human and mouse normo-cholesterolemic macrophages were analysed, so 
that the anti-inflammatory effects of HDL could be applied to a range of 
inflammatory diseases beyond atherosclerosis. HDL inhibited TLR-induced 
pro-inflammatory cytokine expression, at the level of transcription. The 
transcriptional modulator ATF3 was identified as being responsible for HDL's 
anti-inflammatory effects on macrophage activation.  HDL induced ATF3 
expression both in vitro and in vivo, increased ATF3 binding across the 
genome, as analysed by ChIP Sequencing, and was no longer able to inhibit 
TLR-induced pro-inflammatory cytokine secretion in ATF3-deficient 
macrophages. The mechanism by which HDL induces ATF3 is still unclear, 
however some evidence presented here suggests that this is independent of 
cholesterol efflux and may require lysosomal catabolism of HDL's 
phospholipids. This work identifies a new biology for HDL as an anti-
inflammatory modulator of macrophage activation via the transcription factor 
ATF3.  	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1.  Introduction  
Host defence 
 
The body has highly effective mechanisms of host defence to protect against 
microbial invasion. Physical barriers, such as skin or chemical barriers, such 
as mucus and mucus membranes, prevent many microbes from entering the 
body. Microbes that have breached this first line of defence then encounter 
the non-specific host innate immune system. The cells of the innate immune 
system include granulocytes (basophils, eosinophils, mast cells, neutrophils), 
phagocytes (monocytes, macrophages, dendritic cells (DCs) and natural killer 
(NK) cells. This ancient system recognises invading pathogens, such as 
bacteria, viruses or fungi resulting in either direct clearance of the pathogen or 
activation of the third and most specific form of host defence: the adaptive 
immune system. The adaptive immune system is a tailored immune response, 
which most effectively neutralises the pathogen and is continually refined and 
adjusted through the lifetime of the host, allowing for quicker responses upon 
re-infection.  The adaptive immune system consists of both a humoral and a 
cellular response, with B cells producing specific antibodies against antigens 
and T cells containing the infection by eliminating compromised host cells.  
 
The innate immune system: 
 
The innate immune system has several critical functions in host defence: it 
recognises invading pathogens, initiates host responses, and subsequently 
mediates repair processes for restoring homeostasis. Cells of the innate 
immune system recognise conserved microbial patterns, termed pathogen 
associated molecular patterns (PAMPs); e.g. bacterial cell wall components, 
via specialised receptors, termed pattern recognition receptors (PRRs). PAMP 
engagement of these receptors initiates intracellular signalling cascades, 
resulting in the release of antimicrobial peptides and inflammatory mediators 
such as cytokines, and activation of intracellular killing pathways. The 
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secreted antimicrobial peptides can act directly on extracellular microbes, 
while intracellular pathogens are neutralised by mechanisms within the cell, 
such as by respiratory burst or degradation in lysosomes. Inflammatory 
mediators such as cytokines and chemokines amplify the immune response 
by recruiting further immune cells to control the infection. This process is 
known as inflammation. Once the infection is cleared, the inflammatory 
response is then silenced in the resolution phase (1). However, when 
inflammation is dysregulated, or occurs in the absence of an infection, it is 
generally considered detrimental (1). Among the key inflammatory cells, which 
express PRRs are the so-called 'professional phagocytes', (from the greek: 
'phago': to eat, 'cyto': cell) which include monocytes, macrophages, and 
neutrophils. Epithelial cells, mast cells and platelets also express PRRs, and 
are essential for recruiting other immune cells to sites of microbial invasion. 
Finally, dendritic cells, which also express PRRs, activate the adaptive 
immune response by presenting parts of the pathogen (the 'antigen') to B cells 
and T cells, allowing these cells to mediate a specific immune response 
against the pathogen in question.  
 
Macrophages: the big eaters 
 
Macrophages were first described by Elie Metchnikoff for their ability to engulf 
and kill whole bacteria, hence their greek name; 'macro': big, 'phage': eater 
(2). They are found in most adult tissues and are functionally diverse; along 
with their fundamental role in pathogen recognition, they play important roles 
in development (tissue remodelling), tissue repair and homeostasis (apoptotic 
cell clearance) (3). Indeed, resident tissue macrophages (e.g. microglia in the 
brain, Kupffer cells in the liver) are phenotypically and functionally different 
depending on their host tissue, most likely because in each tissue they will 
encounter different pathogens and will maintain homeostasis under different 
metabolic conditions (3). The prevailing view of macrophage development is 
that a common myeloid progenitor in the bone marrow gives rise to circulating 
monocytes, which are able to detect pathogens in the blood stream, and to 
inflammatory monocytes, which are recruited especially to sites of infection. 
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Upon migration into tissues these monocytes can then differentiate into 
macrophages (4). Macrophage differentiation is dependent on Colony 
Stimulating Factor 1 (CSF1), a growth factor that signals through the CSF1 
Receptor (CSF1R), which is expressed on most mononuclear phagocytic cells 
(3). In vitro culture of mouse bone marrow-derived macrophages (BMDMs) or 
human monocyte-derived macrophages (HMDMs) provide a model system to 
study macrophages and their responses to pathogens (5). 
 
PAMP/DAMP sensing by PRRs 
 
There are several families of PRRs expressed in macrophages, including the 
Toll like receptors (TLRs), the Rig-I like Receptors (RLRs), the Nod like 
receptors (NLRs), and the C-type Lectin receptors (CLRs). In addition to 
PAMPs, these PRRs are also able to recognize endogenous stimuli, termed 
danger associated molecular patterns (DAMPs), which are often released by 
dying cells and are a sign of injury or infection. In general, PRR activation by a 
ligand (either PAMP or DAMP) leads to pro-inflammatory gene expression via 
activation of the key inflammatory transcription factor nuclear factor kappa B 
(NFκB) and/or expression of the anti-viral mediators, interferons (IFN) via 
activation of the Interferon Regulatory Factors (IRFs).  
 
Toll Like receptors and their ligands (TLRs) 
 
TLRs were initially identified and characterized based on their similarity to the 
Toll receptor protein in Drosophila, protein N in plants and their homology to 
the Interleukin -1 receptor (IL-1R) (6). There are 10 functional TLR genes in 
humans and 12 in mice, with TLRs 1 to 9 conserved between species (7). 
TLR 10 is non-functional in mice, and TLRs 11, 12, and 13 appear to have 
been lost from the human genome (7). TLRs are composed of an extracellular 
domain with a leucine rich repeat (LRR) that is involved primarily in pattern  
recognition, a short transmembrane domain, and an intracellular Toll - IL-1 
receptor (TIR) domain, which interacts with adaptors to initiate downstream 
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signalling. Of the TLR family, TLRs1,2,4,5,6 and 11 are expressed on the cell 
surface and mainly recognize microbial membrane components, while TLRs  
3,7,8 and 9 are localised on intracellular compartments such as endosomes,  
and mainly recognise bacterial and viral nucleic acids (7). Together TLRs  
have the ability to recognise a vast array of microbial, endogenous and 
synthetic ligands (Table 1).  
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TLR Species Microbial Ligand 
or Synthetic 
Ligand 
Endogenous 
Ligand 
Subcellular 
Localization 
Signaling 
Pathway 
2 
(hetero
dimeriz
es with 
1 and 
6) 
Human 
and 
mouse 
Tri-acylated 
lipopeptides (1/2), 
di-acylated 
lipopeptides (1/2), 
P3CSK4 
HMGB1,Heat 
Shock proteins 
(HSPs), 
Extracellular Matrix 
(ECM) proteins 
Cell surface 
membrane 
MyD88 
3 Human 
and 
mouse 
Virally derived 
double stranded 
DNA (ds DNA), 
poly I:C 
mRNA Endosomes TRIF 
4 (with 
CD14 
and 
MD2) 
Human 
and 
mouse 
LPS HMGB1 Oxidised 
phospholipids, 
Oxidised LDL, Heat 
Shock Proteins, 
Extracellular Matrix 
Proteins, Amyloid β 
Cell Surface 
and 
Endosomes 
MyD88 
(cell 
surface) 
5 Human 
and 
mouse 
Flagellin n.d. Cell Surface MyD88 
7 Human 
and 
mouse 
Viral single 
stranded RNA 
(ssRNA) and 
synthetic 
analogues e.g. 
R848 
ssRNA (as an 
immune complex) 
Endosomes MyD88 
8 Human Viral ssRNA and 
synthetic 
analogues e.g. 
R848 
ssRNA (as an 
immune coomplex) 
Endosomes MyD88 
9 Human 
and 
mouse 
Viral and bacterial 
CpG DNA 
DNA (as an 
immune complex) 
Endosomes MyD88 
10 
(hetero
dimeriz
es with 
2) 
Human Unknown but 
L.Monocytogenes 
n.d. Cell Surface n.d. 
11 Mouse Uropathogenic 
bacteria, 
Toxoplasma 
Gondii 
n.d. n.d. n.d. 
12 Mouse Toxoplasma 
Gondii 
n.d. n.d. n.d. 
13 Mouse Vesicular 
Stromatitis virus, 
Bacterial 23s 
ribosomal RNA 
n.d. n.d. n.d. 
 
Table 1.1. Overview of mammalian TLRs, their ligands, cellular localisation and signalling 
pathways. Table adapted from (7) and (8) 
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TLR Signalling  	  
The TLRs can either homo or hetero-dimerize upon ligand binding. This 
brings their TIR domains into closer proximity, leading to adaptor protein 
recruitment. All TLRs except for TLR3 signal via the adaptor molecule, 
myeloid differentiation primary response protein 88 (MyD88), which also has a 
TIR domain and upon activation can interact directly with the TIR domains of 
the TLRs (9). TLR3 signals via TIR-domain containing adaptor inducing 
interferon beta (TRIF) alone, while TLR4 can signal through both MyD88 and 
TRIF, depending on its cellular localisation (e.g. cell surface - MyD88, 
endosomal - TRIF) (10). TLR2 and TLR4 also require the sorting adaptor 
MyD88 adaptor-like protein (MAL, also known as TIRAP), for subsequent 
signalling via the MyD88-dependent pathway (11). In addition to MAL, TLR4 
also requires the sorting adaptor TRIF related adaptor molecule (TRAM) for 
signalling along the TRIF pathway (7). The subsequent signalling cascade 
(detailed in Figure 1), results in the inhibitors of NFκB  (IκB) kinases (IKKs) 
phosphorylating and subsequently degrading the IκBs, thereby releasing 
active NFκB to translocate to the nucleus and active pro-inflammatory gene 
expression (6). Meanwhile, the mitogen activated protein kinases (MAPKs), 
including p38, Erk1 and Erk2 and JNK, are also activated. MAPK activation in 
turn activates other transcription factors required for pro-inflammatory gene 
expression, such as activator protein 1 (AP-1) and cyclic adenosine 
monophosphate - (cAMP) responsive element proteins (CREB) (6).  TRIF 
signalling also activates NFκB but additionally, it activates the transcription 
factor IRF3 for type I interferon gene expression (7).  
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Figure 1.1: TLR activation and subsequent signalling. TLR activation results in 
recruitment of adaptors MyD88 or TRIF. The signalling cascade culminates in activation of 
CREB, AP1, NFκB or IRF transcription factors. Figure from (6) 
 
Transcriptional modulation in response to PRR signalling 
 
Transcription Factors and chromatin architecture 
 
Transcription factors are able to bind to sequence specific DNA motifs within 
the promoters of genes, which are proximal to the transcription start site 
(TSS). Transcription factors may influence gene expression by binding to 
enhancer regions, which are generally more distal to the TSS. Binding of 
particular transcription factors to promoters and enhancers is thought to alter 
the DNA conformation to allow for enhanced transcription initiation by RNA 
Polymerase II (12). Indeed, the requirement for co-operativity between 
transcription factors may explain the differential expression of genes in 
Nature Reviews | Immunology
Flagellin
Uropathogenic
bacteria
TLR5 TLR11 TLR4
Endocytosed
TLR4
TLR2–TLR1
or
TLR2–TLR6
MYD88
TIR
domain
MAL
TRIF
TRAM
LPS
IRAK4
IRAK1 IRAK2
IRAK4
IRAK1 IRAK2
TAB2 TAB3
p38 JNK IKKε IKKαTBK1
RIP1TRAF6
TRAF6
TRAF3
TRAF3
TAK1
MKK3
or MKK6
MKK4
or MKK7
IKKα
IKKβ
CREB
CREB
AP1
AP1
NF-κB
NF-κB
2TQKPȯCOOCVQT[
cytokines
Type I IFNs
(IFNα and IFNβ)
IRF3
IRF3
IRF7
IRF7 Nucleus
Cytoplasm
TLR3
TLR7–
TLR8 TLR9
TLR13
CpG- 
DNA
dsRNA
ssRNA
rRNA
Triacylated 
lipopeptides  
or diacylated 
lipopeptides  
Endosome
bacteria48 and, in cooperation with mouse 
TLR12, to bind to the Toxoplasma gondii  
profilin protein49–51. Moreover, mouse TLR13 
has been very recently shown to recognize 
bacterial ribosomal RNA52–54.
Before the discovery of TLR3 in 2001, it 
was thought that TLRs were not involved in 
antiviral responses; however, the previous 
discovery, in 2000, that viral proteins antag-
onized TLR4 signalling (REF. 55), together 
with the observation that the fusion protein 
from respiratory syncytial virus mediated 
responses via TLR4 (REF. 56), had already 
prompted the idea that TLR ligands might 
be derived from viruses as well as from 
Figure 1 | Mammalian TLR signalling pathways. A detailed knowledge 
of how mammalian Toll-like receptors (TLRs) signal has developed over the 
RCUV|[GCTU6.46.46.4CPFVJGJGVGTQFKOGTUQH6.4s6.4QT
TLR2–TLR6 bind to their respective ligands at the cell surface, whereas 
TLR3, TLR7–TLR8, TLR9 and TLR13 localize to the endosomes, where they 
sense microbial and host-derived nucleic acids. TLR4 localizes at both the 
plasma membrane and the endosomes. TLR signalling is initiated by ligand-
induced dimerization of receptors. Following this, the Toll–IL-1-resistence 
(TIR) domains of TLRs engage TIR domain-containing adaptor proteins 
(either myeloid differentiation primary-response protein 88 (MYD88) and 
MYD88-adaptor-like protein (MAL), or TIR domain-containing adaptor 
protein inducing IFNβ (TRIF) and TRIF-related adaptor molecule (TRAM)). 
TLR4 moves from the plasma membrane to the endosomes in order to 
switch signalling from MYD88 to TRIF. Engagement of the signalling adap-
tor molecules stimulates downstream signalling pathways that involve 
interactions between IL-1R-associated kinases (IRAKs) and the adaptor 
molecules TNF receptor-associated factors (TRAFs), and that lead to the 
activation of the mitogen-activated protein kinases (MAPKs) JUN 
N-terminal kinase (JNK) and p38, and to the activation of transcription fac-
tors. Two important families of transcription factors that are activated 
downstream of TLR signalling are nuclear factor-κB (NF-κB) and the inter-
feron-regulatory factors (IRFs), but other transcription factors, such as 
cyclic AMP-responsive element-binding protein (CREB) and activator pro-
tein 1 (AP1), are also important. A major consequence of TLR signalling is 
the induction of pro-inflammatory cytokines, and in the case of the endo-
UQOCN6.4UVJGKPFWEVKQPQHV[RG|+KPVGTHGTQP
+(0FU40#FQWDNG
stranded RNA; IKK, inhibitor of NF-κB kinase; LPS, lipopolysaccharide; 
MKK, MAP kinase kinase; RIP1, receptor-interacting protein 1; rRNA, 
ribosomal RNA; ssRNA, single-stranded RNA; TAB, TAK1-binding protein; 
TAK, TGFβ-activated kinase; TBK1, TANK-binding kinase 1.
PERSPECT IVES
456 | JUNE 2013 | VOLUME 13  www.nature.com/reviews/immunol
© 2013 Macmillan Publishers Limited. All rights reserved
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response to various ligands, even when much of the upstream signalling is 
common.  
Transcriptional activation is also influenced by chromatin architecture. TF and 
RNA Polymerase binding is able to occur when the chromatin is 'open', 
therefore a 'closed' chromatin conformation, where DNA is not accessible to 
TF binding is considered transcriptionally repressive.  Chromatin consists of 
nucleosomes, which are an octamer of the four histone proteins around which 
147 base pairs of DNA are wound (13). Histones are subject to covalent 
modifications including acetylation, methylation, phosphorylation and 
ubiquitylation, which influence how open the chromatin conformation is (13).  
Histone acetylation, mediated by Histone Acetyl Transferase (HAT) enzymes, 
is associated with open, accessible chromatin (14) . This is reversed by 
histone deacetylase (HDAC) enzymes, which are considered general 
transcriptional repressors (14). Other chromatin modifiers include SWI/SNF 
complexes, which weaken the histone-DNA interaction and make DNA more 
accessible to transcription factor binding (15).  Many histone-modifying 
enzymes work in concert with transcription factors to induce, or repress, gene 
expression. 
Transcription factor activation by the innate immune system 	  
Many key transcription factors are constitutively expressed in macrophages 
but are activated on the post-translational level; e.g. by phosphorylation or by 
nuclear translocation (16). NFκB comprises a family of transcription factors, 
consisting of 5 proteins: p50, p52, p65 (Rel A), c-Rel and Rel B (17). These 
proteins are able to form homo- and hetero-dimers, the combination of which 
dictates the subsequent gene expression program activated. TLR-mediated 
NFκB activation results in translocation of p65/p50 heterodimers from the 
cytoplasm into the nucleus (17). These heterodimers can then bind 
consensus NFκB binding elements within the promoter region of target genes, 
such as pro-inflammatory cytokines Tumour Necrosis Factor (TNF) and 
Interleukin (IL)-6 (17). The mammalian IRF family consists of 9 members, of 
which IRF3 and IRF7 are the key IRFs involved in TLR signalling (18). IRFs 
bind to a consensus interferon-stimulated response element (ISRE) within 
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target gene promoters, including the promoters for type I IFNs themselves 
(18).The AP-1 transcription factor is a complex consisting of proteins of the 
Fos (c-Fos, FosB, Fra1 and Fra2), Jun (c-Jun, JunB and JunD), Activating 
Transcription factor (ATF) and Maf families of transcription factors (19) . 
These proteins are able to form homo- and hetero-dimers depending on their 
activation by upstream kinases (e.g. JNK activates c-Jun dimers) and are able 
to bind with differing specificity to target inflammatory gene promoters (19). 
Similarly, MAPK activation, especially of p38, leads to activation of CREB1 
and associated transcription factors, such as CREB binding protein (CBP) 
p300 and c/EBPβ, which are required for transcription of cytokines such as IL-
10, IL-12p40, IL-1α and IL-1β (20). Many of these transcription factors work in 
concert with other co-factors to activate specific programs of gene expression 
in response to an inflammatory stimulus.  
Control of inflammation - negative regulators: 	  
While inflammation is necessary in the early stages of infection and injury, 
excessive or persistent inflammation can be highly damaging, and is indeed 
considered the basis of many disease states (8). The inflammatory response 
is therefore tightly regulated at various levels; from the influx and 
concentration of particular immune cells within tissues, to PAMP 
sequestration and receptor responsiveness, to cell-intrinsic signalling, to 
transcription itself and finally post-transcriptional and post-translational 
regulation (16, 21). In addition, the expression of anti-inflammatory molecules 
such as decoy receptors and anti-inflammatory cytokines (e.g. transforming 
growth factor beta (TGFβ) and Interleukin 10 (IL-10)) further dampens 
inflammation (21). 
Negative Regulation of TLR signalling 	  
TLR signalling is subject to multiple levels of negative regulation. This 
includes TLR-inducible negative regulators, such as inactive splice variants of 
the various adaptor proteins MyD88 and TRAM, which compete to block 
downstream signalling (8), or phosphatases and de-ubiquitinases which target 
almost every step of the TLR signalling pathway (8). Chromatin modifications 
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and transcription factor/repressor recruitment can regulate the transcriptional 
response, while post-transcriptionally, induction of micro-RNAs (miRNA) and 
other enzymes which destabilise mRNA modulate the levels and duration of 
pro-inflammatory gene expression (21). The induction of these TLR negative 
regulators is critical as it leads to transient rather than prolonged expression 
of pro-inflammatory genes and prevents excessive inflammation.  
Regulation of the transcriptional response to TLR activation 	  
TLR stimulation, of which TLR4 stimulation with LPS is the best characterised, 
induces a rapid and extensive transcriptional response in which many genes 
are either induced or repressed (22). For many of the cytokines, their 
induction is transient, reflecting rapid induction and subsequent repression of 
both signalling and transcription. Indeed, many LPS-inducible genes are 
themselves negative regulators of signalling, as well as proteases and anti-
inflammatory cytokines, which directly inhibit or target the inflammatory 
effectors themselves (22).  
The genes directly activated by TLRs can be divided into two classes based 
on their temporal induction. Firstly, there are primary response genes, such as 
TNF and IL-1β (23) which are rapidly induced without the need for de novo 
protein synthesis; these are genes controlled by transcription factors that are 
constitutively expressed in cells but post-translationally modified for activation, 
like NFκB (12). The secondary response genes are induced more slowly 
because they require new protein synthesis (12). Secondary response genes 
may require the de novo expression of inducible transcription factors, 
signalling molecules or other cytokines (12). IL-6 is a secondary response 
gene that requires synthesis of the transcription factor C/EBPδ to amplify its 
expression by NFκB (24). Furthermore, secondary response genes, such as 
IL-6 and IL-12p40, tend to require nucleosome remodelling by the SW1-SNF 
complex, which is thought to allow greater NFkB accessibility, and reflects 
their delayed induction by LPS in macrophages (15). Consistent with the 
additional levels of regulation around secondary response genes, these genes 
are typically only induced in response to selective stimuli, while primary 
response genes are induced in response to a broad range of stimuli (15). 
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Recruitment of transcriptional repressors, either basal or inducible, and 
associated chromatin remodelling proteins can subsequently shut down gene 
expression (16).  
ATF3 	  
A key transcriptional repressor involved in inflammation is ATF3. ATF3 is part 
of the Activating Transcription Factor (ATF)/CREB family of transcription 
factors. These TFs contain basic region leucine zipper (bZIP) domains, which 
allow for specific DNA binding and homo or heterodimer formation (25). 
ATF/CREB family members (ATF1, CREB, CREM, ATF2, ATF3, ATF4, ATF5, 
ATF6, ATF7 and B-ATF) were identified based on their ability to bind to the 
cAMP responsive element (CRE) consensus sequence, TGACGTCA, in 
target promoters (25). ATF3, however, appears to be the only transcriptional 
repressor within this family. In 2006, Aderem and colleagues described a 
novel function for ATF3 as a negative regulator of LPS-mediated TLR4 
activation. They showed that LPS induced rapid expression of ATF3, which 
subsequently bound to the promoters of Il6 and Il12b, where it acted as a 
transcriptional repressor (26). ATF3 was shown to interact directly with 
HDAC1 and as such ATF3 occupancy of the Il6 and Il12b promoters 
correlated with a decrease in Histone 3 and Histone 4 acetylation, indicating 
that ATF3 recruits HDACs to repress transcription (26). In keeping with its role 
as a transcriptional repressor, ATF3-deficient macrophages had higher basal 
and LPS- inducible levels of IL-12, IL-6 and TNF cytokines (26). Furthermore, 
ATF3-deficient mice were also more susceptible to LPS-induced shock (26). 
In a separate study, a protective role for ATF3 in sepsis, particularly in 
mediating sepsis-associated immunosuppression (SAIS) was attributed to its 
up-regulation by reactive oxygen species (ROS) (27). Crucially, ATF3 also 
determines susceptibility to secondary infections in mouse models of SAIS 
(27), indicating that too much negative regulation can also be detrimental. 
ATF3 is also induced by TLR2/6, TLR3, TLR5, TLR7 and TLR9 stimuli in 
mouse DCs and negatively regulates the levels of IL-6 and IL-12p40 in 
response to these ligands (28).  
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Macrophages and PRR signalling in disease: 
 
As discussed earlier, macrophages and other cells of the innate immune 
system are essential for responding to and clearing infections. This 
inflammatory response is also important for tissue repair and wound healing. 
Inflammation that occurs in the absence of micro-organisms, such as in 
response to trauma, ischaemia-reperfusion injury or chemically induced injury, 
is termed 'sterile inflammation' (29). In both microbial and sterile inflammation, 
unresolved or exacerbated inflammatory responses can lead to disease. 
Sepsis development is associated with excessive pro-inflammatory cytokine 
production in response to infection, however, as unsuccessful clinical trials 
with cytokine blocking antibodies have shown, the complexity of sepsis 
extends beyond a dysfunctional innate immune response (30) (31). In 
contrast, diseases driven by sterile inflammation may develop in response to 
an accumulation of metabolic bi-products. This includes the recognition of 
DAMPs, such as cholesterol crystals in atherosclerosis, monosodium urate 
crystals in gout, islet amyloid beta polypeptide in type II diabetes and β-
amyloid in Alzheimer’s disease leading to NLRP3 inflammasome mediated IL-
1β release(32). Macrophage release of other pro-inflammatory cytokines, 
such as TNF, IL-12, and IL-23 has also been implicated in the pathogenesis 
of other sterile inflammatory diseases such as Crohn's disease, rheumatoid 
arthritis (RA), multiple sclerosis and autoimmune hepatitis (33).  
 
Atherosclerosis Development and Progression: The role of inflammation 
 
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality 
worldwide. CVD arises from the underlying chronic inflammatory condition of 
atherosclerosis, which often manifests clinically as acute coronary syndrome, 
myocardial infarction or stroke (34). Atherosclerosis results from dysregulated 
lipid metabolism and subsequent activation of an immune response. Animal, 
epidemiological and clinical studies have all established that high levels of 
cholesterol promote atherosclerosis development (35). Cholesterol obtained 
from the gut, through diet, is transported to peripheral tissues by low-density 
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lipoprotein (LDL). Changes in endothelial permeability and in extracellular 
matrix composition beneath the endothelium allow for retention of LDL 
cholesterol in the sub-endothelial space (36). Concurrently, an increase in 
leukocyte adhesion molecule expression and chemokine release by vascular 
cells results in immune cell infiltration (e.g. monocytes and T cells) (37). Upon 
entry into the tunica intima (the innermost layer of the arterial wall) circulating 
monocytes differentiate into macrophages due to the presence of M-CSF 
produced locally by vascular cells (37). LDL trapped in the intima is then 
prone to oxidation, which enhances its uptake by scavenger receptors 
expressed on macrophages (37). The macrophages are unable to clear the 
large amounts of LDL cholesterol they take up and subsequently cholesterol 
ester droplets accumulate in the cytosol. This gives the macrophages a lipid-
laden appearance, hence their description as ‘foam cells’ (37).  As these foam 
cells accumulate in arterial walls they recruit more immune cells, including T 
cells, resulting in the formation of an atherosclerotic plaque (36).  Generally 
atherosclerosis manifests clinically when the fibrous cap of the atherosclerotic 
plaque ruptures, leading to thrombus formation and subsequent arterial 
narrowing and blood flow limitation (36). Apart from the key role of 
macrophages in atherosclerosis progression, it is commonly accepted that 
inflammation is a major driver of CVD. Furthermore, risk of CVD increases 
with chronic inflammatory diseases such as Systemic Lupus Erythamatosus 
(SLE) or RA (38).  
 
Mouse Models of atherosclerosis 
 
Apart from their contribution as foam cells, macrophages are key drivers of 
the underlying inflammation in atherosclerosis. The contribution of PRRs, in 
particular TLRs and NLRs, has been elucidated using various mouse models. 
As wild type mice are generally resistant to diet-induced atherosclerosis, 
transgenic mice lacking either Apolipoprotein E (ApoE) or the LDL receptor 
(LDLR) and fed on a high fat (21% w/w) and high cholesterol (0.2% w/w) diet 
are typically used as models for human atherosclerosis development (39).  
ApoE is the major lipoprotein ligand for the LDLR, and defects in either the 
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ligand or the receptor result in high serum cholesterol because of impaired 
LDL/atherogenic lipid remnant clearance from the blood (39).  
 
TLRs and atherosclerosis 
 
The role TLRs play in atherosclerosis developments is complex. TLRs are 
expressed on the key cell types present in atherosclerotic lesions, including 
macrophages, monocytes, DCs, B and T lymphocytes, smooth muscle cells 
and endothelial cells (40). In addition, MyD88- deficient mice show reduced 
atherosclerotic development indicating a role for TLRs in atherosclerosis 
progression(41). However, as MyD88 is also critical for signals emanating 
from the IL-1R, much of this effect could be due to a reduction in IL-1 
signalling. The involvement of specific TLRs in atherosclerosis progression 
remains controversial, with differing results dependent on the model used. An 
outline is given in Table 1.2. 
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TLR Expression increased 
in human 
atherosclerosis 
Germline -
TLR/(ApoE or 
LDLR) dko  
Myeloid -
TLR/(ApoE or 
LDLR) dko  
1 Monocytes, 
macrophages and 
endothelial cells 
No effect on 
atherosclerosis 
progression 
n.d. 
2 Monocytes, 
macrophages and 
endothelial cells 
~50% plaque 
reduction compared 
to LDLR alone 
No effect on 
atherosclerosis 
progression 
TLR3 Smooth muscle cells Increased 
atherosclerosis (in 
ApoE or LDLR ko) 
Decreased 
atherosclerosis in 
LDLR ko. 
TLR4 Monocytes, 
macrophages and 
endothelial cells 
Decreased 
atherosclerosis 
(LDLR ko) 
n.d. 
TLR6 Monocytes, 
macrophages and 
endothelial cells 
No effect on 
atherosclerosis 
progression 
n.d. 
TLR7 n.d. Decreased 
atherosclerosis 
(LDLR ko) 
n.d. 
TLR9 n.d. Decreased 
atherosclerosis 
(ApoE ko) 
n.d. 
 
Table 1.2: Contribution of TLRs to atherosclerosis progression. Expression of TLRs in human 
lesions, and results of germ-line or myeloid genetic TLR deficiency on atherosclerotic 
development in mouse models is detailed. Knockout (ko), double knockout (dko) or not 
determined (n.d.) abbreviations are used Table adapted from (41) and (42). 
 
In vitro studies of potential atherosclerosis associated endogenous ligands 
suggest that TLRs do play a role in macrophage activation. A novel 
TLR4/TLR6 heterodimer, along with the scavenger receptor CD36 recognises 
oxidised LDL (oxLDL) to initiate an NFκB response (43), while High Mobility 
Group Protein B1 (HMGB1), an endogenous ligand that binds strongly to DNA 
and is released from dying cells, may act as a TLR9 ligand in atherosclerosis 
(44). While the exact role of TLRs, and especially myeloid TLRs in 
atherosclerosis development remains to be clarified, it is clear that pro-
inflammatory cytokines activated downstream of NFκB -mediated signalling, 
such as IL-6, IL-12 and IL-1β are pathogenic in this disease setting.  
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Cytokines in Atherosclerosis Development: 
 
Pro-inflammatory cytokines are major mediators of the chronic inflammation 
underlying atherosclerosis. Cytokines are small glycoproteins that are able to 
act in an autocrine, paracrine or endocrine manner to activate and amplify an 
immune response (45). IL-1β was first described in 1977 as leukocytic 
pyrogen for its ability to induce fever, a key hallmark of inflammation.  TLR 
stimulation induces expression of an mRNA and protein precursor (pro-IL-1β), 
which is then cleaved by caspase-1 into its mature, active form. 
Inflammasomes mediate this caspase-dependent processing of IL-1β (46). 
One of the key drivers of atherosclerosis formation is the recognition of early, 
intracellular cholesterol crystals by the NLRP3 inflammasome, which leads to 
IL-1β release (47) (see Table 1.3 and Figure 1.2). Currently, blockade of IL-1β 
with either soluble receptor antagonists (such as Anakinra) or antibodies 
against IL-1β (Canakinumab) is used for treatment of auto-inflammatory 
disorders, such as Cryopyrin associated periodic syndromes (CAPS) (48). 
Canakinumab is also now in clinical trials for treatment of CVD, known as the 
Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) 
(49).  
 
IL-6 is a pleiotropic cytokine also involved in atherosclerosis that initiates the 
acute phase response and activates the adaptive immune system during an 
infection (50). It is a major mediator of auto-immune diseases such as RA and 
Crohn's disease and blocking of IL-6 signalling in these diseases with 
antibodies against the IL-6 receptor is highly therapeutic (50). IL-6 plays a 
pivotal role in atherosclerosis progression, as established in mouse models 
and in causal association studies in humans (see Table 1.3).  
 
IL-12 is a 70 kDa hetero-dimeric cytokine consisting of subunits encoded by 
two separate genes: IL12a (IL-12p35) and IL12b (IL-12p40) and is essential 
for driving a Th1 adaptive immune response (51). IL-12p40 can also form a 
homodimer (IL-12p80) as well as another heterodimer with IL-23p19 to form 
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the related cytokine IL-23 (51). IL-12p40 deficiency is protective in mouse 
models of atherosclerosis (Table 1.3) (52), suggesting a role for IL-12 in 
atherosclerosis progression. TNF, a 17-kDa cytokine, can further amplify 
inflammation via NFκB signalling upon activation of the TNF receptor. TNF is 
also present in human atherosclerotic plaques, elevated TNF is a risk factor 
for CVD and TNF deficient mice are protected from atherosclerosis 
development, indicating a likely role for TNF in atherosclerosis (Table 1.3) 
(52).  
 
 
Table 1.3. Summary of evidence from mouse and human studies of involvement of pro-
inflammatory cytokines in atherosclerosis progression. 
 
Finally, chemokines such as monocyte chemotactic protein -1 (MCP-1), also 
known as C-C motif ligand 2 (CCL2), also contribute to atherosclerosis 
disease progression. MCP-1 signals through the receptor CC Chemokine 
Receptor 2 (CCR2) to mediate macrophage and monocyte recruitment to 
sites of tissue damage, and fittingly, in murine models of atherosclerosis 
Cytokine Recep-
tor 
Evidence from mouse 
models of atherosclerosis 
Evidence of from human 
studies 
Referen-
ces 
IL-1β IL-1R Bone Marrow transplantation 
from NLRP3, ASC or IL-1α/β 
ko mice into LDLR ko mice 
protect against 
atheroscerlosis progression 
IL-1β blockade now in 
clinical trials 
(47) 
(53) 
IL-6 IL-6R IL-6R/ApoE dko mice 
protected against 
atherosclerosis, recombinant 
IL-6 administration 
exacerbates atherosclerosis 
Asp358Ala SNP in IL-6R, 
causes IL-6 signalling 
defects and associated 
with decreased CVD risk 
(52) 
(54) 
(55) 
IL-12p40 IL-12R IL-12p40/ApoE dko mice 
protected against 
atherosclerosis, recombinant 
IL-12p40 administration 
exacerbates atherosclerosis 
n.d. (52) 
TNF TNFR TNF/ApoE dko mice 
protected against 
atherosclerosis  
Elevated expression in 
atherosclerotic plaques, 
decreased CVD risk in RA 
patients receiving anti-
TNF therapy 
(52) 
(45) 
MCP-
1(CCL2) 
CCR2 MCP-1/LDLR dko mice 
protected against 
atherosclerosis 
Elevated plasma MCP-1 
in CVD, SNPs in CCR2 
disrupting signalling 
associated with 
decreased CVD risk 
(56) 
	   18	  
MCP-1-deficient mice are protected against disease (56). While direct 
inhibition of cytokine signalling with antibodies is proving therapeutically 
beneficial, understanding the regulation of these cytokines may provide an 
additional avenue for anti-inflammatory and anti-atherosclerosis drug 
development. A summary of macrophage, TLR and cytokine involvement in 
atherosclerotic inflammation is given in Figure 1.2.  
 
 
Figure 1.2: Macrophage sterile inflammation in atherosclerosis. Macrophages sense 
DAMPs such as LDL or cholesterol crystals leading to pro-inflammatory cytokine and 
chemokine expression, which contribute to atherosclerosis progression. Figure from (35) 
 
Therapeutic effects of HDL in Atherosclerosis 
 
HDL and disease risk in humans - epidemiological studies.  
 
High-density lipoprotein (HDL) associated cholesterol (HDL-c) has long been 
referred to as the "good" cholesterol. An inverse correlation between HDL-c 
levels and CVD risk was first reported over 50 years ago, and has been 
consistently reported in the decades since in large scale epidemiological 
studies such as the Norway Tromso study and the Framingham heart 
study(57, 58). Further studies showed that therapies which reduced CVD risk 
also appeared to increase HDL-c (58). Indeed, Gordon and colleagues 
concluded that for a 1 mg/dL increase in HDL-c, there is a 2-3% decrease in 
CVD risk (59).  The clear relationship between HDL level and CVD risk can be 
Macrophages and TLRs in 
atherosclerosis
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plaque4 and has pathogenic effects, including less collagen fiber 
formation, higher expression of major histocompatibility complex 
class II, enhanced protease and chemokine secretion, upregulation 
of adhesion molecules, induction of proinflammatory cytokines, and 
enhanced activation of macrophages and endothelial cells4. Mice 
deficient in interferon-γ or its receptor have a lower lesion burden, 
and mice that receive interferon-γ have larger lesions than those of 
control mice68–71. Injection of IL-12 also promotes the formation 
of early lesions72, whereas targeted deletion of the gene encoding 
IL-12 or vaccination against IL-12 inhibits early but not late lesion 
development73,74. Furthermore, mice lacking IL-18, a TH1-promoting 
cytokine, have smaller lesions29, whereas mice treated with IL-18 
have more atherosclerosis75. Finally, targeted deletion of Tbx21, 
which encodes the major TH1-differentiating transcription fac-
to  T-bet, leads to much less lesion development in Ldlr–/– mice76. 
Collectively these data demonstrate that TH1 cells have a major role 
in the pathogenesis of atherosclero is. IL-4, the signature cytokine 
of the TH2 lineage, is not frequently observed in human plaques77, 
and experimental studies examining the involvement of TH2 cells are 
contradictory, with some showing proatherosclerotic effects73,78 and 
others showing protective effects79 or no significant effect80. IL-33, a 
powerful inducer of TH2 responses, results in less atherosclerosis in 
Apoe–/– mice81. On balance, then, the role of TH2 immune responses 
in atherosclerosis remains unclear.
Contradictory data have also been presented for IL-17-producing 
helper T cells (TH17 cells). Although IL-17 mRNA seems to be pres-
ent at low abundance in atherosclerotic plaques, IL-17 protein has 
been detected in several cell types of human atherosclerotic tis-
sue, including T cells, mast cells, B cells, neutrophils and smooth 
muscle cells82,83. Studies of Apoe–/– mice treated with antibodies 
or decoy receptors to IL-17, and of Ldlr–/– mice reconstituted with 
IL-17 receptor–deficient bone marrow, suggest a proatherogenic 
role for this cytokine84–86. In contrast to those studies, mice with a 
(discussed below), other experiments have 
suggested that B cells have a protective role. 
Splenectomy aggravates atherosclerosis in 
Apoe–/– mice, whereas transfer of splenic 
B cells from aged atherosclerotic Apoe–/– 
mice has a protective effect on splenecto-
mized recipients49. Transfer of bone marrow 
from B cell–deficient μMT mice into Ldlr–
/– mice has shown that B cells and/or anti-
bodies are protective in both early and late 
atherosclerosis50. In line with those results, 
bone marrow–chimeric Ldlr–/– mice lacking 
IL-5, a cytokine that promotes the population 
expansion of B-1 cells, have lower concentra-
tions of immunoglobulin M (IgM) antibodies 
to phosphocholine and, concomitantly, more 
atherosclerosis51. Reports demonstrating the 
atheroprotective effects of B cell–depleting 
antibody to CD20 (anti-CD20)52 and the 
proatherosclerotic effects of transferred 
B-2 cells, but not of B-1 cells53, suggest that 
certain subsets of B cells exert contrasting 
effects on disease. Of note, plasma cells are 
not depleted by anti-CD20, and B220loIgM+ 
B cells and IgM production are also affected 
less than IgG-producing B cells are.
Antibodies to oxLDL in particular are 
atheroprotective. Many experimental studies 
of rabbits and mice in which oxLDL is used for immunization have 
shown a positive correlation between high titers of anti-oxLDL and 
the degree of protection against atherosclerosis54–56. Accordingly, 
infusion of anti-LDL results in less atherosclerosis in hypercholester-
olemic mice12. As is often the case, the situation is more complex in 
humans, with various studies showing a positive or negative correla-
tion or no correlation between anti-LDL titers and atherosclerosis or 
its manifestations57–60. Interestingly, titers of IgM and IgG antibodies 
to oxLDL have been found to show differences in their associations 
with CAD, which suggests that their biological roles also differ61.
T lymphocytes: key participants in atherogenesis
T cells of the atherosclerotic plaque are of the memory-effector pheno-
type and are mostly positive for the αβ T cell antigen receptor (TCRαβ) 
and CD4+, although many CD8+ T cells can also be found, as well as 
a small population of TCRγδ+ cells4. Clonal expansion of T cells has 
been demonstrated in lesions from humans and Apoe–/– mic 62,63; this 
suggests that antigen-specific reactions take place in the lesion (Fig. 2). 
This idea is also supported by the finding that Ldlr−/− mice in which 
CD40 ligation is interrupted have smaller lesions64. Reconstitution of 
Apoe–/– mice with severe combined immunodeficiency using CD4+ T 
cells from atherosclerotic Apoe–/– mice accelerates atherosclerosis, with 
homing of T cells to the lesions48. CD8+ T cells stimulated by injection 
of an agonist to the tumor necrosis factor–like surface protein CD137 
or activated toward an artificial antigen expressed by smooth muscle 
cells increase atherosclerosis in Apoe–/– mice65,66. Ldlr–/– mice deficient 
in the inhibitory molecules PD-L1 and PD-L2 have larger plaques with 
massive lesional infiltration of CD8+ T cells, which indicates that these 
cells might be controlled by PD-1 in atherosclerosis67.
Role of helper T cell subsets
Atherosclerosis is driven by the T helper type 1 (TH1) response. 
Interferon-γ, the signature TH1 cytokine, is present in the human 
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Figure 3  Activation of innate immune responses in the atheroma. Macrophages, DCs and endothelial 
cells display a large repertoire of PRRs. Uptake of modified LDL particles such as oxLDL through 
scavenger receptors leads to the intracellular accumulation of cholesterol that can activate the 
inflammasome, leading to IL-1β secretion. Components of modified LDL can also ligate TLRs, 
triggering an intracellular signaling cascade that leads to the expression of a series of genes encoding 
proinflammatory molecules, including cytokines, chemokines, eicosanoids, proteinases, oxidases and 
costimulatory molecules. NF-LB, IRF and AP-1 are transcription factors.
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seen in Figure 1.3. In addition, combined therapies that involved lowering 
LDL-c via statin treatment and raising HDL-c via niacin treatment showed 
improved risk for CVD over statin monotherapy alone (58).  
 
However, to date, clinical trials investigating the effect of raising HDL-c alone 
have shown no benefits in decreasing CVD risk, and indeed one trial showed 
significant harm (58). Limitations to these clinical trials notwithstanding, these 
studies suggest that merely raising HDL-c levels does not lower CVD risk, and 
that HDL functionality may be a more pertinent factor in CVD. 
 
Figure 1.3. Plasma HDL-c inversely correlates with CVD risk. The association between 
plasma HDL levels and number of clinical events from various studies is plotted.  Figure from 
(58) 
 
HDL Structure and composition 
 
HDL particles are macromolecular complexes consisting primarily of lipids and 
proteins. The key structural proteins in HDL are of the apolipoprotein family, in 
particular ApoA1 and ApoAII, which comprise approximately 65% and 15% of 
the human HDL protein mass respectively (58). These proteins are 
amphipathic and together with phospholipids such as phosphatidylcholine, 
form a hydrophilic outer shell that surrounds a hydrophobic inner core, 
consisting of free cholesterol, cholesterol esters and triglycerides (60). In 
addition to ApoA1 and II, HDL particles normally also contain the enzymes 
lecithin cholesterol acetyl transferase (LCAT) and the antioxidant molecule 
of hyperlipidemia in 1988,23 that minimal emphasis was
placed on screening for low HDL-C. Among the most con-
troversial recommendations of ATP I was the recommenda-
tion not to perform a lipoprotein analysis if screening total
cholesterol (total-C) was desirable, defined as ,200 mg/dL.
However, it was well recognized that at least 20% of MI
survivors in the FHS had ‘‘desirable’’ total-C levels
(Fig. 3).24,25 This finding raised the possibility that, in ad-
dition to cigarette smoking, hypertension, and diabetes mel-
litus, low HDL-C was an important contributor to MI risk
in normocholesterolemic subjects. To further explore the
role of HDL-C in subjects with desirable cholesterol
concentrations, the FHS found incident CVD risk to be in-
creased in subjects with low levels of HDL-C, independent
of other cardiovascular risk factors.26 This was followed by
arteriographic evidence consistently showing that low
HDL-C was the most common lipoprotein abnormality in
patients with established CVD, irrespective of total-C
levels27–30 and that a low HDL-C in the absence of elevated
cholesterol was also predictive of future CVD events.31
The validity of the inverse association generated in
observational studies extended to randomized clinical trials
in which it was observed in both placebo- and drug-treated
groups. The Lipid Research Clinics Coronary Primary
Prevention Trial32 found that increases in HDL-C after
treatment with the bile acid resin, cholestyramine, corre-
lated with reduced risk of initial MI or CVD death. In a
follow-up analysis of men in the FHS, the Lipid Research
Clinics Prevalence Mortality Follow-up Study, the Coro-
nary Primary Prevention Trial, and the Multiple Risk Factor
Intervention Trial it was concluded that that each 1-mg/dL
rise in HDL-C was associated with a 3% to 4% reduction in
CVD mortality rates (Fig. 4).33 This result heightened inter-
est in the possibility that increasing HDL-C would translate
into clinical improvement in CVD risk. This possibility was
further supported in the primary prevention Helsinki Heart
Study (HHS) in which a 1% increase in HDL-C with gem-
fibrozil was associated with a 3% decrease in CVD
events.34 Another randomized controlled trial that tested
the fibric acid gemfibrozil was the Veterans Affairs HDL
Intervention Trial (VA-HIT), a secondary prevention study
of male veterans with CVD who had a low HDL-C at base-
line (,35 mg/dL).35 Even though HDL-C levels rose mod-
estly (6%), a significant proportion of the clinical benefit in
CVD risk (22%) was attributable to HDL-C.36
The suggestion that raising HDL-C contributed to
reduced CVD risk in HHS and VA-HIT was subsequently
evaluated in st tin-bas d randomized controlled trials. A
common theme emerged related to CVD risk in placebo-
treated patients. Specifically, placebo-assigned subjects
with low HDL-C (as defined by median or lowest tertile)
levels in the Scandinavian Simvastatin Survival Study, West
of Scotland Coronary Prevention Trial, and Air Force/Texas
C ronary Atherosclerosis Prevention Study all exhibited
higher event rates than patients with higher HDL-C levels
at baseline. Moreover, arteriographic progression of CAD
was also higher in patients with low vs higher HDL-C
levels at baseline.37 These data indicated that low HDL-C
was both prevalent and predictive of CVD events, indepen-
dent of other associated risk factors for major coronary
he rt disease (CHD). Further work by Brown et al38 found
Figure 2 Kaplan–Meier survival curves by HDL-C and TC
levels: 21-year CHD mortality from the Israeli Ischemic Heart
Disease Study.19 HDL-C, high-density lipoprotein cholesterol;
TC, total cholesterol.
Figure 3 Distribution of TC concentration among men with and
without CHD in the Framingham Heart Study, 16-year follow-
up.24,25 CHD, coronary heart disease; TC, total cholesterol.
Figure 4 Correlation of HDL-C (low, middle, and high sub-
groups) with incidence of CHD in Framingham Heart Study, Lipid
Research Clinics Follow-up, Coronary Primary Prevention Trial,
and Multiple Risk Factor Intervention Trial.33 CHD, coronary
heart disease; H, HDL-C $ 50 mg/dL; HDL-C, high-density lip-
oprotein cholesterol; L, HDL-C , 40 mg/dL; M, HDL-C 40–49
mg/dL.
486 Journal of Clinical Lipidology, Vol 7, No 5, October 2013
	   20	  
paraoxygenase 1 (PON1), which may contribute to HDL's function (60). HDL 
particles are largely formed in the extracellular space and are constantly 
remodelled in the circulation during the process of accepting and transporting 
cholesterol (58). HDL particles therefore exist at various sizes and densities; it 
is generally accepted that HDL particles have a density of between 1.063 and 
1.21 g/ml (58). In general, 5 distinct sizes of HDL particle have been 
determined by density gradient ultra-centrifugation, 2D Gel Electrophoresis, 
and nuclear magnetic resonance (NMR), ranging from very small HDL, also 
known as pre-β HDL particles, through to very large HDL, which are full of 
cholesterol esters (58).  
 
Reconstituted HDL and CSL-111 
 
Much of the current knowledge about HDL function comes from using 
chemically defined HDL, obtained by in vitro reconstitution of purified 
Apolipoproteins and phospholipids at defined ratios. The reconstituted HDL  
CSL-111 (produced by CSL- Behring) has been widely used to investigate 
HDL's beneficial actions on atherosclerosis development in vitro and in vivo. 
CSL-111 consists of purified human ApoA1 isolated from patient serum and 
subsequently reconstituted with soybean phosphatidylcholine at a ratio of 
1:150 (61). Short term infusions of 40 mg/kg CSL-111 in patients with acute 
coronary syndrome showed improvement in plaque characterisation index 
and coronary score, despite no significant changes in plaque volume, 
suggesting that reconstituted HDL is a potential therapeutic option for 
treatment of CVD (62). CSL-111 can efflux cholesterol via both ABCA1 and 
SR-B1 (SD Wright, Personal Communication). Indeed excessive cholesterol 
efflux from the liver via SR-B1 by CSL-111 may explain why a high dose of 80 
mg/kg in patients resulted in liver toxicity (62) . A newer recombinant HDL 
produced by CSL Behring, CSL-112 shows no liver toxicity in initial trials, 
most likely because it mainly effluxes cholesterol via ABCA1 (63, 64).  The 
efficacy of CSL-112 in treating acute coronary syndrome, without potential 
liver toxicity side effects, remains to be determined.  
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Functions of HDL 
 
The failure of HDL-c raising therapies in clinical trials has accompanied an 
increased interest in characterising the function of HDL.  Accordingly, the HDL 
'flux' hypothesis, where HDL functionality is a better predictor of its protective 
effect in CVD than HDL quantity, has also gained popularity (58). A key study 
supporting this hypothesis showed in an ex vivo assay (measuring cholesterol 
efflux to HDL isolated from patients from lipid-laden macrophages) that HDL 
efflux capacity is indeed a better predictor of CVD risk than HDL-c levels 
alone (65). This confirmed earlier studies in mice, where the rate of 
cholesterol efflux to HDL correlated with disease severity across a variety of 
genetic models and pharmacological interventions (58, 66).  
 
Reverse Cholesterol Transport  
 
Reverse cholesterol transport (RCT) is considered to be the primary 
protective function of HDL in atherosclerosis (66). In RCT (see also Figure 
1.4), ApoA1 synthesised in the liver interacts with hepatic ATP-binding 
cassette transporter ABCA1 to form nascent, lipid poor HDL (66). This HDL, 
also known as pre-β HDL, is discoidal in shape with a phospholipid shell and 
a free cholesterol core (60). Pre-β HDL is a substrate for LCAT, which 
esterifies free cholesterol into cholesterol esters (67) which are then stored in 
the lipid core of the HDL, giving the HDL a more spherical shape (60).  
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Figure 1.4. Reverse Cholesterol Transport. ApoA1 acquires phospholipids to form HDL, 
and is then able to accept cholesterol from macrophage foam cells via the receptors ABCA1 
and ABCG1. This cholesterol loaded HDL is transported back to the liver for excretion. Figure 
from (68) 
 
Excess cholesterol is toxic to cells and therefore cholesterol homeostasis is 
tightly regulated at the level of biosynthesis, uptake, esterification and export 
(60). Cholesterol-laden macrophages therefore either convert excess free 
cholesterol to cholesterol esters (which are then stored in lipid droplets) or 
they efflux excess cholesterol to HDL for excretion (66). Foam cell cholesterol 
efflux is mediated by ABCA1, which interacts with lipid-poor HDL, and 
ABCG1, which effluxes cholesterol to lipid-rich HDL (60). Consistent with this, 
ABCA1- and ABCG1-deficient mice have much lower RCT levels, which 
correlates with increased atherosclerosis progression (66). Finally, this lipid-
rich, cholesterol-laden HDL either transfers cholesterol to LDL via the 
cholesterol ester transfer protein (CETP) or is removed from the circulation via 
Scavenger Receptor B1 (SR-B1) in the liver, for subsequent excretion in bile 
or faeces (60). While SR-B1 expressed on macrophages appears to not be 
important for direct macrophage cholesterol efflux, haematopoietic SR-B1 
may nevertheless be important for RCT in general (66).  
 
The key role of ApoA1 in mediating HDL's protection against CVD 
development has been investigated in numerous mouse models.  
Overexpression of the human ApoA1 transgene (69), (70) in various models 
protected against atherosclerosis, at least in part by enhancing RCT (71). 
B E T W E E N  B E D S I D E  A N D  B E N C H
depleted of the atherogenic lipoproteins LDL 
and VLDL, which deliver cholesterol to mac-
rophage foam cells5. They showed that human 
serum HDL’s ability to promote sterol efflux 
from cultured macrophages can vary markedly, 
despite similar levels of HDL-C and apoA-I5, 
indicating the level of HDL-C is not the major 
determinant of macrophage sterol efflux in this 
system. It will be of great interest to determine 
the bioche ical and genetic factors that regu-
late sterol efflux by serum HDL, as these factors 
may represent new therapeutic targets for the 
prevention of cardiovascular disease.
The capacity of serum HDL to promote 
macrophage sterol efflux associated strongly 
and negatively with coronary artery disease 
status in two independent populations of 
humans6. That association was als  indepen-
dent of HDL-C and apoA-I levels. Differences 
in efflux capacity of serum HDL correlated 
with altered efflux by th  ABCA1 pathway in 
macrophages. Taken together, these observa-
tions suggest that serum HDL’s capacity to pro-
mote sterol efflux from macrophages reflects 
its functionality, raising the possibility that the 
assay provides insights into HDL biology and 
cardiovascular disease risk.
A key metric for assessing HDL function 
may be the concentration of HDL particles 
in blood (Fig. 1), which in turn could affect 
the concentration of HDL in the artery wall. 
However, the protein and lipid compositions 
of large and small HDL particles differ7,8, 
making interpretation of HDL-C and apoA-
I levels problematic for the assessment of 
HDL particle number. Thus, a rucial issue 
confounding the interpretation of HDL-C as 
a measure of HDL concentration may be the 
relative balance between large and small HDL 
particles. At a given level of HDL-C, it is pos-
sible to have many small cholesterol-poor 
particles or far fewer large, cholesterol-rich 
particles7. Sterol efflux by the ABCA1 pathway 
is strongly dependent on the concentration of 
lipid-poor HDL, raising the possibility that 
particle number is an important determinant 
of macrophage cholesterol efflux. Notably, both 
niacin and CETP inhibitors promote the for-
mation of large HDL particles1, which might 
not change HDL particle concentration despite 
the increase in HDL-C.
One potential approach to quantifying 
HDL number and size uses nuclear magnetic 
resonance (NMR). Clinical studies suggest that 
HDL particle number can provide information 
on cardiovascular disease status that is indepen-
dent of HDL-C9. In a multiethnic study of 5,598 
men and women, HDL-C no longer associated 
with two measures of cardiovascular disease 
status after adjustm nt for LDL-cholesterol 
and LDL particle number9. In contrast, HDL 
particle number remained strongly and 
independently associated with cardiovascular 
disease status. One potential limitation is that 
the NMR method is based on assumptions 
about the physical properties of HDL lipids, and 
it has not been validated biochemically.
A completely different approach focuses on 
the protein cargo of circulating HDL (Fig. 1), 
as mass spectrometric studies demonstrate 
that HDL carries a rich cargo of more than 50 
proteins8. Some of those proteins seem to be 
enriched or depleted in subjects with cardio-
vascular disease8. Moreover, aggressive lipid-
lowering therapy partially reverses the changes 
in the protein composition seen in HDL of 
people with cardiovascular disease, raising the 
possibility that quantifying the HDL proteome 
provides insights into the therapeutic efficacy 
of antiatherosclerotic interventions10. In future 
studies, it will be important to use quantitative, 
high-throughput methods to investigate and 
monitor the HDL proteome and to link spe-
cific proteins to cardiovascular disease risk and 
HDL function.
It is clear from recent clinical and transla-
tional studies that elevating HDL-C levels 
may not lower cardiovascular disease risk1; 
however, animal studies provide compelling 
evidence that HDL has key roles in atheroscle-
rosis2–4. The development of new metrics for 
quantifying HDL, based on a better under-
standing of reverse cholesterol transport, will 
expand our knowledge of the factors that are 
important in atherogenesis and lay the foun-
dation for identifying HDL therapeutics that 
lower cardiovascular disease risk. 
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Correspondingly, ApoA1- and LDLR-double deficient mice developed 
increased atherosclerosis (72), and this was later attributed to decreased RCT 
and increased vascular inflammation (73). In accordance with these studies, 
infusions of reconstituted HDL (rHDL) from purified ApoA1 reconstituted with 
phosphatidylcholine are beneficial in both animal models and human studies 
of atherosclerosis (74).  
 
Intracellular Cholesterol Regulation 	  
Cholesterol is an essential lipid that is required for membrane stability and 
function and as a precursor for steroid hormones and other signalling 
molecules (75). However, as excess cholesterol is dangerous, cholesterol 
biosynthesis and cholesterol efflux pathways are also tightly regulated at the 
cellular level.  The enzymes of the cholesterol biosynthesis pathway are under 
control of the Sterol Response Element Binding Protein (SREBP) transcription 
factor. Under conditions of low cellular cholesterol SREBP is activated and 
cholesterol biosynthesis genes expressed, while under conditions of high 
cellular cholesterol SREBP is held inactive in the ER (76). SREBP activation 
upon cellular sensing of cholesterol depletion is detailed in Figure 1.5. The 
receptors required for cholesterol efflux, such as ABCA1 and ABCG1 are 
under control of the Liver X Receptors (LXRs) (76). Cholesterol precursors 
such as desmosterol and oxysterols such as 27-hydroxycholesterol act as 
LXR ligands (76). LXRs can also act as a transcriptional repressors to inhibit 
pro-inflammatory NFκB gene expression (76). In keeping with its primary role 
as a cholesterol efflux receptor, ABCA1 is not expressed on resting 
macrophages, and is only induced upon cholesterol loading or treatment with 
an LXR agonist (77). The balance of LXR and SREBP activation therefore 
also controls efflux of cholesterol to HDL. 
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Figure 1.5: SREBP activation. In cells with high cholesterol SREBP, along with its 
chaperone SCAP, is anchored in the ER by the inhibitor INSIG (left panel).    When cells have 
low cholesterol, SREBP and SCAP are released from INSIG and move to the Golgi where 
SREBP is proteolytically activated (right panel). The active SREBP then translocates to the 
nucleus where it can bind Sterol Response Elements (SREs) in the promoters of target genes 
(e.g. genes involved in cholesterol biosynthesis). Figure adapted from (78) 
 
Other anti-atherogenic functions of HDL 
 
The beneficial properties of HDL in protecting against atherosclerosis extend 
beyond RCT (see Figure 1.6). HDL also possesses anti-oxidant properties. 
HDL can protect both lipid and protein moieties of LDL from oxidation, render 
lipid hydroperoxides (LOOH) non-reactive by reducing them into non-reactive 
lipid hydroxides, or remove LOOH directly from LDL (79). Furthermore, HDL 
can protect against oxLDL-induced macrophage apoptosis, by promoting the 
efflux of cytotoxic oxysterols, such as 7-ketocholesterol (80). 
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Figure 1.6. Anti-atherogenic functions of HDL. HDL affects many processes involved in 
atherosclerosis progression beyond cholesterol efflux.  
 
HDL also promotes healthy endothelial function. HDL stimulates endothelial 
nitric oxide (NO) production, inhibits endothelial adhesion molecule 
expression, enhances endothelial repair by increasing endothelial cell 
migration and inhibits tissue factor expression (81). Interestingly, HDL induces 
endothelial NO synthase (eNOS) via endothelial SR-B1, which activates 
downstream kinases including phosphoinosotide 3 kinase (PI3K), MAPK and 
Akt (also known as Protein Kinase B) (82).  
 
HDL also inhibits thrombin-, collagen-, adrenalin- or Adenisine Diphosphate 
(ADP)-induced platelet aggregation, as well as platelet activation and 
subsequent release of thrombotic mediators, such as thromoxane A2 (83). 
These anti-thrombotic effects on platelet function also appear to be mediated 
by SR-B1(83), suggesting another important role for non-hepatic SR-B1 in 
mediating HDL functions in addition to cholesterol efflux. Finally, HDL can 
also directly solubilize cholesterol crystals, and thereby potentially clear 
cholesterol crystals from atherosclerotic plaques, removing a key DAMP and 
mediator of sterile inflammation in atherosclerosis progression (75). 
 
In addition to these various protective properties, HDL is anti-inflammatory. 
HDL has various effects on the immune system, which, considering the 
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extensive role that immune cells play in disease pathogenesis may go some 
way to further delineating why HDL is protective in both CVD and other 
inflammatory diseases.  
 
Anti-inflammatory effects of HDL 
 
HDL and Haematopoiesis 
 
HDL can directly influence immune cell numbers by suppressing 
haematopoietic stem/progenitor cell (HSPC) proliferation. Leukocytosis, (high 
leukocyte numbers), is associated with an increased risk for CVD (84), and 
ApoE-/- mice fed on a high fat diet develop monocytosis and neutrophilia (85). 
HDL was shown to suppress HSPC proliferation via cholesterol efflux through 
ABCA1/ABCG1, leading to reduced monocytosis and neutrophilia in 
hypercholesterolemic animal models (86). Similarly, increased platelet 
production in a mouse model of atherosclerosis was attenuated by rHDL 
infusion, attributable to cholesterol efflux from megakaryocytes (the platelet 
progenitor cells) via the transporter ABCG4 (87). As cholesterol biosynthesis 
pathways are activated during cell proliferation to accommodate for increased 
sterol demand for new membrane synthesis, cholesterol efflux via HDL is 
therefore likely to suppress HSPC proliferation (87).  
 
HDL and Sepsis 
 
HDL is highly protective in animal models of septic shock. HDL reduced 
circulating pro-inflammatory cytokines and lethality in sepsis models in rats, 
mice and rabbits (88). In addition, HDL is protective in haemorrhagic shock 
and ishcaemia - reperfusion injury models in rats (88). Accordingly, HDL 
levels decrease markedly in septic patients, and low plasma HDL is 
considered a poor prognostic indicator for severe sepsis (89). This protective 
effect of HDL in sepsis is likely due to HDL's ability to bind to, neutralise (88) 
and subsequently clear (90) PAMPS from both gram negative and gram 
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positive bacteria (e.g. LPS and Lipoteichoich Acid - LTA respectively)  which 
are key drivers of septic shock and potent TLR ligands. Indeed, infusions of 
rHDL dampened endotoxemia resulting from low-dose LPS administration in 
healthy human volunteers (91, 92). HDL may also promote LPS clearance via 
uptake by SR-B1, as SR-B1-deficient mice showed the same level of 
endotoxin neutralisation as WT mice, but defective LPS clearance (90). 
Furthermore, SR-B1 mediates adrenal glucocorticoid synthesis from HDL-
derived cholesterol (90). Glucocorticoids are anti-inflammatory because they 
can suppress pro-inflammatory cytokine production (e.g. TNF, IL-6, IL-1β) and 
stimulate anti-inflammatory cytokine (e.g. IL-10, TGF β) production and 
accordingly adrenal glucocorticoid insufficiency is often associated with sepsis 
(90).  
 
HDL and other anti-inflammatory effects in vivo  
 
HDL also protects against acute endothelial inflammation in normo-
cholesterolemic animals. In a porcine model of IL-1α-induced inflammation, 
rHDL administration inhibited local endothelial inflammation (93). In New 
Zealand White Rabbits, prior administration of rHDL inhibited acute vascular 
inflammation induced by a peri-arterial collar, particularly by reducing 
neutrophil recruitment and ROS generation (94). In this study, the animals 
were sacrificed 24 h after collar administration, before monocyte and 
macrophage recruitment to the damaged tissue, as the authors wished to 
focus on endothelial inflammation. Interestingly, similar anti-inflammatory 
effects were seen whether rHDL, lipid-poor ApoA1 or small unilamellar 
vesicles (SUVs) of phosphatidylcholine species were infused into the rabbits, 
suggesting that the anti-inflammatory effects may be independent of 
cholesterol efflux capacity (94). In a follow up study, rHDL was shown to 
inhibit carotid injury-induced endothelial inflammation in rabbits when 
administered up to 9 h after injury (95). Finally, a recent report showed that 
HDL inhibited peptidoglycan-polysaccharide induced rheumatoid arthritis in 
the Lewis rat, with HDL treated rats showing decreased pro-inflammatory 
cytokines in the synovial fluid, decreased white blood cell counts, decreased 
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synovial macrophage infiltration and decreased pro-inflammatory cytokine 
mRNA expression (96). 
  
Mechanism of HDL's anti-inflammatory actions 
 
The anti-inflammatory properties of HDL established in vivo have not yet been 
completely elucidated in vitro, but various studies investigating the effect of 
HDL on immune cell activation have hinted at the molecular mechanisms 
involved.  
 
HDL and Endothelial Cell Inflammation 
 
Endothelial cells, while not strictly immune cells, play an important role in 
inflammation. In particular, expression of adhesion molecules such as E-
Selectin, Vascular cell adhesion molecule 1 (VCAM1) and Intracellular cell 
adhesion molecule 1 (ICAM1) promote neutrophil/monocyte attachment and 
extravasation into the tissue (97). Recombinant HDL inhibited TNF- and IL-
1β-induced E-Selectin, VCAM1 and ICAM1 expression in human umbilical 
vein endothelial cells (HUVECs) (98). E-Selectin, VCAM1 and ICAM1 are all 
NFκB responsive genes, and early studies suggest that HDL inhibits their 
expression by inhibiting NFκB nuclear translocation and NFκB -DNA 
interaction (99) (100). Further studies elucidated that HDL inhibits TNF-
inducible VCAM1 expression via endothelial SR-B1 either by an Akt and 
Heme Oxygenase -1 (HO-1) pathway (101) or via an alternate NO dependent 
pathway (102). Furthermore HDL induces the anti-inflammatory cytokine TGF-
β in an SR-B1-dependent manner which may also block the expression of 
adhesion molecules (103). Interestingly, many of the studies in endothelial 
cells suggest that the anti-inflammatory actions of HDL in this context may be 
independent of RCT and rather mediated by the HDL associated 
phospholipids (101, 104). 
HDL effects on monocytes and macrophages 	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Anti-inflammatory effects of HDL have also been observed in human 
monocytes and macrophages (i.e. HMDMs). rHDL blocked the phorbol 12-
myristate 13-acetate (PMA) induced activation of Cd11b on monocytes, and 
this subsequently inhibited monocyte migration along an MCP-1 chemotactic 
gradient (105). This supported an earlier study where HDL blocked M-CSF-
induced monocyte spreading, surface molecule expression and chemotaxis 
along an fMLP (N-formyl-methionyl-leucyl-phenylalanine, - a synthetic 
peptide) gradient (106). Finally ApoA1 or an ApoA1 mimetic, 4F, reduced 
HMDM cytokine expression in response to LPS, with reduced IL-6, TNF, 
MCP-1 and Macrophage Inhibitory Protein 1 (MIP-1) and a concurrent 
increase in the anti-inflammatory cytokine IL-10 (107).  These studies also 
suggest that the anti-inflammatory effects of HDL in these settings were 
ABCA1-dependent and related to reverse cholesterol transport. Furthermore, 
some preliminary analysis of the HDL treated HMDM phenotype suggested 
that ApoA1 and 4F induce a global anti-inflammatory state in macrophages 
(107).  
Similarly, studies in the mouse system have also shown profound anti-
inflammatory effects of HDL on macrophages. CD68+ plaque macrophages 
isolated from mice after treatment with HDL showed an anti-inflammatory 
phenotype (108). This was confirmed in vitro, where treatment of murine 
BMDM with HDL resulted in up-regulation of typical anti-inflammatory 
macrophage markers Arg1 and Fizz1 in a STAT6-dependent manner (109). 
HDL was also shown to inhibit the Type 1 Interferon response in human 
cholesterol-laden macrophages in response to LPS, supposedly by disrupting 
TRAM function and localization (110).  
The lipid raft hypothesis and TLR Signalling 	  
The most popular hypothesis concerning HDL and inhibition of macrophage 
activation is that cholesterol efflux to HDL via ABCA1 and ABCG1 disrupts 
lipid raft formation, and therefore disrupts TLR signalling. Cholesterol is a key 
component of cellular membranes and is required for membrane permeability, 
fluidity, protein trafficking and signalling (111). In particular, cholesterol 
increases the lateral order of membrane lipids and associates with the more 
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rigid saturated lipid chains in micro-domains known as lipid rafts, which are 
sphingolipid and protein-rich nanoscale assemblies within the membrane 
(111, 112). Initially lipid rafts and lipid raft-associated proteins were identified 
based on their resistance to detergents in vitro, which is controversial 
because of the highly artificial nature of this biochemical characterisation 
(113).  More recent work using microscopy and spectroscopy has confirmed 
that many membrane proteins are indeed ordered in nanoscale domains in 
situ, apparently in a cholesterol dependent manner (112). TLR4 and its co-
receptor for LPS, CD14, which is a Glycosyl-Phosphatidyl-Inositol (GPI) linked 
protein, are thought to be lipid raft associated receptors, based on studies 
identifying TLR4 and CD14 in detergent resistant membranes (DRMs) after 
stimulation with LPS (114, 115). TLR2 and TLR9 are also thought to be 
recruited into DRMs following stimulation with their respective ligands, 
whereas TLR3 signalling appears not to be lipid raft-dependent (116). Lipid 
rafts are therefore thought to form a platform where TLRs can cluster in 
response to polymeric ligands, such as LPS, and thereby recruit downstream 
adaptors such as MyD88 to initiate signalling. 
Increased TLR signalling from lipid rafts in Abca1-/- macrophages. 	  
Complementing the reports of TLR clustering and recruitment into lipid rafts 
are studies using cholesterol-depleting agents such as methyl-β-cyclodextrin 
(MCD), which is a cyclic oligosaccharide used to deplete cholesterol from 
membranes (117). MCD inhibited TNF release from LPS and Pam3CysK4 
(P3C) stimulated macrophages, suggesting that intact rafts are required for 
effective TLR4 and TLR2 signalling respectively (116) (118). Conversely, 
loading macrophages with cholesterol via cyclodextrin or acetylated LDL led 
to enhanced TLR signalling and recruitment into lipid rafts (119). Furthermore, 
ABCA1- and ABCG1-deficient macrophages reportedly have excess free 
cholesterol and a hyper-inflammatory response to TLR2, 3,4,7 and 9 ligands, 
which is attributed to increased TLR accumulation in lipid rafts (118, 120, 121) 
(122). Therefore, HDL is hypothesized to disrupt lipid rafts by cholesterol 
efflux through ABCA1, and thereby inhibit TLR signalling (123, 124) as 
described in Figure 1.7.   
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Figure 1.7. The lipid raft hypothesis of HDL mediated inhibition of TLR signalling. In 
resting cells, TLRs are located outside cholesterol rich lipid raft domains. Upon ligand binding, 
TLRs are recruited into lipid rafts where adaptor molecules are able to form a signalling 
platform, leading to downstream activation (left panel). HDL may deplete membrane 
cholesterol from lipid rafts, thereby disrupting receptor/adaptor-signalling platforms from 
forming and subsequently inhibiting downstream activation (right panel).  
 
Recent studies have also suggested that ABCA1 may function as an anti-
inflammatory receptor for ApoA1. ApoA1 binding to ABCA1 has been shown 
to initiate JAK2/STAT3 signalling to suppress pro-inflammatory cytokine 
expression (125). This anti-inflammatory signalling from ABCA1 appeared to 
be independent of its cholesterol efflux capabilities, as ABCA1 mutants that 
were no longer anti-inflammatory in response to ApoA1 were still able to 
effectively efflux cholesterol (125). HDL may therefore suppress TLR-
mediated pro-inflammatory cytokine expression via disruption of lipid rafts and 
receptor clustering, or directly via ABCA1-mediated activation of a 
downstream JAK2/STAT3 pathway. Alternatively, HDL may affect 
macrophage activation by an as yet undefined mechanism. 
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Rationale for study: 	  
Despite the many studies investigating the benefits of HDL in CVD and other 
inflammatory diseases, the mechanisms by which HDL mediates its anti-
inflammatory effects remain poorly characterised. Considering that 
macrophages, TLRs and pro-inflammatory cytokines are major contributors to 
the inflammation underlying atherosclerosis and other diseases, the effect of 
HDL on TLR-induced pro-inflammatory cytokine production in macrophages 
was investigated. Based on previous studies, it was anticipated that HDL 
would inhibit TLR-induced macrophage activation as part of its anti-
inflammatory functions. Furthermore, to delineate whether these effects were 
independent from RCT, the anti-inflammatory properties of HDL in 
macrophages with normal cholesterol levels rather than foam cells was also 
investigated. In this way, if HDL had effects beyond cholesterol efflux they 
would be more apparent than in studies performed in cholesterol-loaded 
macrophages. Secondly, by investigating the effects of HDL on normo-
cholestrolemic macrophages the potential for HDL as anti-inflammatory 
therapeutic in diseases other than atherosclerosis was also indirectly 
assessed. Understanding the molecular mechanism of how HDL is anti-
inflammatory in macrophages, such as how it may be negatively regulating 
TLR activation, may provide more insight into TLR activation itself and provide 
new targets for drug development. Finally, understanding the biology of HDL 
in the context of macrophage activation will further contribute to both the fields 
of innate immunity and macrophage metabolism. 
 
Therefore, whether HDL inhibited TLR-induced pro-inflammatory cytokine 
production in normo-cholesterolemic macrophages and therefore beneficial 
for treating inflammatory diseases beyond atherosclerosis was investigated. 
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As such, the specific aims of this project were: 
1. To characterise the effect of HDL on TLR induced pro-inflammatory 
cytokine production in human and mouse macrophages 
2. To define the molecular mechanism of HDL's anti-inflammatory effect 
in macrophages by: 
a. Determining at which level of TLR activation HDL is mediating 
its anti-inflammatory effect. Therefore, the effect of HDL on early 
TLR signalling by assessing ligand-receptor interactions in the 
presence of HDL (e.g. ligand sequestration) and TLR clustering 
and signalling upon HDL mediated cholesterol depletion was 
investigated.  
b. Investigating the genome-wide changes induced by HDL 
treatment, particularly in the context of macrophage activation, 
by microarray analysis 
3. To determine whether HDL is mediating these effects by cholesterol 
depletion, via a particular receptor, or through phospholipid 
metabolism.  
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2. Materials and Methods: 
 
Cell Culture: 
 
PBMCs 
 
Human peripheral blood mononuclear cells (PBMCs) were isolated from 
human buffy coats obtained from the University Clinic of Bonn blood donation 
service. Buffy coats were diluted 1:1 with PBS (Invitrogen) before being 
layered over Ficoll-Paque plus (GE Healthcare). This was then centrifuged at 
800 x g for 25 min with the brake off, to allow the cells to separate. The PBMC 
layer was then isolated and any contaminating red blood cells lysed by 
hypertonic lysis.  PBMCs were then washed with PBS and low speed 
centrifugations (300 x g for 10 min) until platelets were eliminated. PBMCS 
were then resuspended in RPMI media (Invitrogen/Gibco) supplemented with 
10% Fetal Calf Serum (FCS) and the antibiotic 10µg/ml Ciprobay-500 (Bayer) 
for experiments.   
 
Monocytes 
 
Monocytes were isolated from purified PBMCs using positive selection. 
PBMCs were incubated with CD14-labelled magnetic MACS beads (Miltenyi). 
CD14-positive cells were then isolated from other PBMCs by magnetic 
separation. Isolated monocytes were resuspended in RPMI media 
supplemented with 10% FCS and the antibiotic Ciprobay for experiments.  
 
Thp1s 
 
Thp1s were grown in suspension in RPMI supplemented with 10% FCS and 
Ciprobay in T75 flasks. Thp1s were counted, plated and differentiated with 
500 nM phorbol 12-myristate 13-acetate (PMA) (Sigma). After 3 h the media 
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on the cells was changed, and cells were left to rest overnight before 
stimulation the following day. 
 
HEK-TLR4-CFP 
 
Human Embryonic Kidney (HEK) cells stably expressing TLR4-cyan 
fluorescent protein (CFP) (126) were grown in DMEM (Invitrogen/Gibco) 
supplemented with 10% FCS and Ciprobay in T75 flasks. Cells were 
passaged by removal of media, incubation with Trypsin-EDTA, and 
dislodgement of adherent cells by light tapping. The trypsin was then 
inactivated by FCS-containing DMEM and cells passaged into fresh flasks. 
 
Immortalised BMDMs 
 
Immortalised mouse BMDMs were generated as described previously (127).  
Cells were grown in DMEM supplemented with 10% FCS and Ciprobay in T75 
flasks. Cells were passaged by first removing media from adherent cells, 
washing cells with PBS, then incubating adherent cells with Trypsin-EDTA 
(Invitrogen/Gibco) for 5 min at 37°C. Cells were then dislodged by light 
tapping and trypsin inactivated by addition of FCS containing DMEM and 
passaged into fresh flasks.  
 
Primary BMDMs  
 
Femurs and tibias from 6 - 8 week old C57BL/6 male mice, or age and sex 
matched wild type and ATF3-/- mice, were isolated and any associated muscle 
and tissue was removed using 70% ethanol. Bones were cut sterile at both 
ends and bone marrow flushed using a 25G needle and DMEM supplemented 
with 10% FCS and Ciprobay. Bone marrow was collected and pelleted (5 min 
at 340 x g), resuspended in 1 ml of DMEM (as above) supplemented with 
either 20% L929 supernatant or 40 ng/ml M-CSF (R & D Systems), and 
filtered through a 70 µm Nylon cell strainer. BMDMs were differentiated over 7 
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days in 20 ml of media in T175 flasks. Adherent BMDMs were harvested by 
removing media, washing cells in PBS and then incubating cells at 4°C for 10 
min in cold PBS supplemented with 2 % FCS and 2 mM EDTA. Gentle 
tapping dislodged cells and scraping dislodged any remaining adherent cells. 
Cells were collected, pelleted (5 min at 340 x g) and resuspended in DMEM 
with 10% FCS and Ciprobay and plated for experiments.  
 
 
Ligand Receptor Purchased 
from 
Stock 
Concentration 
Working 
Concentration 
P3CSK4 TLR 2 Invivogen 1mg/ml in H20 100-1000ng/ml 
(human) 25-200 ng/ml 
(mouse) 
Poly I:C TLR 3 Invivogen 1mg/ml in H20 
(heat to 70°C for 10 
min before use) 
1µg/ml (mouse) 
LPS  
(E. coli 
0111:B4 
TLR 4 Invivogen 1mg/ml 500 pg/ml (human) 
10-100ng/ml (mouse) 
R848 TLR 7/8 Invivogen 1mg/ml 25-100 ng/ml (human) 
5 ng/ml (mouse) 
HKSC  Dectin-1 Invivogen 109 cells/ml 5 x 106/ml (human) 
CMA STING(murine) Sigma  200mg/ml 500µg/ml (mouse) 
IL-1β IL-1R R & D 
Systems 
100 µg/ml 3 ng/ml (human) 
TNF TNFR R & D 
Systems 
100 µg/ml 10 ng/ml (human) 
 
Table 2.1: Ligands used in the study 
 
Phosphorothioate-backbone modified CpG DNA oligonucleotides for 
stimulating TLR9 were purchased from Metabion. 
 
 
CpG Name Sequence Stock 
concentration 
Working  
Concentration 
1826 (Mouse 
type B) 
5’-TCCATGACGTTCCTGACGTT-3’ 1mM 100nM 
2216 (Human 
type A) 
5’-GGGGGACGATCGTCGGGGGG-3’ 1mM 1000 nM 
Table 2.2: CpG sequences used in this study. 
 
 
Inhibitor Source Stock 
Concentration 
Working 
Concentration 
Bafilomycin Biomol 160 µM 10-100nM 
NH4Cl Sigma 5M 20 mM 
Akt IV Inhibitor (From AG 
Hornung,IMMEI) 
8.14 mM 5 µM 
Table 2.3: Inhibitors used in this study. 
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HDL and Cyclodextrin: 
Reconstituted HDL was prepared by dialysis of soybean phopshatidylcholine 
against purified human ApoA1 at a protein: phospholipid ratio of 1:160 was 
prepared as described previously (61) by CSL-Behring. Cholesterol 
reconstituted HDL (cHDL) was prepared as for HDL, but with a protein: 
phospholipid: cholesterol ratio of 1:95:11 and was also from CSL-Behring. 
Commercial HDL was purchased from Meridian Life Sciences; catalogue 
number A95132H, having been purified from human normo-lipidemic plasma 
by ultracentrifugation. 2-hydroxypropyl-β-Cyclodextrin was from Cyclodextrin 
Technologies Development and was reconstituted in water to a concentration 
of 100 mM.  
ELISAs 
Human ELISAs: 
 
PBMCS were plated at 5 x 105 cells per well of a 96-well plate and stimulated 
in a total volume of 100 µl. Thp1s were plated at 1 x 105 cells per well, and 
differentiated in the well with PMA, and were stimulated in a total volume of 
100 µl. HMDM and CD14+ monocytes were plated at 1 x 105 cells per well and 
stimulated in a total volume of 100 µl. After stimulation, supernatants were 
collected by centrifugation at 340 x g for 5 min.  IL-6, TNF and CCL5 
(RANTES) ELISAs were from R & D Systems.  ELISA plates (NUNC, 
Maxisorp Imunoplates, Thermo Scientific) were coated overnight at room 
temperature with coating antibody diluted in PBS in 50 µl. Plates were then 
blocked in reagent diluent (1% bovine serum albumin - BSA - in PBS) for 
approximately 2 h before incubation with supernatants or standards. 
Supernatants were all diluted 1:2 in 50 µl for analysis. After 2 h incubation at 
room temperature, plates were washed and incubated with detection antibody 
in 50 µl of reagent diluent, followed by incubation with streptavidin HRP 
(diluted 1:200 in reagent diluent). ELISAs were then developed with TMB 
substrate (R & D Systems), the reaction stopped with 2 N Sulfuric Acid and 
absorbance at 450 nm read on the Spectramax i3 (Molecular Devices).  
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Human IFNα ELISAs were from eBiosciences. Briefly, ELISA plates were 
coated in 50 µl coating antibody (1 µg/ml) in PBS overnight. Plates were then 
blocked in Assay buffer (0.5% BSA with 0.05% Tween) for 2 h before 
incubation with supernatants, standards and HRP-Conjugate all together. 
Either 40 µl of undiluted supernatant or standard was added directly to wells, 
along with 10 µl of HRP-Conjugate  (secondary antibody conjugated directly 
to horseradish peroxidase; diluted 1:1000 in assay buffer) and subsequently 
incubated for 2 h shaking at room temperature. Wells were then washed three 
times and ELISAs were developed with TMB substrate, stopped with 2 N 
Sulfuric Acid and absorbance at 450 nm read on the Spectramax i3.  
 
Human IL-8 ELISAs were from BD Biosciences. Briefly, ELISA plates were 
coated with 50 µl coating antibody diluted in coating buffer (0.1M Sodium 
Carbonate pH 9.5) overnight at 4°C. Plates were then blocked in assay buffer 
(10% FCS in PBS) for 2 h, before supernatants and standards were added 
(undiluted) for 2 h at room temperature. Plates were then incubated for 1 h at 
room temperature with "Working Detector" reagent (secondary antibody with 
HRP conjugate) in assay buffer. ELISAs were developed with TMB substrate, 
stopped with 2 N Sulfuric Acid and absorbance at 450 nm and 570 nm read 
on the Spectramax i3.  
 
Mouse ELISAs: 
 
Differentiated primary BMDMs and immortalised BMDMs were plated at 1 x 
105 cells per well of a 96-well plate and stimulated in a total volume of 100 µl.  
Mouse IL-6, IL-12 and TNF ELISAs were from R & D Systems, and were 
performed as described for the human R & D Systems ELISAs described 
above.  
 
Murine IFNβ ELISAs were performed according to a protocol from Professor 
Kate Fitzgerald (University of Massachusetts Medical School, USA). Briefly, 
ELISA plates were coated with 50 µl of 1µg/ml antibody (Rat anti-Mouse IFNβ 
from US Biological) in PBS, at 4°C overnight. Plates were then blocked in 
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assay buffer (1% BSA in PBS) for 2 h at room temperature. Standards 
(recombinant mouse IFNβ from PBL) and supernatants (not-diluted) were 
incubated at 4°C overnight. Plates were washed and subsequently detection 
antibody at a final concentration of 40 ng/ml (PBL Rabbit polyclonal antibody 
against mouse IFNβ) was added in assay buffer, and incubated at room 
temperature for 4 h. HRP-conjugated anti-rabbit antibody (Jackson 
ImmunoResearch) was diluted 1:10 000 in assay buffer and incubated at 1.5 
h at room temperature. ELISAs were developed with TMB substrate, stopped 
with 2 N Sulfuric Acid and absorbance at 450 nm read on the Spectramax i3.  
 
Receptor Mediated Clustering: 
 
HTA125 TLR4 hybridoma cells were grown for in suspension in DMEM 
supplemented with 10% FCS and Ciprobay for one month and ~ 300 µl 
supernatant was collected during cell passaging over this time.  The 
supernatant was clarified by centrifugation at 340 G for 5 min, and then 
filtered through a 0.45-micron filter. The HTA125 antibody was then purified 
over a 1 ml Protein A Hi-Trap column (GE Healthcare) using the FPLC as 
described above. Briefly, the column was washed with water and PBS before 
sample was loaded. Once sample was bound, the column was washed with 
PBS, and then the antibody was eluted using 0.1M Citric Acid (pH 3.0). The 
eluted protein was then neutralised with 10x PBS. Antibody purity and 
functionality were assessed using Coomassie stain and flow cytometry. 
Briefly, 2 x 105 HEK 293 cells or HEK 293 cells overexpressing TLR4-yellow 
fluorescent protein (YFP) were incubated with 2 µg of purified HTA125 
antibody (in 3% FCS in PBS). Cells were then washed 3 times and then 
stained with secondary antibody (anti-mouse Alexa 647 at 1:2000).  YFP 
fluorescence was measured on the FITC channel of the LSR 1 FACS 
machine (BD Biosciences), while Alexa 647 fluorescence was measured on 
the APC channel.  
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Figure 2.1: Specificity of HTA125 binding to TLR4, measured by staining of 
HEK293 cells versus TLR4-YFP expressing HEK293 cells. 
 
Clustering ELISAs: 
 
Sterile high-protein ELISA (Co-Star, Corning) plates were coated with 
HTA125 in PBS overnight at 4°C. Wells were washed 3 times with PBS, 
before HEK-TLR-CFP cells were added to antibody coated wells, at 7 x 104 
cells per well. Cells were also immediately stimulated with HDL or CD, in a 
final volume of 100 µl. After 16 h supernatants were harvested and measured 
by ELISA. 
 
CellTiter-Blue® (CTB) Cell Viability Assay (Promega): 
 
BMDMs were plated at 1 x 105 cells per well of a 96-well plate and stimulated 
in a total volume of 100 µl. Supernatants were removed for ELISA, and cells 
were then incubated with 50 µl of CTB reagent (Diluted 1:10 in DMEM 
supplemented with 10% FCS and Ciprobay) at 37°C for 3 h. Plates were then 
read on the Spectramax i3, with fluorescence measured as follows: excitation 
from 530-570nm and emission from 580-620 nm.  
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Fast Performance Liquid Chromatography (FPLC): 
 
Size exclusion chromatography was analysed using an Äkta Purifier FPLC 
from GE Healthcare. A Superdex S200 10/300 GL column (GE Healthcare) 
was used for size exclusion. Briefly, the column was washed out of storage 
buffer (20% ethanol) with water, and then PBS was washed onto the column. 
Samples were injected onto the column with a flow rate of 0.5ml/minute. 
Absorbance was detected at 280 nm (unlabelled protein) at 505 nm (Bodipyl) 
and at 647 nm (Alexa 647).  40 µg of LPS-Bodipyl (Invitrogen), 10 µg of P3C-
Alexa 647 (self-labelled by Dr Dominic De Nardo) or 2 nmoles of CpG-1826- 
Alexa 647 (Eurofins MWG Operon) were incubated either in PBS alone or 
with 60µg HDL in PBS in a total volume of 50 µl for 2 h at 37°C before being 
run over the column. After the runs, the column was washed again in water 
and then stored in 20% ethanol. 
 
Western Blotting: 
 
1.5 x 106 primary BMDMs or immortalised BMDMs, or 2 x 106 CD14+ human 
monocytes were plated in 12-well plates and stimulated in a final volume of 
500 µl. Cells were placed on ice, washed once with ice cold-PBS and 
subsequently lysed with 200µl 1x RIPA buffer (20 mM Tris-HCl pH 7.4, 150 
mM NaCl, 1 mM EDTA, 1% Triton X-100, 10% glycerol, 0.1% SDS, 0.5% 
deoxycholate) supplemented with 0.1 µM PMSF, cOmplete protease inhibitors 
and PhosSTOP (Roche Biochemicals). Lysates were incubated on ice for 30 
min, before clarification by centrifugation at 13,000 x g for 10 min at 4°C. 
Protein concentrations were measured by BCA assay (Pierce). An equal 
amount of protein per sample was then run on 4-12% pre-cast SDS-PAGE 
gels (Novex, Invitrogen) with MES or MOPS buffer (Novex, Invitrogen). The 
separated proteins were then transferred onto PVDF membranes (Millipore) 
and blocked in 3% BSA in Tris Buffered Saline with Tween-20 before 
overnight incubation with specific primary antibodies. The following day, 
membranes were washed and incubated with the appropriate secondary 
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antibodies, and immunoreactivity was observed by near-infrared detection 
(Odyssey, LI-COR). 
 
Antibody Secondary 
Antibody 
Dilution Purchased From 
phospho p38 MAPK Thr180/Tyr182 anti-rabbit 1:1000 Cell Signalling 
phospho SAPK JNK Thr183/Tyr185 anti-rabbit 1:1000 Cell Signalling 
IκB-alpha (L35A5)  (N-term. Antigen) anti-mouse 1:1000 Cell Signalling 
phospho NFκB p65 Ser536 anti-rabbit 1:1000 Cell Signalling 
NFκB p65 anti-rabbit 1:1000 Cell Signalling 
Phospho-Akt (Thr308) anti-rabbit 1:1000 Cell Signalling 
ATF-3 (C-19) Antibody anti-rabbit 1:200 Santa Cruz 
poly (ADP-ribose) polymerase (PARP) anti-mouse 1:500 Trevigen 
β-Actin anti-mouse 1:1000 Li-Cor Biosciences 
β-Tubulin anti-rabbit 1:1000 Li-Cor Biosciences 
 
Table 2.4: Antibodies used for western blotting in this study. 
Nuclear and Cytoplasmic Extract Preparation 
 
BMDMs were plated at 20 x 106 cells per well of a 10 cm dish. Cells were 
stimulated in a total volume of 1ml. Media was removed and cells were 
washed twice in PBS and harvested in 700 µl PBS. Cells were pelleted by 
centrifugation and then lysed in 500 µl cytoplasmic lysis buffer (10 mM 
HEPES pH 7.4, 1.5 M MgCl2 and 10 mM KCl with 0.1% NP-40) supplemented 
with 0.1 µM PMSF and cOmplete protease inhibitors (Roche) before intact 
nuclei were separated from cytoplasmic content by centrifugation at 2000 x g 
for 10 min at 4°C. Supernatants were harvested as the ‘cytoplasmic extract’. 
Nuclei were washed with cytoplasmic lysis buffer, before being lysed in 150 µl 
nuclear lysis buffer (20 mM HEPES pH 7.8, 420 mM NaCl, 20% glycerol, 0.2 
mM EDTA and 1.5 mM MgCl2) for 10 min on ice and then centrifuged at 
>13,000 x g for 15 min at 4°C. The supernatant was then harvested as the 
‘nuclear extract’. Protein content of cytoplasmic and nuclear extracts was 
determined by BCA assay (Pierce). Protein was then subjected to 
immunoblotting as described above. β-tubulin was used as a cytoplasmic 
loading control while PARP was used as a nuclear loading control.  
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Quantification of cellular cholesterol. 
 
BMDMs, HEKs or CD14+ monocytes were plated as described for the 
ELISAS. After supernatants had been removed for ELISA, cells were lysed in 
1x RIPA buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% 
Triton X-100, 10% glycerol, 0.1% SDS, 0.5% deoxycholate) and cholesterol 
content was measured using the Amplex® Red Cholesterol Assay Kit 
(Invitrogen) according to manufacturer’s instructions.  
 
Quantification of sterols by mass spectrometry. 
 
Immortalised BMDMs were plated at 3 x 106 cells and stimulated in 1 ml. 
Tissue culture supernatants and cells were then collected before being 
processed and subjected to Gas chromatography-mass spectrometry-
selected ion monitoring (GC-MS-SIM) to determine cholesterol and 
cholesterol precursor levels (performed by Anja Kerksiek from the Institute for 
Clinical Pharmacology, University of Bonn). 
 
Electromobility Shift Assay (EMSA). 
 
BMDMs were plated at 3 x 106 cells per well of a 6-well dish and were 
stimulated in a total volume of 1ml. Cells were washed twice with ice cold 
PBS and were then gently lysed in buffer I (10 mM Tris pH 7.8, 5 mM MgCl2, 
10 mM KCl, 1 mM EGTA pH7, 5% Sucrose with DTT, cOmplete protease 
inhibitors, 0.6% NP-40) and centrifuged at 2000 x g for 10 min at 4°C. The 
nuclei were then lysed in buffer II (20 mM Tris pH7.8, 5 mM MgCl2, 330 mM 
KCl and 200 µM EGTA pH7, 25% glycerol with DTT and protease inhibitors), 
centrifuged at >13,000 x g for 15 min at 4°C. The supernatant was then used 
as ‘nuclear extract’. Protein content of the nuclear extract was determined by 
BCA assay (Pierce) and 5 µg of nuclear extract was incubated with the 
IRDye-700 NF-κB consensus oligonucleotide (LI-COR) with Poly dI:dC, DTT 
and NP-40 from the Odyssey EMSA buffer kit as per the instructions. 
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Samples were run on a 4% TBE native polyacrylamide gel and bands 
observed by near-infrared detection (Odyssey, LI-COR). 
 
RNA/cDNA analysis. 
 
3 x 106 BMDMs, CD14+ monocytes, isolated Kupffer cells, hepatocytes, non-
parenchymal cells or homogenised tissue samples were lysed and RNA 
isolated with RNeasy or miRNeasy mini kits according to the manufacturer’s 
protocol (Qiagen).  On-column DNAse digestion was performed according to 
kit instructions (Qiagen). RNA concentration and purity was measured using 
the Spectramax i3 (Molecular Devices). Approximately 1 µg of isolated RNA 
from each sample was synthesised into cDNA using an oligo dT(18) primer and 
SuperScript™ III Reverse Transcriptase (Invitrogen) with associated buffer, 5 
mM DTT and 0.5 µM dNTPS  in a final volume of 20 µl. A no reverse 
transcriptase control was included to control for genomic DNA contamination. 
cDNA abundance was measured by quantitative real time PCR (qPCR) using 
the Maxima™ SYBR Green/ROX qPCR 10x Master Mix (Fermentas), along 
with 0.4 µM primers in a final volume of 20 µl in a 996-well plate (Bioplastics) 
on a 7900T thermocycler (Applied Biosystems). Relative mRNA abundance to 
the housekeeping gene HPRT was calculated using the ΔΔCT method 
(Applied Biosystems), using a spreadsheet created by Associate Professor 
Matthew Sweet and Dr Angela Trieu (University of Queensland, Australia).  
 
Gene specific qPCR primers were designed across exon boundaries to avoid 
amplification of genomic DNA, with minimal potential secondary structure (e.g. 
primer dimer or hairpin formation) with high specificity for the target gene (to 
improve efficiency and accuracy) with an optimal temperature of 63°C. 
Primers amplified between 100 and 150 bp of the specific gene. Primer 
specificity and secondary structure were subsequently assessed by melt 
curve analysis to ensure that primers were optimal.  
 
. 
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Gene Forward Primer (5' to 3') Reverse Primer (5' to 3') 
Il6 CCAGAAACCGCTATGAAGTTCC CGGACTTGTGAAGTAGGGAAGG 
Tnf CCAAATGGCCTCCCTCTCAT TGGTGGTTTGCTACGACGTG 
Il1b TTGACGGACCCCAAAAGATG CAGCTTCTCCACAGCCACAA 
Ifnb CCAGCTCCAAGAAAGGACGA TGGATGGCAAAGGCAGTGTA 
Atf3 GAGCTGAGATTCGCCATCCA CCGCCTCCTTTTCCTCTCAT 
Klf7 GGGTTTCTCCTCCGGTTTTG ATGTCTGCTGCCAGGTCTCC 
Stat1 AAGCACCAGAACCGATGGAG GGGAAGCAGGTTGTCTGTGG 
Irf7 AAGCTGGAGCCATGGGTATG CGATGTCTTCGTAGAGACTGTTGG 
Il12b GGAAGCACGGCAGCAGAATA AACTTGAGGGAGAAGTAGGAATGG 
Ch25h TGACCTTCTTCGACGTGCTG AGCCAAAGGGCACAAGTCTG 
Lss1 AGGCTGGGGAGAGGACTTTG TGAGCAGTGATGTCGGGATG 
Isg15 TGTGAGAGCAAGCAGCCAGA CCCCCAGCATCTTCACCTTT 
Usp18 AGAGAGCAGCAGGAGGAGCA TTTGGGCTGGACGAAACATC 
Hprt TGAAGTACTCATTATAGTCAAGGGCA CTGGTGAAAAGGACCTCTCG 
 
Table 2.5: mouse qPCR primers used in this study 
 
Gene Forward Primer (5' to 3') Reverse Primer (5' to 3') 
TNF CCCAGGCAGTCAGATCATCTTC TCTCTCAGCTCCACGCCATT 
IL6 TGAGGAGACTTGCCTGGTGAA TGCACAGCTCTGGCTTGTTC 
ABCG1 GCTCCTGTTCTCGGGGTTCTT CCCCTTCGAACCCATACCTG 
ATF3 
Isoform 1 
CCAACCATGCCTTGAGGATAA GGCAAGGTGCTGAAAATCCTT 
ATF3 
Isoform 2 
TGGGTCCAGAAGACCTGCAT AAACCCTGGTGATGCCACAG 
HPRT TCAGGCAGTATAATCCAAAGATGGT AGTCTGGCTTATATCCAACACTTCG 
 
Table 2.6: Human qPCR primers used in this study. 
Genome-wide transcriptome assessment by microarray. 
 
BMDMs were plated at 3 x 106 cells per well of a 6-well dish and were 
stimulated in a total volume of 1ml. Total RNA was purified using the MinElute 
Reaction Cleanup Kit (Qiagen) prior to array based gene expression profiling. 
By using the TargetAmpTM Nano-gTM Biotin-aRNA Labeling Kit for the Illumina 
System (Epicentre), biotin-labelled cRNA was generated. The biotin-labelled 
cRNA (1.5 µg) was hybridised to MouseWG-6 v2.0 Beadchips (Illumina) and 
scanned on an Illumina iScan system. All Arrays and Data analysis were 
performed Prof. Joachim Schultze and Colleagues and are detailed in (128) 
Chromatin Immunoprecipitiation (ChIP) Assays: 
ChIP-PCR 
 
ChIP for ATF3 was performed using the EZ-Magna ChIP G Kit (Millipore) 
according to the manufacturer’s instructions. WT BMDMs were plated at 1x 
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106 cells per 10 cm dish. Cells were then cross-linked with 1% 
paraformaldehyde, which was then quenched with 0.1M Glycine. Cells were 
then washed twice with PBS, before being lysed and chromatin sheared by 
sonication for 30 min with the Covaris S220 in a volume of 130 µl. An aliquot 
of 'input' sheared DNA was kept for normalising samples. Immunoprecipitation 
was performed over night at 4°C using 2.5 µg of rabbit polyclonal anti-ATF3 
antibody (C-19X, Santa Cruz) or Rabbit sera (Cell Signalling) as an isotype 
control. After washing, eluted samples were reverse cross-linked and 
RNaseA- and proteinase-K-treated as per the manufacturer’s 
recommendations. DNA was subsequently purified using spin columns 
included in the kit, and qPCR using the primers detailed in Table 2.3 used to 
assess the enrichment of specific DNA binding within immunoprecipitated 
DNA compared to input DNA.  
 
Gene Region of 
genomic 
locus 
Forward (5' to 3') Reverse (5' to 3') 
Il6 ATF3 site in 
promoter 
AGGGCTAGCCTCAAGGATGACT GTGGGGCTGATTGGAAACCT 
Il6 1kb 
downstream 
of ATF3 site 
TGGCACAGACCCTTCCAGAT AACGATAAAAACTGCCCAGCAT 
Il2ra Intron TACTGCCCACACTAGAAGTTCCG CAGGCATAAGTTCCATATCAGGC 
Il2ra Promoter GACACTATGAGAGAAGGCAAAGGG ACACCTCGGTATTGGTTCACTCC 
 
Table 2.7: Primers used to detect specific promoter sites in ChIP analysis. 
  
ATF3 ChIP Sequencing (ChIP-seq) 
 
ChIP for ATF3 was performed using the EZ-Magna ChIP G Kit (Millipore) 
according to the manufacturer’s instructions. In brief, three biological 
replicates of BMDMs from WT and Atf3-deficient mice were treated with HDL, 
CpG, HDL then CpG or left untreated. Cells were then cross-linked with 1% 
paraformaldehyde, before being lysed and chromatin sheared by sonication 
for 30 min with the Covaris S220. Immunoprecipitation was performed over 
night at 4°C using 2.5 µg of rabbit polyclonal anti-ATF3 antibody (C-19X, 
Santa Cruz). After washing, eluted samples were reverse cross-linked and 
RNaseA- and proteinase-K-treated as per the manufacturer’s 
recommendations. ChIP fragments were ligated to NEXTflex ChIP-Seq 
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barcode adaptors using the NEXTflex ChIP-Seq Kit (both Bio Scientific). 
Adaptor ligated DNA fragments were size selected (150–250 bp), PCR 
amplified, further size selected (150–250 bp), pooled, and sequenced on an 
Illumina HiSeq-1000 sequencer according to the manufacturer’s instructions. 
 
ChIP-Seq analysis 
 
Reads were aligned to the UCSC mm9 reference mouse genome, using 
Bowtie 0.12.8_ENREF_1. After ChIP-Seq quality control using HOMER v4.2 
(http://biowhat.ucsd.edu/homer), reads of biological replicates were pooled, 
and peak identification was performed using MACS 1.4.2 with the samples 
from Atf3-deficient BMDMs set as unspecific background to identify specific 
ATF3 binding. Afterwards, HOMER v4.2 was used to annotate the genomic 
location of identified peaks. To generate histograms for the distribution of tag 
densities, position-corrected tags in 5 bp windows were normalised using 
Java-genomics-toolkit (http://palpant.us/java-genomics-toolkit/) and the Atf3-
deficient tags subtracted from the WT tags. For visualisation, only enrichment 
in WT cells is depicted. Tag coverage of HDL-specific peaks relative to 
genomic TSS sites was calculated for WT and Atf3-deficient BMDMs for all 
conditions using HOMER v4.2. 
 
Atherosclerosis mouse model. 
 
Apoe-deficient mice were fed a Western diet (1.25% Cholesterol) for 8 weeks.  
During week 8, mice were injected intravenously (i.v.) two times with HDL 
(100 mg/kg) or PBS 4 days apart before the animals were sacrificed and 
livers, aortic roots and Kupffer cells collected for RNA isolation and mRNA 
analysis by qPCR as described above. 
 
Isolation of Kupffer Cells, non-parenchymal cells and hepatocytes 
 
WT mice, (6-8 week old male) were injected i.v. with HDL (100 mg/kg) for 12 
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h. Livers were perfused via the portal vein with a solution of 0.05% 
collagenase (Sigma-Aldrich), a portion removed for direct RNA analysis, then 
mechanically disrupted, filtered through mesh (300 µm) and centrifuged at 
300 rpm for 5 min. The hepatocyte cell pellet and the supernatant containing 
non-parenchymal liver cells were separated and washed once with Hank’s 
Balanced Salt Solution. Non-parenchymal liver cells were labelled with anti-
CD11b antibody-labelled MACS microbeads and purified using 
immunomagnetic separation (Miltenyi). 
 
Fluorescent labelling of HDL 
 
HDL was labelled using Alexa Fluor Succinimidyl Esters (Invitrogen) - either in 
pHrodo or Alexa 488 according to manufacturers instructions. 20 mg/ml HDL 
in 0.1M sodium bicarbonate buffer (pH 8.3) was labelled with 50 µl of dye (10 
mg/ml in DMSO) and incubated at room temperature for 1 h with continuous 
stirring.  The labelled HDL was then purified over a PD MidiTrap G-25 column 
(GE Healthcare), which had been equilibrated into PBS. Approximately 2 ml of 
10 mg/ml labelled HDL was purified. 
 
Immunofluorescence:  
 
BMDMs were plated in a 4-chamber glass bottomed dish at 7 x 105 cells per 
chamber. Cells were stimulated in a total volume of 100 µl. Fluorescent HDL 
was washed away (2 washes in cell culture medium) before 50 nM 
Lysotracker (red or green) (Invitrogen) and 500 ng/ml Alexa 647 labelled 
Choleratoxin B were added to the media and cells were imaged immediately. 
A Leica TCS SP5 SMD confocal system (Leica Microsystems) was used for 
confocal laser-scanning microscopy. The temperature was maintained at 37 
°C with 5% CO2 through the use of an environmental control chamber (Life 
Imaging Services and Solent Scientific).  Images were acquired with a 63× 
water objective, using a sequential scan, with lasers and PMTs detailed 
below, at a pixel size of 512 x 512 with line average of 4. Acquired images 
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were analysed with Leica Application Suite Advanced Fluorescence imaging 
platform, version 2.2.1 (Leica Microsystems), or Volocity 6.01 software.  
. 
Dye Laser Laser 
Power 
PMT Sequential 
Scan 
Alexa 488/Lysotracker 
Green 
488 Laser 19 % PMT 1 (490 - 555 nm) 1 
pHrodo/Lysotracker 
Red 
561 Laser 24 % PMT 3 (575-630 nm) 2 
Alexa 647 633 Laser 24 % PMT 5 (645- 800 nm) 1 
  
Table 2.8. Confocal microscopy settings used for image acquisition 
Flow Cytometry 
 
Immortalized BMDMs were plated in 24 well plates at 3 x 105 cells per well 
and stimulated in a total volume of 500 µl. Cells were washed twice with PBS 
and then resuspended in PBS with 0.5% FCS and sodium azide. Cells were 
then assayed by flow cytometry using a Miltenyi MACS Quant, with pHrodo 
fluorescence measured on the Y1 Channel (561 nm laser with a 586/15nm 
filter). Voltages were set based on unstained cells. A minimum of 50 000 
events were recorded.  
 
Lipidomics: 
 
BMDMs were plated at 9 x 106 cells per 10cm dish and stimulated with HDL in 
a total of 10 ml of medium (DMEM with 10% FCS and Ciprobay). After the 
stimulation, supernatants were removed to 15ml falcon tubes. Cells were then 
washed twice with ice-cold PBS, before they were harvested in 1 ml ice-cold 
PBS and transferred to eppendorf tubes. Cells were pelleted at 800 x g for 5 
min at 4°C and excess PBS removed. Supernatants and cell pellets were then 
snap frozen and stored at -80°C before being sent to the Kansas Lipidomics 
Research Center (courtesy of Assistant Professor Michael Fitzgerald, 
Harvard) for further analysis.  
 
Statistics. 
Data are typically represented as mean values ±S.E.M, where a p value of 
<0.05 was considered significant as determined by a Student’s t test; or as 
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described in individual figure legends. Analyses were performed with Excel 
(Microsoft), Prism (GraphPad Software, Inc.), or for microarray data with 
Partek Genomics Suite (Partek) using ANOVA-models. 
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3. Results: HDL inhibits TLR-induced cytokine expression in 
macrophages 
 
Introduction 
 
HDL's anti-inflammatory effects in macrophages have to date been poorly 
characterised. In endothelial cells, HDL inhibited cytokine-induced adhesion 
molecule expression in an NFκB dependent manner (100) while monocyte 
activation, as measured by Cd11b expression, was also inhibited by HDL, and 
this was associated with decreased lipid rafts (105). Studies in mice with 
ABCA1- and ABCG1-deficient macrophages show that these macrophages 
are unable to efflux cholesterol efficiently to HDL (66) and are hyper-
inflammatory in response to TLR ligands (120). However, the direct effect of 
HDL on macrophage activation by TLRs has not been studied. Furthermore, 
the effect of HDL on normo-cholesterolemic macrophages is also of interest, 
as HDL is also anti-inflammatory in disease settings not associated with 
excess cholesterol (94-96). I therefore investigated the effect of HDL on TLR- 
induced macrophage activation. 
 
HDL inhibits TLR-induced cytokine release in human monocytes and 
macrophages. 
 
To investigate whether HDL blocks TLR-induced pro-inflammatory cytokine 
release, I examined the effect of HDL on primary human immune cells; 
namely peripheral blood mononuclear cells (PBMCs) isolated from blood. This 
mixed cell population is comprised of approximately 70-90% lymphocytes 
(e.g. T cells, B cells and NK cells), 10% monocytes and 1-2% dendritic cells 
(DCs). TLRs are expressed on all of these cell types (129) 	  
(130, 131), but much of the pro-inflammatory cytokine response has been 
shown to come from monocytes, while type I IFN is produced predominantly 
by the DC subset, plasmacytoid (p)DCs (132) .  To gage a general anti- 
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Figure 3.1
HDL inhibits TLR-induced cytokine production in human myeloid cells.
A,B) PBMCs were pre-treated with HDL for 6 h at indicated doses before stimulation with TLR 
ligands (at indicated doses) for 16 h. Cytokines in supernatants were measured by ELISA. 
Graph shows mean of three independent donors with S.E.M. C,D) Human monocyte derived 
macrophages (HMDMs) were pre-treated with HDL at indicated doses for 2 h and then 
stimulated with P3C (125 ng/ml or indicated doses) HKSC (5 x 106) LPS (625 pg/ml) and 
R848 (50 ng/ml) for 16 h. Cytokines in supernatants were measured by ELISA. Data points 
show individual donors and mean from two independent donors. D, E) Thp1s were differenti-
ated for 3h with 0.5μM PMA before pre-treatment with HDL (2 mg/ml) for 2 h and subsequent 
stimulation with indicated doses of Flagellin (D) or IL-1β (E). Cytokines in supernatants were 
measured by ELISA. Graph shows mean of three independent experiments with S.E.M.
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inflammatory response, I first investigated the effect of HDL pre-treatment on 
TLR-induced IL-6 and TNF cytokine secretion from PBMCs. Cells stimulated 
with the synthetic TLR2 ligand; Pam3CysK4 (P3C), the TLR4 ligand; LPS, or 
the synthetic TLR7/8 ligand; R848, secreted high amounts of IL-6, as 
measured by ELISA. This IL-6 response was inhibited in a dose dependent 
manner by HDL pre-treatment (Figure 3.1 A). TLR9 is primarily expressed on 
human B cells and pDCs  (132) and PBMC stimulation with the synthetic 
TLR9 ligand oligonucleotide 2336, a Type A CpG DNA, induces strong IFNα 
secretion, presumably from the pDC population. Similar to its effect on the 
other TLR ligands tested, HDL dose-dependently inhibited the release of IFNα 
from CpG A-stimulated PBMCs (Figure 3.1B).  As macrophages are key 
mediators of the pro-inflammatory response, I investigated the effect of HDL 
on TLR-induced TNF secretion from primary human monocyte-derived 
macrophages (HMDMs). HMDMs were derived in vitro by culturing isolated 
monocytes for 3 days in the presence of GM-CSF. Stimulation of HMDMs with 
either P3C, LPS or R848 induced TNF release, as did stimulation with Heat 
Killed S.Cerevisae (HKSC), a preparation of yeast that activates the C-type 
Lectin receptor Dectin-1 (133).  HDL co-treatment reduced TNF release from 
HMDMs (Figure 3.1 C) in response to all of these agonists, indicating that 
HDL is indeed anti-inflammatory on the immune cell populations present in 
PBMCs as well as on mature macrophages.  Furthermore, HDL also reduced 
P3C-mediated induction of IL-6 and the chemokine CCL5 (RANTES) in 
HMDM, indicating that the effect is also apparent across several pro-
inflammatory cytokines (Figure 3.1 D). To investigate whether HDL also 
blocks cytokine production in response to the TLR5 ligand Flagellin, I 
stimulated a human monocytic cell line, Thp1 cells, with Flagellin and HDL. 
Again, HDL dose-dependently inhibited Flagellin-induced TNF secretion 
(Figure 3.1 E).  
 
IL-1β is a key inflammatory cytokine that is produced in response to microbial 
challenge and upon sterile inflammation. It amplifies the inflammatory 
response by signalling through the IL-1β receptor (IL-1R), which shares 
homology with the TLRs in its cytoplasmic TIR domain. IL-1R signalling also 
results in NFκB activation and pro-inflammatory gene expression and cytokine  
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Figure 3.2
HDL inhibits TLR-induced cytokine production in mouse macrophages.
A) BMDMs were pre-treated with HDL (2 mg/ml) or media alone (-) for 6 h before 
stimulation with P3C (50 ng/ml), LPS (100 ng/ml), R848 (500 ng/ml) or CpG (100 nM) 
overnight. Cytokines in supernatants were measured by ELISA. Graphs show the 
mean of three independent experiments with S.E.M. This experiment was performed 
by Dr Dominic De Nardo. B) BMDMs were pre-treated with indicated doses of HDL for 
6 h before overnight stimulation with P3C of CpG at indicated doses. Cytokines in 
supernatants were measured by ELISA. Graphs show the mean of three independent 
experiments with S.E.M. This experiment was performed together with Dr Dominic De 
Nardo. C) BMDMs were treated with HDL overnight and cell viability was assayed 
using Cell Titre Blue assay (CTB). Data shows the mean of three independent experi-
ments with S.E.M. This experiment was performed by Dr Dominic De Nardo. 
56
	   57	  
(e.g. TNF) release (134).  I therefore investigated whether HDL could block IL-
1β induced TNF release from Thp1 cells. Indeed, HDL dose-dependently 
inhibited IL-1β induced TNF release (Figure 3.1 F). Therefore, HDL was able 
to block pro-inflammatory cytokine production from PBMCs, HMDMs and 
Thp1s in response to TLR2,4,5,7/8,9 and Dectin-1 ligands, as well as IL-1β. In 
addition, this inhibitory effect of HDL was consistent across a number of pro-
inflammatory cytokines (IL-6, TNF, CCL5, and IFNα) indicating that HDL is 
broadly anti-inflammatory at numerous levels.  
 
 
HDL blocks TLR-induced pro-inflammatory cytokine release in mouse 
macrophages: 
 
Murine systems provide a useful model for studying inflammation, allowing for 
easier manipulation of cells and genes. Thus, the effect of HDL on primary 
murine bone marrow-derived macrophages (BMDMs) was investigated. 
Mouse macrophages, unlike human macrophages, express TLR9 and 
produce pro-inflammatory cytokines in response to the synthetic 
oligonucleotide 1826, a type B CpG. As with human monocytes and 
macrophages, HDL blocked the induction of various key pro-inflammatory 
cytokines, including IL-6, IL-12 and TNF in response to P3C, LPS, R848 and 
CpG in BMDMs (Figure 3.2 A).  Furthermore, this effect was dose-dependent 
(Figure 3.2 B).  To confirm that HDL's effect was not due to decreased cell 
viability, a cell titre blue (CTB) assay was performed. In this assay, viable cells 
are able to enzymatically process the redox dye resazurin into the fluorescent 
end product resorfin, which is subsequently measured as a marker for cell 
viability. Indeed, HDL did not appear to affect the viability of the macrophages 
(Figure 3.2 C), indicating that HDL has an anti-inflammatory effect without 
compromising the overall health of the cells. An overview of the effect of HDL 
on TLR induced pro-inflammatory cytokine production in various cell types is 
given in Table 3.1. 
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TLR/PRR  Ligand Ligand Composition Cell Type Cytokine Reduced 
by HDL 
2 P3C Synthetic triacylated 
lipopeptide 
PBMC, HMDM, 
BMDM 
IL-6, IL-12, 
TNF, CCL5 
Yes 
4 LPS Lipid moiety with sugar 
tail 
PBMC, HMDM, 
BMDM 
IL-6, IL-12, 
TNF 
Yes 
5 Flagellin 32 kDa protein Thp1 TNF Yes 
7 and/or 8 R848 Small imidazoquinoline 
compound (base 
analog) 
PBMC, HMDM IL-6, IL-12, 
TNF 
Yes 
9 CpG A 
(human), 
CpG 
(mouse) 
Synthetic 
oligodeoxynucleotides 
containing CpG motifs 
PBMC, BMDM IFNa, IL-6, 
IL-12, TNF 
Yes 
Dectin-1 HKSC Whole yeast  HMDM TNF Yes 
IL-1R IL-1b 17.5kDa protein Thp1 TNF Yes 
 
Table 3.1: Summary of experiments in Figures 3.1 and 3.2 and overall effects of HDL on 
TLR-induced cytokine release in mouse and human immune cells. 
 
HDL directly binds and sequesters LPS, but not CpG or P3C. 
 
HDL's ability to bind and sequester LPS is well documented (88). However, as 
HDL is able to inhibit cytokine induction by a variety of structurally distinct TLR 
ligands including protein, DNA, and small molecules as well as lipid-based 
ligands, HDL may be having an effect beyond ligand sequestration.  I 
therefore analysed whether HDL can bind directly to P3C and CpG as well as 
to LPS.  I incubated fluorescently labelled LPS (LPS- Bodipyl), P3C (P3C-
Alexa-647) or CpG 1826 (CpG - Alexa 647) with HDL for 2 h at 37°C before 
running them over an S200 size exclusion column. In these size exclusion 
columns, biomolecules are separated by size, with the largest molecules 
eluting first followed by smaller molecules. A UV detector was used to analyse 
the elution of protein (measured by absorbance at 280 nm) or of fluorescent 
ligands (505 nm for Bodipyl, 647nm for Alexa 647).  The elution profile of HDL 
alone was distinct, with 2 clear peaks at approximately 10 ml and 13 ml 
(Figure 3.3 A). This elution profile is consistent with published biochemical 
characterisation of the HDL used, CSL-111, where the two peaks represent 
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the two main fractions which the HDL separates into (61). These fractions 
represent a larger HDL particle of  ~ 600 kDa, with 3-4 ApoA1 molecules per 
particle and a protein - lipid ratio of 1:200, and a second smaller HDL particle 
of about 200 kDa with approximately 2-3 ApoA1 particles and a protein- lipid 
ratio of 1:100 (61). When LPS-bodipyl was run alone over the column, it 
eluted with a peak at approximately 14 ml (Figure 3.3 B). However, when 
LPS-bodipyl was incubated together with HDL before being run over the 
column, the fluorescent profile shifted into the HDL fraction, indicating that 
HDL had bound the LPS, as expected (Figure 3.3 B). In contrast, when 
P3CSK4 - 647 and HDL were run over the column after incubation there was 
no strong shift into the HDL fraction (Figure 3.3 C).  In addition, the 
fluorescent peak for CpG- Alexa 647 did not shift in the presence of HDL, 
indicating that HDL does not bind CpG (Figure 3.3 D). The fluorescent peaks 
at ~ 21 ml present in both the P3C and CpG Alexa 647 runs are likely to be 
free Alexa 647 dye, as the 280 nM profile does not show this second peak.  
This data reflects the ELISA data from Figures 3.1 and 3.2, where HDL 
completely ablates the LPS response at all doses, indicating ligand 
sequestration, while the HDL effect on CpG- and P3C-induced responses are 
less pronounced and more dose-dependent. Therefore HDL may actually 
directly act on the cells themselves, rather than by only sequestering TLR 
ligands. 
 
To confirm this hypothesis, Dr Dominic De Nardo pre-incubated HDL with 
LPS, P3C or CpG for 2 h, and then added them together to cells. He 
hypothesised that if the HDL bound and sequestered the ligand, early 
downstream signalling (e.g. phosphorylation of p38), should be inhibited.  As 
seen in Figure 3.3 E, HDL only inhibited phosphorylation of p38 when 
incubated with LPS, but not with P3C or CpG. Together with Figures 3.3 A-D, 
these data indicate that HDL must also mediate its anti-inflammatory effect 
directly on cells.  As HDL clearly did not sequester CpG, it was chosen as the 
primary TLR ligand for further investigation of HDL's anti-inflammatory effects,  
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HDL binds to and sequesters LPS but not CpG or P3C.
HDL (1 mg/ml) was incubated with either PBS alone (A) or with 40μg of Bodipyl- 
labelled LPS (B), 10 μg of Alexa 647 labelled P3C (C), or with 2 nmoles of Alexa 647 
labelled CpG (D) in a total volume of 50 μl for 2 h at 37°C. Fluorescently labelled 
ligands alone were also incubated in PBS for 2 h at 37°C. The samples were then 
run over an S200 size exclusion column and absorbance profiles were measured. 
Absorbance is measured as milli absorbance units (mAU). Profiles are representa-
tive of three independent experiments. E) HDL or PBS was incubated with LPS (200 
ng/ml), CpG (100 nM) or P3C (50 ng/ml) for 2 h before being added to BMDMs for 
30 mins. Phosphorylation of p38 and β-Actin levels were measured by immunoblot. 
Blot is representative of three independent experiments and densitometry analysis 
shows the mean of three independent experiments with S.E.M. This experiment (E) 
was performed solely by Dr Dominic De Nardo. 
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while P3C and R848 were used to confirm that the HDL effect was not just 
TLR9 specific.  
 
HDL depletes cellular cholesterol and initiates cholesterol biosynthesis 
programs.  
 
Considering that HDL's best characterised property is cholesterol efflux, it 
seemed likely that HDL's anti-inflammatory effect was related to cellular 
cholesterol depletion. Indeed, the current popular hypothesis for the anti-
inflammatory actions of HDL suggests that by depleting membrane 
cholesterol, HDL disrupts lipid rafts, and therefore receptor signalling 
platforms (123). To determine if HDL was indeed depleting cellular cholesterol 
from BMDMs, I analysed cholesterol depletion using an Amplex Red 
cholesterol assay kit. In this assay, cholesterol is oxidised by Cholesterol 
Oxidase to yield H2O2. The H2O2 then reacts with the Amplex Red reagent in 
the presence of horseradish peroxidase (HRP) to produce the fluorescent 
product resorfin. By using a cholesterol standard, the amount of cholesterol 
within a sample can be estimated. As expected, HDL depleted BMDM-
cholesterol in a time-dependent manner, with significant depletion after 2 h 
and strong depletion after 24 h (Figure 3.4 A). This was comparable to 
another cholesterol depleting agent, β-hydroxyl Cyclodextrin (CD) a cyclic 
sugar (Figure 3.4 A).  To maintain cholesterol homeostasis, cells initiate a 
program of cholesterol biosynthesis upon cholesterol depletion. Consistent 
with this, after 2 h of cholesterol depletion by HDL it took between 2 and 6 h 
for cellular cholesterol levels to reach baseline again (Figure 3.4 B).  
 
In collaboration with Professor Dieter Lütjohann from the Institute of Clinical 
Pharmacology (University of Bonn), mass spectrometry was used to measure 
the cholesterol content of immortalised-BMDMs after 2 h HDL treatment. As 
shown in Figure 3.4 C, HDL dose-dependently removed cellular cholesterol, 
which reappeared in the cell supernatants, indicating effective cholesterol 
efflux to extracellular HDL. Mass spectrometry analysis also confirmed that  
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Figure 3.4
HDL depletes cellular cholesterol and activates cellular cholesterol biosyn-
thesis. 
A,B) immortalized wt macrophages were treated with either HDL (2 mg/ml) or 
β-hydroxy cyclodextrin (10 mM) for the indicated times and cellular cholesterol 
was measured using an Amplex Red assay. Cholesterol levels are shown as 
relative to the non-treated control. Graphs show the mean of three independent 
experiments with S.E.M. p values were calculated using a paired, two tailed t 
test. Significance is indicated as follows: *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001.  C) 
BMDMs were treated with HDL at the indicated concentrations for 6 h and 
cholesterol in the cells and cell supernatants was measured by mass spectrom-
etry.  p values were calculated using a paired, two tailed t test. Significance is 
indicated as follows: *p≤ 0.05. D) BMDMs were treated with 2 mg/ml HDL for 
indicated times and cholesterol precursors in the cells and cell supernatants 
were measured by mass spectrometry. (C,D) Graphs show the mean of three 
independent experiments with S.E.M. These cell culture experiments (C,D) were 
performed together with Dr Dominic De Nardo, while Anja Kersiek at the Institute 
for Clinical Chemistry performed the mass spectrometry analysis. 
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HDL treatment corresponded to an increase in the cholesterol precursor 
molecules cholestanol, desmosterol, lanosterol and lathosterol, consistent 
with increased cholesterol biosynthesis (Figure 3.4 D).  
Therefore, HDL, as expected, depleted cholesterol from normo-
cholesterolemic, non-lipid laden macrophages and activated cholesterol 
biosynthesis without impacting cellular viability.  
 
HDL does not inhibit antibody-induced TLR4 receptor clustering in HEK 
cells. 
 
Earlier studies in Human Embryonic Kidney (HEK) cells overexpressing 
human TLR4 showed that IL-8 production can be induced by antibody 
mediated receptor clustering alone, without addition of LPS as a ligand (126).  
In these experiments, a mouse anti-human TLR4 antibody, HTA125, was 
coated on sterile, high binding, 96 well plates, cells were added to the wells, 
and cytokine production measured the next day. Furthermore, TLR4 antibody 
mediated IL-8 production in these cells was enhanced by addition of 
choleratoxin B, presumably because the Choleratoxin B cross-linked the GM1 
proteins present in lipid rafts, causing lipid rafts to cluster with TLR4 and 
thereby enhancing downstream signalling (126). Based on these experiments, 
I hypothesised that if HDL depletes cellular cholesterol to disrupt lipid rafts, 
then it should also inhibit TLR4 antibody-mediated IL-8 production in HEK-
TLR4 cells. HEK cells do not express FC receptors and therefore the effect of 
the antibody should be mediated primarily by cross-linking of the receptor. 
Indeed, no increase in IL-8 production in HEK-TLR4 cells was seen using a 
control anti-TLR2 antibody (126).  A schematic of the hypothesised clustering 
effect is given in Figure 3.5 A.  
 
I assessed TLR4 antibody mediated IL-8 production in HEK-TLR4-CFP cells, 
which respond to LPS when MD2 is also present (Figure 3.5 B), with either no 
treatment, HDL or CD added as the cells were plated onto the antibody 
coated wells. However, while TLR4 antibody mediated cross-linking induced a  
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HDL does not disrupt antibody mediated TLR4 receptor clustering.
A) Schematic of hypothesised receptor mediated clustering. Antibodies or ligands bring the 
extracellular domain of the TLRs into close proximity in cholesterol rich lipid rafts. This 
brings the TIR domains of the TLRs into close proximity, allowing a scaffold for subsequent 
adaptor recruitment (e.g. MyD88, IRAKs) and pro-inflammatory cytokine production. B) 
HEK-TLR4-CFP cells were stimulated for 16 h with 10 μg/ml HTA125 antibody, 10 ng/ml 
LPS or 10 ng/ml TNF in the presence of MD2 supernatant and IL-8 secretion measured by 
ELISA. Graphs shows average + S.D. from one experiment, representative of three inde-
pendent experiments. C,D) Sterile ELISA plates were coated with indicated concentrations 
of anti-TLR4 antibody (HTA125) in PBS overnight. HEK 293 cells stably expressing TLR4-
CFP were plated onto the antibody coated ELISA plates and treated with immediately with 
2 mg/ml HDL or 10 mM CD. After 16 h supernatants were collected and IL-8 measured in 
culture supernatants (C). Graphs show the mean of three independent experiments with 
S.E.M. p values were calculated using a paired, two tailed t test. Significance is indicated 
as follows: *p≤ 0.05. (C). Alternatively cells were lysed in RIPA buffer and cholesterol 
content analysed by Amplex Red assay (D). Graph shows average  with S.D. of duplicate 
wells, from one experiment (D). 
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robust IL-8 response, HDL and CD did not inhibit this response but rather 
somewhat enhanced it (Figure 3.5 C). HDL and CD still depleted cellular 
cholesterol (Figure 3.5 D), indicating that cholesterol (and therefore lipid rafts) 
may not be necessary for antibody mediated receptor clustering.  
 
The anti-inflammatory effect of HDL is delayed but persistent. 
 
The temporal dynamics of HDL's effects were key to understanding HDL's 
underlying anti-inflammatory mechanism. In the experiments depicted in 
Figure 3.1, HDL was added either at the same time or 2 h before the ligand, 
which was then incubated with the cells overnight. It was therefore difficult to 
assess how HDL was being anti-inflammatory when using ELISAs as a read-
out due to these long incubation times. The minimum incubation time required 
for HDL to induce an anti-inflammatory effect was therefore investigated. To 
this end, immortalised-BMDMs were pre-incubated with HDL for 2 h, 6 h or 12 
h, before HDL was either left on the cells or washed away and the cells 
subsequently stimulated with CpG. While 2 h pre-treatment with HDL was 
sufficient to block CpG-induced TNF when it remained on the cells, the anti-
inflammatory effect was lost when it was washed away (Figure 3.6 A). 
However, when cells were pre-incubated longer with HDL (e.g. 6 h or 12 h) 
the anti-inflammatory effect of HDL persisted, even when the HDL was 
washed away (Figure 3.6 A). This suggests that HDL must be on cells for at 
least 6 h prior to subsequent stimulation with TLR ligand to have an anti-
inflammatory effect. 
 
The duration of the anti-inflammatory effect of HDL is difficult to assess when 
HDL is still present in the media. Therefore BMDMs were pre-treated with 
HDL for 12 h before either washing the HDL away or leaving it on the cells. 
Cells were subsequently stimulated for 4 h, 8 h or 12 h with either CpG or 
P3C before cytokines in the supernatants were measured (a schematic is 
given in Figure 3.6 B). HDL was consistently able to inhibit CpG- or P3C- 
P3C 4h P3C 8h P3C 24h P3C 
0.0
0.5
1.0
1.5
IL
-6
 (f
ol
d)
+ HDL
**
*** ***
* *
CpG 4h CpG 8h CpG 24h CpG 
0.0
0.5
1.0
1.5
IL
-6
 (f
ol
d)
+ HDL
*
** **
**
*
0 2 6 12
0.0
0.5
1.0
1.5 CpG 
wash/CpG
HDL (h pre-treatment)
R
el
at
iv
e 
TN
F 
no wash wash
A
C
HDL
12h
CpG 
DNA P3CSK4
Collect S/NNo Wash
Wash
4h 8h 24h
B
Figure 3.6
HDL must be on cells for at least 6 h to be anti-inflammatory, but its 
anti-inflammatory effects persist up to 24 h after this.
A) Immortalized wt macrophages were pre-treated with HDL for the 
indicated times. The HDL was then either left on the cells or washed away 
before 100nM CpG was added. After 16h, cytokines in the cell supernatants 
were measured by ELISA. Graphs show the mean of three independent 
experiments with S.EM. This experiment was performed solely by Dr 
Dominic De Nardo. B) Schematic of the experiment shown in C). BMDMs 
were treated with 2 mg/ml HDL for 12h. Cells were then either washed twice 
with serum free medium, or not, before stimulation with 100 nM CpG or 50 
ng/ml P3C. Supernatants were then collected after 4 h, 8 h and 24 h of 
stimulation, and IL-6 in the supernatants measured by ELISA. Graphs show 
the mean of three independent experiments with S.E.M.p values were 
calculated using a paired, two tailed t test. Significance is indicated as 
follows: *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001 
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induced IL-6, even when it had been removed from cells up to 24 h before the 
final cytokine levels were assessed, indicating that the anti-inflammatory 
effects of HDL persist long after cholesterol may have been replaced in the 
cells (Figure 3.6 C). The long incubation time required for HDL's anti-
inflammatory effects, and the longevity of these effects, suggest that HDL may 
be modulating the de novo expression of a negative regulator of inflammation.  
 
HDL does not inhibit upstream TLR signalling. 
 
To confirm whether HDL was disrupting TLR-signalling, either through 
cholesterol depletion or through induction of a negative regulator, the effect of 
HDL on various stages of the TLR-signalling pathway was investigated. 
Firstly, Dr Dominic De Nardo analysed whether HDL pre-treatment inhibited 
CpG-induced MAPK signalling. BMDMs were pre-treated for 6 h with HDL 
before addition of CpG for 30 or 60 min.  CpG-treatment induced 
phosphorylation of the MAP kinases p38 and JNK, which remained intact 
even following HDL treatment (Figure 3.7 A). This was also the case in the 
NFκB pathway where HDL treatment did not inhibit CpG-induced degradation 
of IκBα nor the phopsphorylation of NFκB p65 (Figure 3.7 A). This data 
suggests that despite cellular cholesterol depletion by HDL, TLR receptor 
dimerization and recruitment of adaptors and signalling proteins remains 
intact.  
 
After NFκB subunits have been released by IκBα degradation and activated 
by phosphorylation, they translocate into the nucleus where they activate a 
transcriptional program. To assess whether HDL inhibited the nuclear 
translocation of NFκB p65, I assessed the subcellular localisation of p65 after 
treatment with CpG and/or HDL. As expected, CpG treatment led to an 
increase in nuclear p65. Interestingly, this remained intact with HDL pre-
treatment (Figure 3.7 B). To confirm that the extracts reflected the correct 
subcellular localisation, the cytoplasmic protein β-tubulin was used as a 
cytoplasmic loading control, while the nuclear DNA binding protein Poly (ADP- 
  
β-tubulin
PARP
̶ ̶ ̶ ̶+ + + +
̶ ̶ ̶ ̶+ + + +
CpG
HDL
NFκB p65
Cytoplasmic Nuclear
CpG (min):
P-JNK
P-p38
0 30 60 0 30 60
HDL
IκBα
α-tubulin
P-p65
Pr
ob
e a
lon
e
̶ ̶ + +
̶ ̶+ +
CpG
HDL
NFκB 
Free Probe
Nuclear Extract
A B
C
Figure 3.7
HDL does not disrupt TLR signalling or NFκB nuclear translocation.
A) BMDMs were pre-treated with 2 mg/ml HDL for 6h before subsequent stimulation 
with 100 nM CpG for indicated times. Cell lysates were then assayed by immunob-
lot for phosphorylation of p38, JNK and NFκB p65 and degradation of IκBα with 
α-Tubulin as a loading control. Blots are representative of three independent 
experiments and were performed solely by Dr Dominic De Nardo. B) BMDMs were 
pre-treated with 2 mg/ml HDL for 6 h before subsequent stimulation with 100 nM 
CpG for 30 mins. Cells were fractionated into nuclear and cytoplasmic fractions and 
were assayed by immunoblot for NFκB p65 with β-Tubulin as a cytoplasmic loading 
control and Poly (ADP- ribose) Polymerase 1 (PARP1) as a nuclear loading control. 
Blots are representative of three independent experiments. C) BMDMs were 
pre-treated with 2 mg/ml HDL before stimulation with 100 nM CpG for 30 mins. 
Cells were then lysed and nuclear extracts were incubated with IRdye - labelled NF
κB consensus probe and protein-DNA interaction were measured by EMSA. Data is 
representative of three independent experiments.
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ribose) polymerase-1 (PARP-1) was used as a nuclear loading control (Figure 
3.7 B).  
 
HDL could potentially inhibit the binding of NFκB to its target DNA sequences. 
It was possible that HDL induced a conformational change in NFκB p65, or 
induced the expression of an inhibitory protein that sequesters NFκB from its 
target DNA. To investigate this, electromobility shift assays (EMSAs) were 
performed, where a fluorescently labelled double-stranded DNA probe 
containing a consensus NFkB-binding sequence was incubated with nuclear 
extracts from HDL- and/or CpG-treated BMDMs. The protein/probe mix was 
then run on a non-denaturing gel, and when the target protein bound to the 
probe, the probe 'shifted' higher in the gel representing the higher molecular 
weight of this complex. As anticipated, CpG treatment of BMDMs induced a 
shift in the probe, however this shift was also present with HDL pre-treatment, 
indicating that HDL did not inhibit NFκB binding to target sequence DNA in 
vitro (Figure 3.7 C). However this experiment does not exclude that HDL 
induces a conformational change in chromatin structure, or the binding of 
transcriptional repressors to target DNA that prevent NFκB binding and 
activation in vivo. 
 
HDL inhibits TLR-induced pro-inflammatory cytokine expression at the 
level of transcription.  
 
To investigate whether HDL was affecting TLR induced pro-inflammatory 
cytokine mRNA expression, mRNA was isolated from BMDMs pre-treated for 
6 h with HDL and subsequently stimulated for 4 h with CpG. All mature, poly 
A-tailed mRNAs in the cell were then reverse transcribed into complementary 
DNA (cDNA) using an oligodT primer.  mRNA transcript abundance for pro-
inflammatory cytokines of interest  was then assessed using quantitative-PCR 
(qPCR) with SYBR green dye. This dye fluoresces when intercalated in 
double stranded DNA, therefore the fluorescent signal is directly proportional 
to the abundance of particular cDNAs in the cell. To account for discrepancies  
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HDL inhibits TLR-induced pro-inflammatory cytokines at the mRNA level in 
both human and mouse macrophages.
A) BMDMs were pre-treated with 2 mg/ml HDL for 6 h before stimulation with 100 
nM CpG or 50 ng/ml P3C for 4 h. mRNA levels of indicated genes were assessed 
by qPCR and were normalised to the housekeeping gene HPRT. Graphs show 
mean of three independent experiments with S.E.M. p values were calculated 
using a paired, two tailed t test. Significance is indicated as follows: *p≤ 0.05. 
These experiments were performed together with Dr Dominic De Nardo. B) 
Human CD14+ monocytes were pre-treated for 6 h with 2 mg/ml HDL before 
stimulation with 1μg/ml P3C for 4 h. mRNA levels of indicated genes were 
assessed by qPCR and were normalised to the housekeeping gene HPRT. 
Graphs show the mean of two independent donors, with individual data points 
indicated as dots and error bars denoting S.D. 
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in cell number and growth, each gene was made relative to a so-called 
'housekeeping' gene, in this case hypoxanthine guanine transferase (HPRT), 
whose levels remain constant despite stimulation (135). Il6, Tnf and Il1b 
mRNAs were all strongly induced by CpG and P3C stimulation (Figure 3.8 A). 
On the other hand, Ifnb was more modestly induced, in keeping with it being a 
TLR9 target gene in pDCs rather than in macrophages, and not being a 
known TLR2 target gene (Figure 3.8 A). Interestingly, HDL significantly 
inhibited the induction of CpG-induced Il6, Il1b and Ifnb (Figure 3.8 A). Tnf 
mRNA levels appeared to be unaffected by HDL at this time-point (Figure 3.8 
A), though in vivo, CpG induced hepatic Tnf mRNA was, along with Il6 mRNA, 
reduced by HDL treatment (128). In addition, in human monocytes, HDL 
inhibited P3C induced IL6 and TNF mRNA (Figure 3.8 B) suggesting that 
HDL's inhibitory effect on TLR-induced pro-inflammatory gene expression is 
conserved across the species.  
 
Conclusions 
 
In summary, the data presented in this chapter show that HDL is directly anti-
inflammatory on monocytes and macrophages in vitro. This complements our 
in vivo studies where HDL inhibited CpG-induced liver damage in an acute 
model of liver toxicity and inflammation (128). Furthermore, HDL's anti-
inflammatory effect was seen in both mouse and human cells. This effect was 
also broad: HDL inhibited a range of TLR ligands, and importantly it also 
inhibited IL-1β-induced TNF in human Thp1 cells, indicating it could 
potentially inhibit IL-1β-mediated sterile inflammation. In accordance with the 
literature, HDL bound and sequestered LPS, however, it did not appear to 
bind other TLR ligands, such as CpG or P3C. This indicated that HDL could 
also mediate an anti-inflammatory effect on the immune cells themselves. 
While HDL did deplete cellular cholesterol, the importance of this for the anti-
inflammatory effects of HDL remains to be elucidated, as TLR clustering and 
downstream signalling remained intact. The observations that HDL pre-
treatment of 6 h is required for inhibition, and that the effect of HDL is most 
likely mediated at the transcriptional level suggests that HDL initiates the de 
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novo synthesis of an inhibitory intermediate.  This work represents a paradigm 
shift from the current understanding of how HDL mediates its anti-
inflammatory effects, and suggests that rather than HDL disrupting lipid rafts 
and therefore receptor signalling platforms, HDL instead reprograms 
macrophages to be less inflammatory.  
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4. Results: Transcriptomic analysis identifies ATF3 as a HDL-
induced transcriptional repressor that mediates the anti-
inflammatory actions of HDL 
 
Introduction: 
 
HDL inhibited TLR-induced pro-inflammatory cytokine expression in human 
and mouse macrophages, without disrupting TLR signalling, however the 
mechanism behind this anti-inflammatory action of HDL remained elusive.  
HDL was previously reported to modulate inflammatory gene expression in 
endothelial cells by inhibiting NFκB activity (100). However, HDL did not 
appear to inhibit CpG-induced NFκB activation in BMDMs; rather the effect 
appeared to be at the transcriptional level. HDL reportedly induced an anti-
inflammatory macrophage phenotype in vivo (108), indicating that HDL might 
modulate gene-expression at the transcriptional level. Therefore, the 
modulation of global macrophage gene expression through a possible anti-
inflammatory intermediate by HDL was investigated using a non-biased 
microarray approach. 
 
Microarray analysis identifies genome wide transcriptional changes 
upon HDL treatment. 	  
We found that HDL significantly reduced circulating MCP-1, IL-10, IL-6, IL-
12p40 and TNF cytokine and mRNA levels in an in vivo CpG-induced acute 
inflammation model (128). HDL also inhibited TLR-induced Il6, Il1b and Ifnb 
mRNA in vitro (Figure 3.8 A) indicating that HDL inhibits a broad range of 
TLR-induced inflammatory genes. To gain a better understanding of the 
scope of HDL's actions on TLR-modulated genes, a microarray experiment 
was performed in collaboration with the laboratory of Professor Joachim  
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Figure 4.1
HDL induces cholesterol biosynthesis in macrophages among genome wide 
changes. 
BMDMs were pre-treated with 2 mg/ml HDL for 6 h before stimulation with 100 nM CpG for 
4 h. This experiment was performed with three biological replicates.A) Visualisation of 
genes (as fold change relative to control) involved in the cholesterol biosynthesis pathway. 
B) Fold Change/Fold Change (FC/FC) plot showing the directional overlap between 
treatment conditions relative to control. In blue are genes differentially expressed in CpG + 
HDL relative to control only, in red are genes differentially expressed in CpG relative to 
control only, and in purple are genes differentially expressed relative to control in both 
treatmentsThe treatment of cells was performed together with Dr Dominic De Nardo while 
the array and subsequent analysis was performed by Prof. Joachim Schultze and 
colleagues.
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Schultze at the Life and Medical Sciences (LIMES) institute (Bonn). BMDMs 
from three individual mice were pre-treated with 2 mg/ml HDL for 6 h, before 
stimulation with 100 nM CpG for 4 h. Principle component analysis confirmed 
that the variance in the data set could be attributed to treatment (i.e. HDL or 
CpG) rather than biological replicate, as the datasets grouped together based 
on treatment (128).   
 
As anticipated, HDL treatment alone induced numerous transcriptional 
changes in BMDMs. For instance, HDL treatment up-regulated many genes 
involved in the cholesterol biosynthesis pathway, consistent with activation of 
SREBP and its target genes upon cellular cholesterol depletion (Figure 4.1 A). 
This reflected the mass spectrometry data from Figure 3.4 D, where HDL 
treatment increased the amount of cholesterol precursors within cells.  
 
However, the most interesting genes were CpG-regulated (i.e. either induced 
or repressed) genes that were then counter-regulated (i.e. repressed or 
induced respectively) by HDL co-treatment. CpG stimulation of BMDMs alone 
changed the expression of 1135 genes, of which 567 were induced and 568 
were repressed. Of the 567 induced genes, the induction was strongly 
blocked by HDL in 209 genes. This is visualised in the FC/FC plot (generated 
and analysed by Professor Joachim Schultze and colleagues) in Figure 4.1 B, 
where each dot is an individual gene, and the red dots are genes that are 
CpG-induced over 1.5 fold relative to control, but not in CpG + HDL treatment. 
Similarly, 210 genes were strongly repressed by CpG treatment, and this was 
reversed with HDL pre-treatment (Figure 4.1 B). There were also genes that 
were only induced or repressed in the presence of HDL (423 genes total, dark 
blue dots) as they showed no fold change differences in the CpG alone 
treatment. Finally, the majority of genes were regulated in the same direction 
relative to control (purple dots), however, as they do not all fall on a strict 
diagonal line (which would indicate the same induction by CpG regardless of 
HDL treatment) this indicates that some genes are either counter regulated 
(i.e. less induced) or enhanced (i.e. more induced) with HDL co-treatment. 
This was consistent with the earlier qPCR data from Figure 3.8 A where HDL 
repressed CpG-induced Il6 mRNA expression by approximately 50%.  
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HDL induces genes associated with lipid metabolism and represses genes associ-
ated with innate immunity.
Network visualization of Gene Ontology Enrichment Analysis (GOEA) based on transcripts 
reduced by CpG and counter-regulated by HDL (red nodes: GO-terms, red edges: 
GO-term relations) or induced by CpG and counter-regulated by HDL (blue edges and 
nodes). Prof. Joachim Schultze and colleagues generated this network analysis.  
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Therefore, genes like Il6 would fall into the purple section, as they are still 
induced by CpG and HDL co-treatment relative to control, but compared to 
CpG treatment alone, this fold induction is lower.   
 
To examine the broad changes induced by HDL treatment in CpG-stimulated 
macrophages, Gene-Ontology (GO) enrichment analysis (GOEA) was 
performed on the 716 genes that were regulated by CpG and further modified 
by HDL. Gene-ontology assigns genes a cellular compartment, molecular 
function and biological process, so that the overall biological outcome from 
treatment can be interpreted from the relative gene expression. The GOEA 
was then visualised as a GO-term network, as shown in Figure 4.2, and this 
showed that many of the genes that were induced by HDL treatment were 
genes associated with cholesterol and lipid metabolism. This is in keeping 
with the known biological role of HDL in removing cellular cholesterol and 
inducing cholesterol biosynthesis.  Interestingly, genes associated with the 
innate immune response were repressed by HDL, confirming the earlier 
observations that HDL is anti-inflammatory. 
 
ATF3 is a potential transcription factor mediating HDL's anti-
inflammatory effects 
 
Considering the broad changes effected by HDL, and the long treatment time 
required, it was hypothesised that HDL might modulate the expression of a 
transcription factor. The transcription factors that were either most induced or 
repressed by HDL in the microarray study described above are presented as 
a heat map in Figure 4.3 A.  Of the transcription factors that were induced by 
HDL, ATF3 appeared the most interesting, based on its prior identification as 
an inducible repressor of pro-inflammatory cytokine expression, especially of 
IL-6 and IL-12p40 (26). Similarly, of the transcriptional factors that were down 
regulated by HDL, KLF7, STAT1 and IRF7 all appeared interesting based on 
their fold change or on their involvement in Type I IFN signalling. As a first 
step to candidate validation, the regulation of these TFs by HDL and/or CpG  
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Figure 4.3
HDL modulates the expression of various transcription factors, of which ATF3 is the 
best candidate to be mediating anti-inflammatory actions.
A) Heat map of the transcription factors most highly regulated by HDL in BMDM. Genes are 
ranked by highest mean expression value, starting with induced genes followed by repressed 
genes. Fold change of CpG + HDL versus CpG alone is listed on the right. The heat map was 
generated by Prof. Joachim Schultze and colleagues. B) qPCR validation of potential TF 
candidates. BMDMs were treated with 2 mg/ml HDL before subsequent stimulation with 100 
nM CpG for 4 h. mRNA was assayed by qPCR using gene specific primers and normalised to 
HPRT expression. To show representative fold induction, data was made relative to the 
untreated control value. Graphs show the mean of three independent experiments with 
S.E.M.p values were calculated using a paired, two tailed t test. Significance is indicated as 
follows: *p≤ 0.05
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was confirmed by qPCR (Figure 4.3 B). Indeed, while HDL significantly 
induced Atf3 mRNA and significantly reduced Stat1 mRNA, validating the 
array results, Klf7 and Irf7 did not appear to be significantly regulated by HDL 
treatment. ATF3 was subsequently confirmed as the best potential candidate 
by bioinformatics analysis performed by Professor Joachim Schultze and 
colleagues and detailed in De Nardo and Labzin et al (128). 
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HDL induces ATF3 expression in mouse BMDMs
A) BMDMs were stimulated with 2 mg/ml HDL for indicated times, or with 200 ng/ml LPS 
as a positive control. Atf3 mRNA levels were assayed by qPCR and normalised relative 
to Hprt. Samples were then normalised to un-stimulated control samples to show fold 
induction. Graph is representative of three independent experiments and shows the 
average and S.D of duplicate wells. This experiment was performed by Dr Dominic De 
Nardo B) BMDMs were stimulated with 2 mg/ml HDL for indicated times, or 200 ng/ml 
LPS and ATF3 protein was measured in cell lysates by immunoblot. β-Actin protein was 
measured as a loading control. Densitometry of the bands was also measured and ATF3 
protein levels normalised to β-actin and then subsequently normalised to un-stimulated 
cells alone. Blot is representative of three independent experiments and graph shows 
the mean of three independent experiments with S.E.M. Dr Dominic De Nardo 
performed this experiment. C) BMDMs were pre-treated with 2 mg/ml HDL 6 h before 
subsequent stimulation with 100nM CpG or 50 ng/ml P3C for 4 h. Atf3 mRNA was 
assayed by qPCR relative to Hprt and then subsequently normalised to the 
un-stimulated control. Graphs show mean of three independent experiments with S.E.M. 
p values were calculated using a paired, two tailed t test. Significance is indicated as 
follows: *p≤ 0.05. This experiment was performed together with Dr Dominic De Nardo. D) 
BMDMs were pre-treated with 2 mg/ml HDL for 6 h and stimulated with 100 nM CpG or 
50 ng/ml P3C for 4 h and ATF3 protein in cell lysates measured by immunoblot. β-Actin 
was included as a loading control. Blot is representative of three independent experi-
ments. Dr Dominic De Nardo performed this experiment. 
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HDL induces ATF3 expression 
 
Fittingly, in BMDMs, HDL induced ATF3 mRNA and protein expression in a 
time-dependent manner, with mRNA expression reaching approximately 2.5 
fold after 6 h for RNA, and later for protein (Figure 4.4 A and B). Furthermore, 
while ATF3 is induced by TLR stimuli alone, including CpG (28), HDL further 
enhanced CpG induction of ATF3 at both the mRNA and protein level, as 
seen in Figure 4.4 C and D.  
 
As HDL was also anti-inflammatory in human monocytes and macrophages, I 
confirmed whether HDL induced ATF3 in human cells. While mice only 
express one isoform of ATF3, which is full length, humans have numerous 
ATF3 isoforms. A detailed description of the ATF3 gene, transcript variants 
and encoded isoforms is given in Figure 4.5 A. Some of these isoforms, e.g. 
isoform 1 (encoded by two transcript variants, NM_001030287 and 
NM_001674.3) act as transcriptional repressors, while another isoform; 
isoform 2 (encoded by NM_001040619.2) lacks the bZip domain, which is 
required for DNA binding. This shorter isoform, isoform 2, is therefore thought 
to act as a transcriptional activator, potentially by sequestering other co-
repressors away from target promoter regions (136). As the different human 
ATF3 transcripts may have different roles in regulating pro-inflammatory 
cytokine expression, I investigated whether HDL differentially induced the long 
(i.e. repressive) isoform 1 compared to the short (i.e. activating) isoform 2. To 
differentiate between the two isoforms, I designed qPCR primers in regions of 
the cDNA that were unique to Isoform 1 (NM_001030287) and Isoform 2 
(NM_001040619.2) respectively. In CD14+ monocytes stimulated ex vivo for  
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Figure 4.5
HDL induces the transcriptional repressor isoform of ATF3 in human monocytes
A) Schematic of the human ATF3 gene, with transcript variants and their respective NCBI 
Refseqs, and diagrams of the isoforms they encode. Figure adapted from (Hunt et al., 2012). 
B) CD14+ monocytes were treated with 2 mg/ml HDL for 6 h. Isoform 1 or 2 ATF3 mRNA was 
detected by qPCR using transcript specific primers and normalised to HPRT. Graphs show 
individual data points from 4 donors (above) and then fold change (HDL/untreated) below, with 
mean of 4 donors and S.E.M. P value was calculated using a paired one-tailed students t 
test.Significance is indicated as follows: *p≤ 0.05. C) CD14+ monocytes were pre-treated with 
2 mg/ml HDL for 6 h and subsequently stimulated with 1 μ/ml P3C for 4 h and ATF3 protein in 
cell lysates assayed by immunoblot. β-Actin was measured as a loading control. Blots are 
representative of two independent experiments. 
Hunt, D., Raivich, G., and Anderson, P.N. (2012). Activating transcription factor 3 and the 
nervous system. Front Mol Neurosci 5, 7.
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10 h with HDL, ATF3 isoform 1 mRNA was induced approx. 2 fold, and this 
effect was seen across 4 independent donors (Figure 4.5 B).  In contrast, HDL 
had little effect on Isoform 2 mRNA expression, and if anything, it appeared to 
down-regulate its expression (Figure 4.5 B). This was confirmed at the protein 
level, where HDL and HDL pre-treatment followed by P3C stimulation induced 
ATF3 expression in CD14+ monocytes (Figure 4.5 C). The antibody used to 
detect ATF3 recognises an epitope at the C-terminus of ATF3, which is only 
present in the long isoform 1, suggesting that HDL indeed induces the 
repressor isoform of ATF3 in human cells.  
 
To confirm that HDL was also inducing ATF3 in vivo, and therefore likely 
mediating the anti-inflammatory effects of HDL seen in the acute model of 
CpG- induced inflammation (128), mRNA was isolated from the livers of mice 
injected with PBS or 100 mg/kg HDL for 10 h. Indeed, HDL induced Atf3 
mRNA expression in the livers of C57/BL6 mice (Figure 4.6). With the 
assistance of Dr Frank Schildberg from the Institute for Molecular Medicine 
and Experimental Immunology (IMMEI) (Bonn), hepatocytes, non-
parenchymal cells and Kupffer cells (resident liver macrophages), were 
isolated to identify which hepatic cell populations were responsible for the 
induction of ATF3 in the liver following HDL injection. In keeping with ATF3's 
role as a repressor of pro-inflammatory gene expression, HDL induced ATF3 
in Kupffer cells, but not in hepatocytes or non-parenchymal cells (Figure 4.6).  
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Figure 4.6
HDL induces Atf3 mRNA expression in vivo
C57/BL6 mice were injected i.v. with 100 mg/kg HDL for 12 h. Livers were isolated, and 
subsequently liver cell populations (Kupffer cells, hepatocytes and non parenchymal 
cells) were isolated and mRNA extracted. Atf3 mRNA was assayed by qPCR and 
normalised to Hprt levels. Data points represent individual mice, from independent 
experiments that were performed on separate days (in groups of 2). P values were 
calculated using an unpaired two-tailed t-test. Significance is indicated as follows: *p≤ 
0.05. Dr Frank Schildberg handled and injected mice, extracted organs and isolated 
cell populations and I performed the RNA extraction and qPCR. 
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As HDL is best known for its protective effects in atherosclerosis, whether 
HDL would also induce ATF3 expression in vivo in a mouse model of 
atherosclerosis was investigated. In collaboration with the Dr Sebastian 
Zimmer and colleagues (Department of Cardiology, University Clinic Bonn), 
ApoE-/- mice were fed on a high fat diet for 8 weeks, before being injected with 
HDL or PBS for 1 week (while still on the high fat diet). The treatment time 
with HDL was limited to one week, as the HDL in this study consists of 
reconstituted human ApoA1; therefore the treatment was stopped before an 
adaptive immune response could begin. The mice were then sacrificed and 
mRNA from various tissues was isolated. Initially mRNA from the aortic root, 
where the majority of atherosclerotic plaques form, was analysed. However 
no difference in Atf3, Il6 or Il12b expression upon HDL treatment was 
observed (Figure 4.7 A). Considering that the section of aortic root isolated 
contains smooth muscle cells, endothelial cells, fibroblasts as well as 
presumably lipid laden macrophages, it is possible that an effect of HDL in 
these macrophages may have been masked by RNA from other cell types. 
Consistent with results in wild type (WT) mice, HDL also induced hepatic Atf3 
mRNA expression in atherosclerotic mice, which correlated with the down 
regulation of Il6 and Il12, and of the known ATF3 target gene Cholesterol-25-
hydroxylase (Ch25h) (137) by HDL (Figure 4.7 B). HDL treatment also 
induced the SREBP target gene Lanosterol Synthase 1 (Lss1), indicating 
cellular cholesterol depletion. Similarly to HDL treatment in the WT mice, HDL 
induced Atf3 mRNA expression in Kupffer cells (Figure 4.7 C). This indicates 
that HDL also induces ATF3 in a physiologically relevant disease model. 
Together, this data suggests that HDL could mediate much of its anti-
inflammatory action by inducing ATF3 expression both in vitro in mouse and 
human immune cells, and in vivo in mice.  
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Figure 4.7
HDL induces ATF3 but decreases pro-inflammatory cytokine expression in livers of atherosclerotic 
mice.
ApoE-/- mice fed on a high fat diet were injected intravenously (i.v.) with 100 mg/kg HDL (animal handling 
by Catharina Lahrmann). A)  Aortic Roots were isolated by Catharina Lahrmann and tissues were homog-
enised by Alena Grebe and I, RNA was then extracted and I analysed mRNA expression by qPCR. B) 
Livers were isolated by Frank Schildberg and C) Kupffer cells were then further isolated, RNA extracted 
and mRNA levels assayed by qPCR analysis. 5 mice per group were treated in one experiment. Signifi-
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HDL induces binding of ATF3 to target gene promoters 
 
The first report of ATF3 as a TLR-inducible transcriptional repressor showed 
delayed ATF3 binding to the promoters of Il6 and Il12b in response to LPS, 
after NFκB had already bound and subsequently dissociated from the 
promoters (26). This was consistent with the kinetics of Il6 and Il12b induction 
by LPS, where mRNA was highly expressed while NFκB was bound and then 
decreased as ATF3 binding to promoters increased (26). It was therefore 
hypothesised that HDL induced ATF3 should bind to the promoters of its 
target genes, which are presumably CpG-induced genes that are inhibited by 
HDL treatment. To assess whether HDL induced ATF3 binding to target gene 
promoters, chromatin immuno-precipitation (ChIP) analysis was performed. In 
this experimental setup, BMDMs that were treated with HDL or CpG were 
cross-linked with formaldehyde, so that any protein- DNA interactions were 
preserved. The cells were then gently lysed and the chromatin sheared into 
~300 base pair (bp) long fragments with any associated proteins still attached. 
The DNA associated with the protein of interest (in this case, ATF3) was then 
isolated by immuno-precipitation using an ATF3-specific antibody. The cross-
linking was then reversed and the isolated DNA fragments were then purified 
for subsequent analysis by qPCR or genome wide sequencing. Previously 
described ATF3 ChIP experiments used an isotype control antibody to control 
for specificity of the antibody binding (26). However, in my preliminary 
experiments, the binding of ATF3 was non-specific, and no enrichment was 
seen at previously defined ATF3 binding sites compared to random sites 
within the genome (Figure 4.8 A, B). Therefore, instead of using an isotype 
control antibody to clarify the specificity of ATF3 binding to true ATF3 target 
genes, ChIP-Sequencing of HDL and CpG treated BMDMs was also 
performed in ATF3-deficient macrophages alongside WT macrophages.  
Once the ATF3-bound DNA fragments had been isolated, they were 
sequenced and the 'hits' aligned to the mouse genome. The signal obtained 
from the ATF3-deficient macrophages was then considered as background 
and subtracted from the WT signal to give ATF3 specific peaks. 
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Figure 4.8
ChIP-Seq shows that HDL increases ATF3 binding across the genome and in particular 
at pro-inflammatory gene loci
A) ChIP qPCR of resting WT BMDMs, showing enrichment of ATF3 at both the ATF3 binding 
site in the mIL-6 promoter as well as 1kb downstream of this specific site, with the ATF3 
antibody and not with the isotype control. B) ChIP qPCR of resting WT BMDMs showing fold 
enrichment (ATF3 ab/isotype control) for different sites within the genome (non ATF3 specific). 
Graphs show average + S.D. from a representative experiment of 3 independent experiments. 
C) WT  and ATF3-/-  BMDMs were pre-treated with 2 mg/ml HDL for 6 h then stimulated with 
100 nM CpG for 4 h. Cell culture and cross-linking was performed together with Dr Dominic 
De Nardo, while  the subsequent processing for ChIP sequencing was perfrmed by Prof. 
Joachim Schultze and colleagues. An overview of ATF3 hits across the genome under the 
different treatment conditions is shown in the upper panel and an overview of promoter 
associated hits across the different treatment conditions is shown in the lower panel. B) 
Analysis of the localisation of ATF3 hits relative to transcription start sites (TSS) between WT 
and ATF3-/-  BMDMs shows the specificity of the ATF3 ChIP signal. C) Individual gene loci of 
known ATF3 target genes (left) with ATF3 binding peaks indicated across the different treat-
ment conditions. Red bars indicate significant peaks after background signal (signal from 
ATF3-/-  BMDM) had been subtracted. Non-ATF3 target genes that were also not affected by 
HDL treatment are shown on the right. This analysis was performed entirely Prof. Joachim 
Schultze and colleagues. 
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Using a new method developed specifically for analysing this dataset, 
Professor Joachim Schultze and colleagues were able to identify specific 
ATF3 binding enrichment across the genome. Consistent with the earlier data 
that HDL induces ATF3 expression, HDL also increased ATF3 binding across 
the genome, including intergenic, promoter and 5’ UTR regions (Figure 4.8 C). 
This increase was also seen in promoter-associated regions, in keeping with 
the known role for ATF3 as a transcriptional repressor (Figure 4.8 C). 
Interestingly, CpG treatment reduced the amount of total and promoter 
associated ATF3 binding, which was rescued by HDL pre-treatment. 
Furthermore, Figure 4.8 D depicts how the ATF3 hits are concentrated just 
before the transcription start site (TSS), which is only seen in WT cells, 
indicating that this is specific ATF3 binding (Figure 4.8 D, blue shading). 
Conversely, in all 4 treatment conditions, there was also a peak of hits ~ 
700bp after the TSS, however this enrichment was likely non-specific, as it 
was also seen in the ATF3-deficient cells (Figure 4.8 D, red shading).   
 
The gene loci of the key HDL-regulated pro-inflammatory cytokines identified 
earlier in the study are shown in Figure 4.8 E. Interestingly, under conditions 
of HDL and CpG treatment, there was significant ATF3 enrichment at the Il6 
and Il12b promoters (indicated by red bars). Conversely, there was only a 
significant peak at the Tnf promoter in the HDL treatment alone condition, 
which may reflect the basal down-regulation of Tnf mRNA by HDL, but not 
CpG-induced Tnf (Figure 3.8 B). Finally, no ATF3 enrichment was seen at the 
promoters of Il18 or Il13, which is consistent with in vivo data where these 
cytokines were not inhibited by HDL(128). This data strongly supports the 
hypothesis that HDL is anti-inflammatory by inducing the expression and 
subsequent binding of ATF3 to pro-inflammatory gene targets.  
 
HDL is no longer anti-inflammatory in ATF3-/- BMDMs 
 
To confirm whether HDL was indeed mediating its anti-inflammatory effects 
through ATF3, ATF3-/- BMDMs and matched ATF3+/+ (referred to as wild type:  
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Figure 4.9
HDL no longer inhibits pro-inflammatory cytokine production or gene expression in 
ATF3 deficient BMDMs.
A) mRNA from WT and ATF3-/- BMDMs was extracted and Atf3 mRNA levels were 
assayed by qPCR. Graph shows mean of three independent experiments with S.E.M. B) 
WT and ATF3-/- BMDMs were treated with 200 ng/ml LPS for 6 h and ATF3 and β-Actin 
protein in cell lysates was analysed by immunoblot. Dr Dominic De Nardo performed this 
experiment. C) WT and ATF3-/- BMDMs were pre-treated with indicated doses of HDL for 6 
h and then with indicated doses of CpG and P3C for 16 h. Cytokines in the supernatants 
were measured by ELISA. Data shows the mean of three independent experiments with 
S.E.M. This experiment was performed together with Dr Dominic De Nardo. D,E) WT and 
ATF3-/- BMDMs were treated with 2 mg/ml HDL for 6 h and then with 100 nM CpG (D) or 
50 ng/ml P3C (E) for 4 h. mRNA was extracted and Il6 and Il12b mRNA was assayed by 
qPCR. Graphs show mean of three independent experiments with S.E.M. P values calcu-
lated using a paired two-tailed t test. p values are as follows: *: p≤ 0.05, **p≤ 0.01, ***p≤
0.001. This experiment was performed together with Dr Dominic De Nardo. 
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WT) controls were derived from bones obtained from Dr. med. Manfred 
Kneilling (Eberhard Karls University, Tübingen). Firstly, these cells were 
confirmed as ATF3-deficient by both qPCR and western blot (Figure 4.9 A,B). 
As observed previously, HDL reduced CpG- and P3C-induced IL-6 production 
in WT BMDMs (Figure 4.9 C), however this effect was either lost (CpG), or 
reduced (P3C) in ATF3-/- BMDMs (Figure 4.9 C). This effect was also seen at 
the mRNA level, where HDL lowered CpG-induced Il6 or Il12p40 mRNA 
expression in WT, but not in ATF3-/- BMDMs (Figure 4.9 D). Similarly, P3C-
induced Il6 mRNA was only inhibited by HDL in WT cells (Figure 4.9 E). This 
data indicates that HDL is mediating much of its anti-inflammatory effect via 
ATF3.  
 
To elucidate the extent to which the HDL effect is mediated by ATF3, a 
microarray was performed comparing WT and ATF3-/- BMDMs treated with 
HDL and/or CpG or P3C. Using the model presented in Figure 4.10 A, Prof. 
Joachim Schultze and colleagues identified 188 genes (detected by 224 
probes) that were regulated by CpG/P3C and counter regulated by HDL in 
WT cells but not in ATF3-/- cells. These 188 genes are represented as dots in 
Figure 4.10 B; WT treated with CpG alone are shown in green, WT treated 
with CpG + HDL are shown in black and ATF3-/- treated with CpG + HDL are 
shown in red. As predicted in the model depicted in Figure 4.10 A, the genes 
that were counter-regulated by HDL in WT cells were no longer affected by 
HDL treatment in ATF3-/- cells. This, along with the in vivo experiments 
showing that ATF3 was also mediating the anti-inflammatory effects of HDL 
on CpG-induced liver damage (128) confirmed that HDL induces ATF3 to 
block TLR-induced inflammation.  
 
HDL inhibition of TLR-induced IFNβ is also ATF3 dependent, indicating 
IFNβ is also an ATF3 target gene. 
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Figure 4.10
ATF3 mediates much of the anti-inflammatory effect of HDL in TLR stimulated 
BMDM.
A,B) WT and ATF3-/- BMDM were pre-treated with 2 mg/ml HDL for 6 h and subsequently 
stimulated with 100 nM CpG or 50 ng/ml P3C for 4 h. Cell Culture and harvest was 
performed together with Dr Dominic De Nardo, while mRNA was extracted and analysed 
by microarray by Prof. Joachim Schultze and colleagues. A) The model used to identify 
ATF3 dependent HDL regulated genes. B) CpG or P3C induced (left panel) or CpG or 
P3C repressed (right panel). Genes are graphed relative to stimuli + HDL treatment 
condition.
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Considering the observation that HDL blocked CpG-induced IFNα cytokine 
expression in human PBMCs and CpG-induced Ifnb mRNA expression in 
mouse BMDMs (Figure 3.1 A and 3.8 A), I therefore investigated whether 
HDL also inhibited IFNβ expression in ATF3-/- BMDMs by ELISA. I focused on 
IFNβ production, as I wanted investigate induction in mouse macrophages 
and IFNα is primarily produced by pDCs. CMA is a synthetic ligand for murine 
STING, and is a potent inducer of IFNβ expression (138). ATF3-/- BMDMs had 
higher inducible IFNβ than WT BMDMs in response to CMA (Figure 4.11 A) 
suggesting that IFNβ may also be regulated in an ATF3-dependent manner. 
Furthermore, HDL significantly reduced CMA-induced IFNβ secretion in WT 
cells, while this inhibition was far less pronounced in ATF3-/- BMDMs (Figure 
4.11 A). Whether HDL can also directly bind to and sequester CMA, or 
modulate downstream STING signalling, was not investigated, so some of the 
HDL effect seen here may be ATF3-independent.  These data suggest that 
ATF3 may also mediate HDL's inhibitory effects on IFNβ expression.  
 
Interestingly, when comparing basal gene expression between WT and ATF3-
/-  BMDMs by microarray, many interferon stimulated genes (ISGs) were more 
highly expressed in the ATF3-/- dataset. In an analysis performed by Dr 
Susanne Schmidt (AG Schultze, LIMES, Bonn), of the 550 differentially 
expressed genes between WT and ATF3-/- resting BMDMs, approximately 
64% (352 genes) are known Type 1 IFN target genes. Based on this, I 
assessed the basal mRNA levels of Ifnb and some target ISGs in WT and 
ATF3-/- BMDMs by qPCR. Interestingly, ATF3-/-  BMDMs expressed higher 
levels of Ifnb, Irf7, Isg15, Ch25h and Usp18 mRNA than WT BMDMs even in 
the absence of stimulation (Figure 4.11 B). This data suggested that IFNβ and 
some of its ISGs might indeed be direct ATF3 target genes.  
 
While the basal differences in IFNβ expression between WT and ATF3-/-  
BMDMs are interesting,  differences in inducible IFNβ expression are more 
important in the context of an anti-viral response. If ATF3 also negatively 
regulates IFNβ expression, then ATF3-/-  BMDMs presumably express more 
IFNβ in response to TLR and viral stimuli.  I therefore assessed mRNA and 
cytokine levels after stimulation with LPS, which itself induces IFNβ in  
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Figure 4.11
ATF3 mediates some of the inhibitory effect of HDL on IFNβ expression in BMDM 
and ATF3 deficient BMDM have higher basal IFNβ and ISG mRNA levels.
A) WT and ATF3-/- BMDM were pre-treated with 2 mg/ml HDL for 6 h before the HDL 
was washed away. The BMDM were subsequently stimulated with 500 ng/ml CMA for 
4h. IFNβ was measured in culture supernatants. Data shows mean + SEM of three 
independent experiments. P values were calculated using an unpaired two-tailed t test. 
p values are as follows: *: p≤ 0.05, **p≤ 0.01 This experiment was performed together 
with Dr Dominic De Nardo B) mRNA levels of indicated genes from WT and ATF3-/- 
BMDM were measured by qPCR.  Data shows mean + SEM of four independent 
experiments. 
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macrophages via the TRIF pathway. LPS induced rapid (3 h) induction of Ifnb 
mRNA in WT cells, which was significantly higher at the same time-point in 
ATF3-/- BMDMs (Figure 4.12 A). Consistent with this, LPS also induced IFNβ 
protein in ATF3-/- cells from 3 h onwards, peaking at 6 h, while WT cells 
produced little detectable IFNβ over this same time course (Figure 4.12 B).  
ATF3-/-  BMDMs also expressed significantly higher IFNβ mRNA and protein in 
response to the TLR3 ligand poly I:C (Figure 4.12 C) and to CMA (Figure 4.12 
D) after 4 h. This data suggests that ATF3 is acting at the transcriptional level 
rather than upstream in the pathway, as the TLRs and STING use different 
upstream adaptors to activate the transcription factor IRF3 (which is required 
for Type I IFN expression), but show the same phenotypic differences when 
ATF3 is absent.  
 
As expected from the microarray data and the basal gene expression from 
Figure 4.11 B, mRNA levels of LPS-induced ISGs such as Irf7 and Ch25h 
were significantly higher in ATF3-/- BMDMs than in WT BMDMs (Figure 4.12 
E). As Irf7 and Ch25h are both IFNβ target genes, it was possible that the 
higher mRNA levels of Irf7 and Ch25h in the ATF3-/- BMDMs were due to 
higher circulating levels of IFNβ. Alternatively, Irf7 could, like Ch25h, also be a 
direct ATF3 target gene. To delineate this further, WT or ATF3-/- BMDM were 
stimulated directly with IFNβ over a time course. As shown in Figure 4.12 F, 
there were no significant differences in IFNβ-induced Irf7 mRNA levels 
between WT and ATF3-/- BMDMs. In contrast, Ch25h is both a direct ATF3 
target gene (137) and an ISG (139, 140) and this was reflected in the higher 
Ch25h mRNA levels observed in ATF3-/- BMDMs in response to both LPS and 
to direct IFNβ stimulation. This data suggests that ATF3-/- BMDMs have 
higher levels of certain ISGs due to increased local IFNβ, but that some ISGs, 
such as Ch25h, are also direct ATF3 target genes.      
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Figure 4.12
ATF3 deficient BMDMs have higher inducible levels of IFNβ
A) WT and ATF3-/- BMDMs were stimulated with 100 ng/ml LPS for indicated times. mRNA 
was extracted and IFNβ mRNA levels were assayed by qPCR. Data shows mean + SEM of 
four independent experiments. B) WT and ATF3-/- BMDMs were stimulated with 100 ng/ml 
LPS for indicated times and IFNβ measured in supernatants by ELISA. Data shows mean + 
SD from two independent experiments (left panel) or mean + SEM from three independent 
experiments (right panel). C and D), WT and ATF3-/- BMDMs were stimulated for 4 h with 1μ
g/ml poly I:C (C) or 500 ng/ml CMA (D) and IFNβ mRNA was measured by qPCR and IFNβ 
in cell supernatants was measured by ELISA. Data shows mean + SEM from three inde-
pendent experiments. P values were calculated using an unpaired two-tailed t test. E) WT 
and WT and ATF3-/- BMDMs were stimulated with 100 ng/ml LPS for indicated times. mRNA 
was extracted and IRF7 or CH25H mRNA levels were assayed by qPCR. Data shows mean 
+ SEM of four independent experiments. E) WT and ATF3-/- BMDMs were stimulated with 
1000 U/ml IFNβ for indicated times. mRNA was extracted and IRF7 and CH25H mRNA 
levels were assayed by qPCR. Data shows mean + SEM of three independent experiments.
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Conclusions 
 
This part of the study identified ATF3 as a transcriptional repressor that is 
induced by HDL to block pro-inflammatory cytokine expression. Using an 
unbiased, bioinformatic approach, ATF3 was identified as a potential 
candidate to mediate HDL's anti-inflammatory effects. ATF3's induction by 
HDL was confirmed in mouse and human cells at both the mRNA and protein 
level, and hepatic ATF3 mRNA induction by HDL was confirmed in vivo. ChIP-
Seq confirmed increased binding of ATF3 to target gene promoters upon HDL 
treatment, indicating that this ATF3 up-regulation by HDL has functional 
consequences. Furthermore, HDL was no longer able to block TLR-induced 
cytokine production in ATF3-/- BMDMs, confirming ATF3's key role in 
mediating HDL's anti-inflammatory effects. Finally, IFNβ also appeared to be 
a direct ATF3 target gene, which was blocked by HDL. This data identifies a 
new biology for HDL, confirms the importance of ATF3 in regulating TLR-
inducible gene expression, and identifies ATF3 as a regulator of the anti-viral 
response by modulating IFNβ production.   
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5. Results: Characterizing the induction of ATF3 by HDL 	  
Introduction. 
 
The anti-inflammatory effects of HDL are mediated, at least in part, via the 
transcriptional repressor ATF3. What remains unclear is how HDL is inducing 
ATF3 expression in macrophages. ATF3 has been shown to be induced in 
response to a range of stimuli, including cytokines, TLR ligands, and cellular 
stress, in a broad range of cell types (141).  These stimuli can induce ATF3 by 
a variety of signalling pathways and transcription factors, including MAPK and 
NFκB, SMAD3, and Protein Kinase C (PKC) (141).  The anti-inflammatory 
effects of HDL have also been linked to RCT and the ApoA1 component 
(107), or alternatively, to the phospholipid component  (101, 104). However, 
the component and mechanism by which HDL induces ATF3 in macrophages 
remains to be determined.  
 	  
HDL induction of ATF3 appears to be independent of cholesterol 
depletion. 	  
A recent study showed induction of ATF3 in response to cholesterol depletion 
in human and mouse prostate cells (142). Therefore, an obvious possibility 
was that ATF3 induction might be a response to HDL mediated cellular 
cholesterol depletion. To elucidate whether this was indeed the case, 
complementary cholesterol-loaded recombinant HDL (cHDL) particles and the 
cholesterol depleting agent, β-hydroxy cyclodextrin (CD) were utilised. As 
expected, HDL and CD depleted cellular cholesterol from both mouse BMDMs 
(Figure 5.1 A) and human CD14+ monocytes (Figure 5.1 B) in a dose-
dependent manner, while in contrast, cHDL did not reduce cellular cholesterol 
levels. However, cHDL was as effective as HDL in blocking R848-induced IL-
12p40 (BMDMs) or TNF (CD14+ monocytes) production, while CD did not  
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Figure 5.1
HDL's anti-inflammatory effects via ATF3 appear to be independent of its choles-
terol efflux capacity.
A) BMDMs were treated with indicated doses of HDL (mg/ml), cHDL (mg/ml) or CD (mM) 
for 6 h and cellular cholesterol was measured by Amplex Red Assay. Graph shows mean 
with S.E.M of three independent experiments B) BMDM were stimulated with 2 mg/ml 
HDL or cHDL or 10 mM for 6 h before stimulation with 2.5 uM R848 for 16 h. IL-12p40 in 
cell supernatants was measured by ELISA.  Graph shows mean with S.E.M of three 
independent experiments. These experiments (A,B) were performed together with Dr 
Dominic De Nardo. C) CD14+ monocytes were stimulated for 6 h with indicated doses of 
HDL (mg/ml) cHDL (mg/ml) or CD (mM) and cellular cholesterol measured by Amplex 
Red assay. D) CD14+ monocytes were stimulated for 2 h with 2 mg/ml HDL or cHDL or 
10 mM CD before stimulation with 125 ng/ml R848 for 16 h. TNF was measured in cell 
supernatants by ELISA. (C,D) Graphs show mean with S.D. from two independent 
donors. E) BMDMs were stimulated for 6 h with 2 mg/ml HDL or cHDL or 10 mM CD and 
Atf3 or Lss1 mRNA analysed by qPCR. Graphs show the mean with S.E.M from three 
independent experiments. F) BMDMs were stimulated for 6 h with 2 mg/ml HDL, commer-
cial HDL or 200 ng/ml LPS. Graphs show the mean with S.E.M of three independent 
experiments. Dr Dominic De Nardo performed this experiment (F). 
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appear to inhibit cytokine expression in these assays (Figure 5.1 C and D). 
This suggests that HDL may mediate an anti-inflammatory effect independent 
of its cholesterol efflux abilities.  
 
To investigate this further, ATF3 induction by HDL, cHDL or CD was 
assessed in BMDMs. As shown in Figure 5.1 E, all three agents induced Atf3 
mRNA expression to a similar extent.  However, Lanosterol Synthase (Lss1), 
a key gene in the cholesterol biosynthesis pathway and an indication of 
SREBP activation, was only modestly induced by cHDL in comparison to HDL 
and CD.  In keeping with these results, it was observed that HDL isolated 
directly from patient serum (native HDL) was also anti-inflammatory both in 
vitro and in vivo (128).  Both HDL and native HDL were able to induce Atf3 
mRNA in BMDMs, however native HDL did not appear to induce cholesterol 
biosynthesis as measured by Lss1 induction, potentially because the native 
HDL was already loaded with cholesterol. (Figure 5.1 F). While this data 
suggests that HDL may be able to induce ATF3 to be anti-inflammatory 
independently of cholesterol depletion, further experiments are required to 
definitively confirm this.  
 
HDL activates Akt signalling, but this does not appear to be involved in 
HDL's inhibitory effect on TLR-mediated cytokine production. 
 
HDL has been shown to interact with several receptors expressed on 
macrophages, such as ABCA1, ABCG1 and SR-B1 (143, 144). HDL may 
therefore initiate signalling pathways, which could potentially lead to ATF3 
induction following activation of these receptors. While ABCA1 and ABCG1 
are required for RCT in macrophages, whether they are also required for HDL 
mediated induction of ATF3 is unclear. Several studies suggested that ABCA1 
plays a role in the anti-inflammatory actions of HDL (125) (107). A student in 
the lab, Johanna Vogelhuber, Dr Dominic De Nardo, and collaboration 
partners Assistant Professor Michael Fitzgerald and colleagues (Harvard  
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Figure 5.2
HDL rapidly induces Akt phosphorylation but an Akt IV inhibitor does not affect 
HDL's anti-inflammatory effects.
A) BMDMs were stimulated with 2 mg/ml HDL for indicated times and Akt phosphoryla-
tion was analysed by immunoblot. β-Actin was analysed as a loading control. Blot is 
representative of three independent experiments and densitometry graph shows mean 
with S.E.M. from three independent experiments. P values were calculated using a one 
sample t test (with 1.0 as a hypothetical mean). p values are as follows: *: p≤ 0.05 B,C) 
BMDMs were pre-treated with 500 nM Akt IV inhibitor for 1 h before addition of indicated 
doses of HDL for 6 h. Cells were subsequently stimulated with indicated doses of CpG 
overninght. IL-6 was measured in cell supernatants by ELISA (B) or cell viability meas-
ured by CTB assay (C). Data shows average with S.D. of duplicate readings and is 
representative of two independent experiments. 
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Medical School, Boston, USA) investigated the involvement of ABCA1 in 
HDL’s anti-inflammatory actions. Preliminary results indicated that ABCA1 
and ABCG1 were not expressed on resting macrophages, indicating that their 
involvement is unlikely. Furthermore, preliminary experiments in ABCA1-
deficient macrophages showed no requirement for ABCA1 in HDL mediated 
inhibition of TLR induced cytokine expression (see also Figure 5.1). Based on 
these results, I did not investigate the involvement of ABCA1 and ABCG1 in 
the HDL-mediated induction of ATF3.  
 
Macrophage SR-B1 is able to efflux cellular cholesterol to HDL and may be 
important for protecting against atherogenesis (145). In endothelial cells, HDL 
is recognised by SR-B1(101) and the sphingosine 1- phosphate receptor 
1(S1P1)(146) to activate Akt signalling and anti-inflammatory NO production 
(147). The PI3K/Akt pathway is also anti-inflammatory in monocytes and 
macrophages and can suppress pro-inflammatory cytokine production as well 
as promote cell survival (148), similar to HDL. I therefore assessed whether 
HDL also induced Akt activation in BMDMs. Indeed HDL was able to induce 
Akt phosphorylation within 15 min of stimulation in BMDMs (Figure 5.2 A). To 
establish whether Akt activation of HDL was responsible for the anti-
inflammatory effects of HDL, I used the Akt inhibitor, Akt IV. The Akt IV 
inhibitor is known to reduce cell viability in various systems, consistent with 
Akt's role in promoting cellular survival (149). However this inhibitor did not 
reduce the ability of HDL to inhibit CpG-induced IL-6 production over a range 
of concentrations of HDL or the inhibitor (Figure 5.2 B). However, as 
expected, the Akt IV inhibitor did decrease cell viability (Figure 5.2 C). While 
this data suggests that ATF3 induction of HDL is independent of HDL-induced 
Akt signalling, and therefore probably also independent of SR-B1, further 
experiments with other PI3K/Akt pathway inhibitors such as wortmannin or 
siRNA targeted knockdown of SR-B1 could more conclusively rule out the 
involvement of this pathway.  
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Figure 5.3
Fluorescently labelled HDL acts similarly to unlabelled HDL
A) 1 mg/ml HDL (unlabelled, pHrodo labelled or Alexa 488 labelled) was run over  run 
over an S200 size exclusion column and absorbance profiles were measured. Absorb-
ance is measured as milli absorbance units. Graph is representative experiment. B) 
BMDMs were stimulated with 2 mg/ml HDL, pHrodo HDL or Alexa 488-HDL for 6 h, 
before subsequent stimulation with 100 nM CpG for 4 h. mRNA in cells was analysed by 
qPCR. Graphs show average with S.D. from duplicate readings from a single experiment
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HDL is rapidly taken up by cells and localises to lysosomes. 
 
Apart from interacting with receptors on the cell surface, HDL has been shown 
to be endocytosed and subsequently re-secreted by cholesterol laden 
macrophages, (150). To investigate whether HDL is also taken up into normo-
cholesterolemic macrophages, recombinant HDL was fluorescently labelled 
with either Alexa 488 dye, or the pH sensitive dye, pHrodo.  pHrodo dye 
dramatically increases in fluorescence when the environmental pH drops from 
neutral to acidic. Both labelled HDLs were subsequently analysed by size 
exclusion chromatography and qPCR to ensure they retained the properties of 
unlabelled HDL. While the labelled HDLs showed a slightly altered size 
exclusion profile (Figure 5.3 A), they still induced Atf3 and Lss1 expression 
and inhibited CpG-induced Il6 mRNA expression (Figure 5.3 B). This 
indicated that the labelled HDL was still functional as an anti-inflammatory 
agent, meriting its use in investigating HDL's fate in the cells.  
 
HDL uptake was initially assessed by flow cytometry. Macrophages were 
gated based on forward and side scatter for viable cells as shown in Figure 
5.4 A, and fluorescence intensity measured in the Y1 channel (561 laser with 
586/15 nm filter). HDL labelled with pHrodo was rapidly internalised (within 15 
min) with almost maximal fluorescence reached at 6 h of incubation (Figure 
5.4 B). As pHrodo is only fluorescent in acidic conditions such as within acidic 
endo-lysosomes, this should exclude that the labelled HDL is attached to the 
outside of the intact cells. As most of the previous experiments had been 
done with 2 mg/ml HDL, I investigated whether HDL uptake might be 
saturated at some point. Therefore I stimulated BMDMs with indicated 
concentrations of pHrodo HDL for 3 h. As shown in Figure 5.4 C, the amount 
of pHrodo-HDL within cells increased dose-dependently, indicating that the 
cells were not saturated with HDL at lower doses. However, the exact 
mechanism of HDL uptake into macrophages, whether receptor mediated or 
independent, remains to be determined.  
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Figure 5.4
HDL is rapidly taken up by BMDMs in a dose dependent manner.
A) Gating strategy used for BMDMs. B) BMDMs were treated with 1 mg/ml pHrodo labelled 
HDL for indicated times. Cells were washed and pHrodo fluorescence was measured by 
flow cytometry in the Y1 channel (561 laser with 586/15 nm filter). FACS plots are repre-
sentative of four independent experiments and graphs show the mean with S.E.M from 
four independent experiments. C) BMDMs were treated with indicated concentrations of 
pHrodo HDL for 3 h. Cells were washed and pHrodo fluorescence were measured by flow 
cytometry. Representative FACS plots and graphs of four independent experiments with 
mean and S.E.M are shown. 
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Having established that HDL particles are indeed internalised, I visualised the 
subcellular localisation of HDL by confocal microscopy. A previous study 
using a murine macrophage cell line, RAW264.7 cells, showed lysosomal 
localisation of fluorescently labelled ApoA1 (151).As pHrodo fluorescence 
increases in acidic conditions, I also visualised lysosomes, the acidic 
organelles, with the lysosomal specific dye, Lysotracker. After only 30 min of 
incubation, Alexa 488- labelled HDL co-localised with Lysotracker Red, 
suggesting its localisation within lysosomes (Figure 5.5 A). In particular, HDL 
staining showed accumulation in tubular structures and in vesicles, which 
were also Lysotracker Red positive. There was also no cell surface staining of 
Alexa 488 HDL, indicating the cell associated HDL had mostly been 
internalised. The HDL staining was not completely lysosome positive, 
indicating that perhaps some HDL is still in endosomes, or other cellular 
compartments. This staining was still visible 6 h after HDL stimulation, and 
indeed all cells appeared to take up HDL (Figure 5.5 B). The staining was 
consistent whether a pHrodo HDL/ Lysotracker green or Alexa 488 
HDL/Lysotracker red staining combination was used (data not shown). This 
suggests that HDL accumulates in lysosomes after uptake. As the fluorescent 
labelling is performed using amine reactive dyes, it is the ApoA1 protein 
component that is fluorescently labelled and therefore visible. Therefore it is 
unclear whether the entire HDL particle is internalised, or just the ApoA1. 
Whether the whole HDL particle is therefore degraded in the lysosome 
remains to be elucidated.  
 	    
AB
Figure 5.5
HDL localises to lysosomes.
A) BMDMs were treated with 1mg/ml Alexa 488 HDL for indicated times. Cells were 
washed twice with serum free media before 50 nM Lyostracker Red and Choleratoxin B - 
Alexa 647 were added to cells. Cells were imaged live at 37°C using confocal laser 
microscopy. Images are representative of three independent experiments. B) BMDMs 
were treated with 1 mg/ml Alexa 488 HDL for 6 h. Cells were washed twice with serum 
free media before 50 nM Lyostracker red was added to cells. Cells were imaged live at 
37°C using confocal laser microscopy. Images are representative of three independent 
experiments.
108
0.5h
0.5 h
HDL
Lysotracker Choleratoxin B 3 h
HDL
Lysotracker Choleratoxin B
6 h
HDL
Lysotracker Choleratoxin B
6h
HDL
Lysotracker
6 h
	   109	  
HDL delivers phosphatidylcholine to cells, some of which is metabolised 
further to other lipid species.  
 
HDL is composed of protein and phospholipid, of which both components 
have been shown to mediate anti-inflammatory effects in macrophages or 
endothelial cells (107, 152). ApoA1, the protein component, did not appear to 
have anti-inflammatory effects in our assay (128). It was therefore possible 
that phosphatidylcholine or a metabolic bi-product of its degradation was 
mediating the anti-inflammatory effects of HDL. To assess this, lipidomics of 
HDL treated macrophages was performed at the Kansas Lipidomics Research 
Centre, with assistance from Dr. Michael Fitzgerald. PC can be further 
metabolised into various other lipid species, including Phosphatidic Acid (PA), 
Phosphatidylserine (PS) and Phosphatidylethalanomine (PE), or they can be 
cleaved to yield lysophosphatidylcholine (LysoPC) and arachadonic acid (AA) 
(For an overview see Figure 5.6)   
 
 
 
As anticipated, HDL alone had large amounts of phosphatidylcholine (PC), 
particularly of the 36:3, 36:4, 36:5 and 34:2 species (Figure 5.7 A), seen in the  
Figure 5.6
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Schematic of PC metabolites and the enzymes mediating the reactions.
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Figure 5.7
HDL delivers phosphatidylcholine to cells, 
some of which is further metabolised.
BMDMs were treated with 2 mg/ml HDL for 6 h, or 
media alone. I performed cell culture and harvest 
and subsequently cell pellets and cell superna-
tants or media with HDL alone (no cells) were 
analysed for lipid content by the KLRC in associa-
tion with Assistant Professor Michael Fitzgerald. A) 
Phosphatidylcholine species, B) Lysophophatidyl-
choline species, C) Phosphatidic Acid species or 
D) Phosphatidylethanolamine species were 
measured in cell pellets or cell supernatants. 
Graphs show mean with S.E.M. from 5 biological 
replicates. Only lipid species that were significantly 
different between control and HDL treatments are 
shown. Significance was calculated using an 
upaired t test. 110
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bars that are denoted HDL alone. Accordingly, HDL treated cells had 
significant intracellular increases in all of these PC species. Of the lipid 
species detected, significant changes upon HDL treatment were only 
observed in LysoPC, PA, and PE. An overview of the general lipid changes 
upon HDL treatment is given in Table 5.1. 
 
Abbreviation Lipid Detectable Present in 
HDL itself 
Significant 
change in 
cells with 
HDL 
lysoPE lysophosphatidylethanolamine very low no no 
PE phosphatidylethanolamine very low no yes 
(increased) 
ePE ether-linked 
phosphatidylethanolamine 
very low no no 
PE-cer ceramide 
phosphorylethanolamine 
(sphingolipid analog of PE) 
very low no no 
lysoPC lysophosphatidylcholine yes yes yes 
(increased) 
PC phosphatidylcholine yes yes yes 
(increased) 
ePC ether-linked 
phosphatidylcholine 
yes yes no 
SM sphingomyelin yes no no 
DSM dihydro-sphingomyelin yes yes no 
PA phosphatidic acid yes yes yes 
(increased) 
PI phosphatidylinositol low no no 
PS phosphatidylserine yes no no 
CE cholesterol ester yes no yes 
(decreased) 
 
Table 5.1. Summary of lipidomics analysis performed by KLRC. 
 
Interestingly, analysis of the LysoPC species showed an increase in LysoPC 
(18:3) and LysoPC (18:2), consistent with metabolism of PC species (34:3) 
and PC (34:2) respectively (Figure 5.7 B). There was no significant increase 
in other LysoPC species. Similarly, PA is generated from PC by cleavage of 
the choline head group. There was also a significant increase in PA species of 
the same composition as the PC (i.e. 36:3, 36:4, 36:5 and 34:2 species), 
indicating metabolism of the PC (Figure 5.6 C). Some of these PA species 
appear to already be present in the HDL, though this was measured together 
with media and some of the phospholipase D enzymes responsible for the PC 
to PA conversion may be present in the serum. Finally, some low levels of PE   
A B
Figure 5.8
Bafilomycin and NH4Cl do not clearly block ATF3 induction by HDL.
A) BMDMs were pre-treated with 20 mM NH4Cl or 10 nM Bafilomycin for 1 h before 
stimulation with 2 mg/ml HDL for 6 h. Cells were lysed and ATF3 and β-actin protein 
analysed by immunoblot. Blots are representative of three independent experiments 
and graphs show densitometry combined from three independent experiments with 
mean and S.E.M. B) BMDMs were pre-treated with 20 mM NH4Cl or 10 nM Bafilomy-
cin for 6.5 h before stimulation with 100 nM CpG for 30 mins. Cells were lysed and 
phosphorylation of p38 and β-actin was measured by immunoblot. Blots are repre-
sentative of three independent experiments and graphs show densitometry combined 
from three independent experiments with mean and S.E.M. 
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species, two of which are comparable with the significant PC species (36:3 
and 34:2) were also detected, indicating further metabolism after PS 
generation (Figure 5.6 D).  This data suggests that HDL delivers substantial 
amounts of PC to the cells, and this may be further metabolised into other 
phospholipid species, with the accompanying release of fatty acids and 
arachadonic acid (which were not detected in this mass spectrometry 
analysis), which may be required for signalling. However, whether 
phospholipids alone are enough to induce ATF3 and to have an anti-
inflammatory effect remains to be determined.  
 
Many of the phospholipase enzymes that are required for PC metabolism 
require an acidic pH environment for optimal activity (153). Considering that 
HDL-derived PC metabolites are detectable in the cell, and the lysosomal 
localisation of HDL, I hypothesised that lysosomal catabolism of HDL may 
result in a signalling molecule that induces ATF3. I therefore tried to 
determine whether inhibiting lysosomal acidification, and therefore 
presumably reducing lysosomal phospholipase activity, might inhibit ATF3 
induction by HDL. Bafilomycin A1, Ammonium Chloride (NH4Cl) and 
Chloroquine are all endo-lysosomal acidification inhibitors (154, 155), albeit 
with other non-specific effects on the cell. High doses of Choloroquine and 
Bafilomycin A1 strongly induced ATF3 protein expression on their own, and 
therefore were not used (data not shown). Lower doses of Bafilomycin and 
NH4Cl were used to study whether these inhibitors could block HDL-induction 
of ATF3. HDL induced ATF3 expression even in the presence of Bafilomycin 
or NH4Cl (Figure 5.8 A). Unfortunately, both low doses of Bafilomycin and 
NH4Cl also induced ATF3 expression making the interpretation of results 
difficult. However, Bafilomcyin and NH4Cl did inhibit CpG-induced p38 
phosphorylation, an event that requires endo-lysosomal acidification, 
indicating that the inhibitors were indeed functional at these concentrations 
(Figure 5.7 B). An intended siRNA screen of potential phospholipases, which 
should inhibit phospholipid catabolism and therefore reduce the amount of 
potential lipid signalling intermediates, might provide some alternate insight 
into the importance of HDL catabolism for ATF3 induction.  
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Conclusions. 
 
Together, the data presented in this chapter provides some preliminary 
evidence towards a mechanism for how HDL induces ATF3. HDL-mediated 
cholesterol depletion does not appear to be necessary for the anti-
inflammatory effects of HDL, similarly, different forms of HDL induced ATF3 
expression, though cholesterol biosynthesis genes were not induced to the 
same extent. Akt activation, while induced by HDL, did not appear to be the 
mechanism by which HDL induces ATF3. Interestingly, HDL is rapidly 
internalised into lysosomal compartments of macrophages and remains there 
for up to 6 h. HDL also delivers large amounts of PC to cells and accordingly, 
cells treated with HDL have higher levels of PC metabolites. These 
metabolites may be involved in HDL mediated ATF3 induction. However, 
inhibitors of lysosomal acidification such as Bafilomycin and NH4Cl are 
unsuitable for studying HDL mediated ATF3 induction as they induce ATF3 
expression themselves.  These experiments provide some evidence towards 
the fate of HDL following treatment of normo-cholesterolemic macrophages, 
and how HDL induces ATF3, however further experiments are needed to rule 
out the involvement of various receptors and obvious cellular pathways like 
cholesterol depletion.  
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6. Discussion 	  	  
The beneficial effect of HDL in CVD and other inflammatory diseases has long 
been attributed to its functions in mediating reverse cholesterol transport. 
While this is undoubtedly a major contributing factor, the other protective 
functions of HDL, such as its anti-inflammatory effects, are becoming more 
widely appreciated. To date, extensive mechanistic studies of HDL's effects 
on macrophage activation, a key step in the initiation of inflammation, have 
been lacking. This study characterized the effect of HDL on TLR-mediated 
pro-inflammatory cytokine release, a key event during both infection and 
sterile inflammation.  
 
HDL inhibits TLR-mediated macrophage activation without disrupting 
TLR signalling 
 
A key finding of this thesis was that HDL inhibited IL-6, IL-12, TNF and IFNβ, 
released from non-lipid laden macrophages in response to a wide array of 
TLR ligands (Figure 3.1). Furthermore, this effect was consistent across 
species and was observed in monocytes as well as macrophages (Figure 3.1 
and 3.2). In contrast to previous studies however, HDL did not appear to 
disrupt TLR signalling, either at the MAPK or NFκB activation level (Figure 
3.7).  
 
Biochemical studies assessing TLR4 localisation to detergent resistant 
membranes (DRMs), i.e. lipid rafts, and lipid raft disruption using Methyl-β-
cyclodextrin (MCD) suggest that lipid rafts are indeed necessary for TLR 
signalling (115, 120). The characterisation of DRMs and associated proteins 
is controversial, as it is performed under highly artificial conditions (e.g. in 
detergent, at 4°C) (156). Similarly, MCD may affect other cellular processes 
that could potentially interfere with TLR activation, such as lateral protein 
immobilisation or membrane depolarisation as well as depleting membrane 
cholesterol (113). While HDL depleted cellular cholesterol (Figure 3.4), 
whether this was depleted from the plasma membrane or from internal cellular 
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organelles was not investigated. To investigate this more thoroughly, isolated 
plasma membranes from HDL treated cells could be analysed for cholesterol 
depletion by mass spectrometry. However, regardless of whether HDL 
depletes cholesterol from the plasma membrane or other cellular 
compartments (e.g. the ER), the anti-inflammatory effect of HDL appears to 
be independent of lipid raft-mediated TLR signalling disruption. Whether lipid 
rafts are indeed necessary for TLR-mediated signalling remains to be 
determined.   
 
The discrepancies between this study and previous studies that suggested a 
role for lipid rafts and ABCA1 may lie in the difference between the 
macrophages used; i.e. cholesterol loaded vs resting/naive macrophages. 
ABCA1 and ABCG1 mediate cholesterol efflux, but primarily from lipid-laden 
macrophages (86).  Indeed, preliminary data suggests that HDL still blocked 
TLR-induced IL-6 production in ABCA1-deficient macrophages indicating that 
ABCA1 does not play a major role in the anti-inflammatory role of HDL in this 
system (Figure 6.1). However, consistent with an earlier report (120) , 
ABCA1-deficient macrophages produced more IL-6 in response to P3C in the 
absence of HDL, indicating it still may be an anti-inflammatory receptor (Data 
from Assistant Professor Michael Fitzgerald, Figure 6.1).   
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Figure 6.1
HDL is still anti-inflammatory in ABCA1-deficient BMDMs
WT and ABCA1 KO BMDMs were pre-treated with HDL (indicated doses) for 6 h before subsequent 
stimulation with 25 ng/ml P3C or 25 nM CpG overnight. IL-6 was measured in cell culture superna-
tants. Graph shows average + S.D and is representative of three independent experiments. This 
experiment was entirely performed by Assistant Professor Michael Fitzgerald and colleagues. 
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HDL modulates pro-inflammatory gene expression via ATF3 
 
By systematically investigating each step of TLR-mediated activation, HDL 
was identified to be mediating its effects at the level of transcription. HDL 
inhibited CpG- and P3C- induced Il6, Il12b, Ifnb and Il1b mRNA expression 
(Figure 3.8). Experiments by Dr Dominic De Nardo using Actinomycin D to 
inhibit transcription confirmed that Il6 mRNA stability was not affected by HDL 
treatment, suggesting that HDL indeed inhibits pro-inflammatory gene 
transcription (128). HDL did not inhibit CpG- or P3C- induced Tnf mRNA 
expression in mouse macrophages, but it did inhibit P3C- induced TNF mRNA 
in human monocytes (Figure 3.8). The discrepancy between TNF mRNA and 
secreted cytokine levels upon HDL treatment in mouse macrophages was not 
investigated further, but it is possible that the timepoint chosen to investigate 
HDL's effects on Tnf mRNA was too late, as TNF is an acutely induced 
primary response gene. Furthermore, the mRNA stability of TNF was not 
investigated, and as TNF is highly post-transcriptionally regulated (157) HDL 
may indeed influence TNF expression at this level. 
 
HDL does not induce an M2-like phenotype.  
 
Macrophages have previously been characterised as either activated (M1) or 
alternatively activated (M2) based on the similarity of their phenotypes to 
activation with IFNγ and TLR ligands or IL-4 and IL-13 respectively (3). The 
M2 macrophage has long been considered anti-inflammatory, and indeed 
HDL has previously been described to induce an M2-like state in plaque-
associated macrophages in mice (108, 158). This M2 phenotype is 
characterised by a decrease in pro-inflammatory M1 markers such as Tnf and 
an increase in M2 markers such as Arg1, Fizz1 and Il10 (108). No evidence of 
a shift to an M2 like phenotype upon treatment with HDL was observed in this 
study, neither in the transcriptomic analysis, nor in analysis of the M2 markers 
listed above by qPCR (data not shown). In a recent study of macrophage  
M2 M1
Figure 6.2 
HDL treated HMDMs show phenotypic similarities to other anti-inflammatory 
treatments rather than to M1 or M2 polarisation.
HMDM were treated for 6 h with 2 mg/ml HDL (by myself and Dr Dominic De Nardo). 
mRNA extraction and microarray analysis was subsequently performed by Prof. Joachim 
Schultze and colleagues. Graph is from Figure 1 (i) of (Xue et al., 2014), and shows a 
matrix of hierarchically clustered treatments  Pearson’s correlation coefficient matrix 
(CCM) standardized from -2.78 to 2.78 (blue to red) based on 1,000 most variable 
probes. The anti-inflammatory treatments (e.g. IL-10, glucocorticoids) are boxed and 
typical M1 or M2 stimuli are indicated. 
Xue, J., Schmidt, S.V., Sander, J., Draffehn, A., Krebs, W., Quester, I., de Nardo, D., 
Gohel, T.D., Emde, M., Schmidleithner, L., et al. (2014). Transcriptome-based network 
analysis reveals a spectrum model of human macrophage activation. Immunity 40, 
274–288.
118
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activation performed by Prof. JLS and colleagues, the traditional M1/M2 
macrophage polarization study was challenged and ultimately deemed to be 
too simplistic. In this study, datasets from human macrophages stimulated 
with a diverse range of stimuli were analysed and the conclusion was that 
macrophage activation was instead best defined as a spectrum model of 
different phenotypes (159). Dr. Dominic De Nardo and I contributed to this 
study by generating samples from HDL treated HMDMs which were included 
in the analysis of macrophage phenotypes. Interestingly, while HDL treatment 
did not cluster with an M2 phenotype on this spectrum, it was nevertheless 
spatially closer to an M2 phenotype than M1 (Figure 6.2 and (159)). HDL also 
clustered with other anti-inflammatory treatments such as IL-10 and 
glucocorticoid treatment (Figure 6.2 and (159)). Consistent with this, a recent 
report also found that HDL did not induce an M2 phenotype in human 
monocytes or macrophages in vitro (160). Whether the M2 phenotype is more 
important for HDL's effects on lipid-laden, plaque-associated macrophages 
rather than for normo-cholesterolemic macrophages derived in vitro remains 
to be confirmed. 
 
Many pro-inflammatory genes are ATF3 targets 
 
HDL treatment leads to global changes in macrophage gene expression. The 
transcriptional repressor ATF3 mediated much of HDL’s effects on TLR-
induced inflammatory gene expression, which was the focus of this study. 
ATF3 is a well established negative regulator of inflammatory gene 
expression (26). This has been confirmed in various studies, and many of the 
genes that were affected by HDL both in vivo and in vitro (128) are indeed 
published ATF3 target genes. A list of these target genes, and the 
inflammatory disease models where ATF3 deficiency leads to increased 
disease susceptibility is detailed in Table 6.1.  
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Target gene (repressed 
by ATF3 unless stated 
otherwise) 
Disease model Cell type  Reference 
CXCL1 
TIAM2 
Neutrophilic airway 
inflammation 
Airway epithelium (in 
vivo lung) 
Neutrophils 
(161) 
IL-6, IL-12, TNF, iNOS LPS-induced Sepsis ATF3-/- versus WT 
BMDM 
(26) 
C/EBPδ TLR4 activation ATF3-/- versus WT 
BMDM 
(24) 
CCL4 (MIP-1β) TLR (2,3,4,5) activation ATF3-/- versus WT 
BMDM 
(162) 
CH25H Atherosclerosis ATF3-/- versus WT 
BMDM 
(137) 
STAT1 (induced) Interferon gamma - induced 
cytotoxicity, type I diabetes 
Pancreatic β cell line (163) 
IL-6,IL-12 Renal 
Ischaemia/Reperfusion 
injury 
Renal tubular epithelial 
cells 
Kidney tissue  (in vivo) 
(164) 
CXCL10 (IP-10) 
(induced) 
TLR9 activation RAW264.7 (siRNA 
knockdown of ATF3) 
(165) 
IFNγ Murine cytomegalovirus 
infection 
ATF3-/- versus WT 
Natural Killer cells 
(166) 
 
Table 6.1: This table lists known inflammatory target genes of ATF3. Furthermore the 
significance of ATF3 and the modulation of these target genes in disease models is also 
outlined. Finally the cells in which these ATF3 target genes were identified is also detailed.   
 
IFNβ may be an ATF3 target gene 	  
During the course of this study IFNβ was also identified as a potential ATF3 
target gene. ATF3-deficient macrophages had higher basal and inducible 
levels of IFNβ mRNA and protein in response to TLR and STING ligands 
(Figures 4.11 and 4.12). This has since also been confirmed in ATF3-deficient 
immortalised BMDMs reconstituted with ATF3, which have lower basal and 
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inducible IFNβ (unpublished results from Larisa Labzin and Dr Dominic De 
Nardo). Furthermore, specific ATF3 binding was predicted in an enhancer 
element of the IFNβ promoter from the ChIP Sequencing described in this 
thesis (see Chapter 4, analysis performed by Dr Susanne Schmidt and 
Professor Joachim Schultze). IFNβ was also reported as an ATF3-target gene 
earlier this year (167), however this was poorly characterised, and the ATF3 
binding site within the IFNβ promoter described needs to be verified, as this 
site showed non-specific binding in ATF3-deficient cells in our ChIP 
Sequencing study. Finally, ATF3-deficient immortalised BMDMs inhibited in 
vitro viral replication better than wild type macrophages, presumably because 
of higher levels of IFNβ (unpublished results from Larisa Labzin and Dr 
Dominic De Nardo). However, whether ATF3 modulation of IFNβ is important 
in a disease setting remains to be determined. ATF3 deficient mice were 
reported to recover more slowly from influenza, as assessed by overall weight 
loss (28), however when we repeated this model (in a collaboration with 
Tristan Holland and Professor Natalio Garbi, IMMEI, Bonn) no significant 
differences in body weight, indicative of disease severity between wild type 
and ATF3-deficient mice were observed (Figure 6.3). The role of ATF3 in 
infectious disease may be difficult to dissect as ATF3 targets both pro-
inflammatory cytokines such as IL-6 and IL-12 as well as IFNγ, a key 
regulator of the adaptive immune response to viral infection (166). As such, 
the beneficial effects of IFNβ for clearing an infection may be difficult to 
distinguish from detrimental effects of a hyper-inflammatory response and the 
contribution of the adaptive immune response.   
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HDL and ATF3 Isoforms 	  
Full length human ATF3 was first isolated and described in 1989 by Hai and 
colleagues (168) and further characterised as a transcriptional repressor in 
1994 (136). While mouse ATF3 has one transcript variant encoding one 
protein, human ATF3 has 6 transcript variants encoding 4 different protein 
isoforms as indicated in Figure 4.5 A. The full length ATF3 isoform (1), 
containing the DNA binding bZIP domain, is best characterised as the 
transcriptional repressor, while isoform 2, also known as ATF3ΔZip is unable 
to bind DNA and therefore may act as a transcriptional activator, presumably 
by sequestering co-repressors away from target promoters (136). However, 
the biological relevance of these different isoforms, particularly for innate 
immunity, remains undefined. HDL induced the long isoform of ATF3 in 
human monocytes (Figure 4.5), indicating that HDL utilises ATF3's 
transcriptional repressor properties.  As well as regulation of ATF3 by 
alternative splicing and different isoforms, ATF3 may indeed by induced via 
alternate promoters depending on stimuli and cell type (169). The induction of 
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Figure 6.3
ATF3-deficient mice show no differences in recovery from PR8 influenza infection.
5-month-old sex matched WT and KO mice were infected intra-nasally with PR8 virus (103 
focus formation units - FFU) (5 mice per group) by Tristan Holland (AG Garbi, IMMEI). Dr 
Dominic De Nardo and myself weighed mice every day for fourteen days. Graphs show mean 
with S.E.M, with weights made relative to the initial weight before infection.  
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ATF3 in human macrophages in response to TLR ligands or HDL, and the 
exact isoforms generated or promoters needs to be characterised in more 
detail.  
Mammalian ATF3 also has a paralog in Jun - dimerizing protein 2 (JDP2), 
which shares 61% overall homology with ATF3. However this similarity is 
limited mostly to its bZIP domain (170).  This suggests that ATF3 and JDP2 
may be able to bind the same target DNA, while their interactions with other 
proteins may differ. JDP2 can also induce ATF3 expression (170). In addition, 
ATF3 may also form heterodimers with other ATF/CREB proteins, including 
ATF2, c-Jun, Jun B or Jun D to act as transcriptional activator or repressor 
depending on the promoter context (25). Whether HDL also affects JDP2, or 
ATF3 heterodimers remains to be investigated.  
There is some evidence that ATF3 may also be subjected to post-translational 
modifications (PTMs). ATF3 appears to be ubiquitinated and targeted for 
degradation by the E3 ubiquitin ligase Mouse Double Minute homolog 2 
(MDM2) (171).  ATF3 has also been shown to be SUMOylated, whereby the 
attachment of small - ubiqutin like modifiers (SUMO) at the lysine residue 42 
of ATF3, may enhance its repressive function for certain target genes (172). 
However, the effect of these PTMs on innate immunity and, whether HDL also 
affects ATF3's activation state as well as its expression, remains to be 
elucidated. 
ATF3's mechanism of action 	  
ChIP sequencing of resting or stimulated BMDMs suggested a model for 
ATF3 binding to inflammatory gene promoters consistent with its role as a 
transcriptional repressor. Some ATF3 was bound to promoters in a resting 
state, and this was lost with CpG treatment, consistent with transcriptional 
activation (Figure 4.8 B). Addition of HDL increased the amount of ATF3 
bound across promoters, consistent with transcriptional repression (Figure 4.8 
B). ATF3 is proposed to mediate its repressor activity by interaction with 
HDAC1 (26), which modulates chromatin conformation. Further ChIP-
Sequencing experiments to determine histone acetylation upon HDL 
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treatment could indicate whether HDL-induced ATF3 is acting as a 
transcriptional repressor via HDAC1. Alternatively, experiments in HDAC1-
deficient cells (173) could confirm a role for HDAC1 in the HDL-mediated anti-
inflammatory effect, rather than using HDAC inhibitors which can have anti-
inflammatory effects themselves (174). 
ATF3 and metabolism 	  
The role of ATF3 as a negative regulator of inflammation appears to be highly 
conserved, as studies in Drosophila show that ATF3 is required for immune 
and metabolic homeostasis (175). Indeed, ATF3-deficient Drosophila showed 
dysregulated gene expression for genes involved in inflammation, immune 
defence and lipid metabolism, resulting in chronic inflammation in the larval 
gut epithelium and lipid overload in the fat body (175). Human ATF3 is some 
450 amino acids shorter than Drosophila ATF3, however there is high 
evolutionary conservation in the bZIP domain, and, consistent with this, 
reconstitution of ATF3-deficient Drosophila with human ATF3 was able to 
partially rescue the phenotype (175), indicating a conserved role for ATF3 
across these species. Further studies in mice have implicated ATF3 in 
regulation of metabolism.  For instance, ATF3 negatively regulates the gene 
Ch25h, which encodes the enzyme cholesterol- 25-hydroxylase and is 
required for lipid body formation and implicated in atherosclerosis progression 
(137). Furthermore, ATF3 was shown to repress low-density lipoprotein 
receptor (LDLR) expression in a human liver cell line under conditions of 
organelle stress (176). ATF3 may therefore be a key regulator of the cross-
talk between innate immunity and metabolism. Importantly however, while 
ATF3 may be protective in the context of inflammation, it is also highly 
expressed in tumour tissues and is associated with tumour progression (177). 
Therefore, the effects of ATF3 on gene modulation may be protective or 
harmful depending on tissue and cellular context.  
Regulation of ATF3 expression 	  
A key question raised by this study is how HDL induces ATF3 expression. In 
addition to its induction by TLR stimuli, ATF3 induction has been described in 
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response to numerous signals, including endoplasmic reticulum (ER) stress, 
growth factors and hormones, cytokines, chemokines, adipokines, nutrient 
deprivation, hypoxia, DNA damage and chemotherapeutic agents (141). A 
summary of studies detailing ATF3 induction by various stimuli is presented in 
Table 6.2.  
 
Stimulus Pathway/Transcription 
Factor 
Cell Type Reference 
Cholesterol depletion n.d. Human prostate 
tumour cells 
(142) 
ER Stress JNK, JDP2 Mouse Embryonic 
Fibroblasts 
(170) 
LPS - Reactive 
Oxygen Species 
(ROS) Stress 
NF-E2 Related Factor 2 
(NRF2) 
BMDM (27) 
Oxygen-glucose 
deprivation 
Calcium signalling, 
CREB 
Mouse hippocampal 
Neurons 
(178) 
TLR ligand NFkB, c-Src BMDM (26, 28, 165) 
MCMV n.d. Mouse livers (166) 
PEG-IFNα n.d. Human PBMCs (179) 
Non-steroidal anti-
inflammatory drugs 
(NSAIDS) 
NSAID-activated gene 1 
(NAG-1), Early Growth 
response-1 gene  (EGR-
1) 
Human colorectal 
cancer cells 
(180) 
Stress signals: 
asinomycin, IL-1β, 
TNF 
p38 HeLa cells (181) 
TGFβ SMAD3 Human epithelial cells, 
human breast cancer 
cell lines 
(182) 
(183) 
Heat shock Heat Shock 
Transcription Factor 1 
(HSF1) 
MEFs (184) 
 
Table 6.2: Induction of ATF3 by various stimuli by various pathways in different cell types.  
 
 
An attractive hypothesis is that ATF3 is a direct SREBP target gene and is 
induced in response to cellular cholesterol depletion by HDL. There are 
numerous Sterol Response Elements (SREs), which are SREBP binding 
sites, in both the mouse and human ATF3 promoters (Dr Susanne Schmidt, 
personal communication). Furthermore, cholesterol depletion induced ATF3 
expression in mouse and human prostate cells (142). In contrast, cHDL, 
which only modestly induced expression of cholesterol biosynthesis genes 
compared to HDL (suggesting modest SREBP activation), induced ATF3 and 
blocked TLR-induced IL-6 expression to the same extent as HDL (Figure 5.1). 
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Whether SREBP is required for ATF3 induction by HDL could be investigated 
using SCAP-deficient mice or siRNA knockdowns of SCAP or SREBP.  
 
HDL and endo-lysosomal localisation. 
 
Similarly, the involvement of SR-B1, ABCA1 and ABCG1 as potential HDL 
receptors for induction of ATF3 cannot be completely ruled out. To this end, 
siRNA knockdown experiments to establish whether these pathways are 
involved in HDL's anti-inflammatory effects could be performed. Interestingly, 
HDL appeared to be rapidly taken up by macrophages, and particularly into 
endo-lysosomal structures. This may however just be fluorescent ApoA1 that 
is visualised, as the protein component, rather than the phospholipid was 
labelled. The endo-lysosomal localisation of HDL is consistent with a study by 
Faulkner et al, however they also showed that ApoA1 uptake is dependent on 
ABCA1 up-regulation by pre-treatment with cyclic AMP (cAMP) (151). While I 
anticipate that ABCA1 will not be required for macrophage HDL uptake, it 
cannot be excluded. If HDL uptake is receptor-mediated, using non-labelled 
HDL to compete with labelled HDL for uptake may allow this question to be 
resolved. The amount of fluorescent HDL that can be internalised in such a 
scenario will be decreased, as non-labelled HDL will compete for receptor 
binding. Further studies could also be performed with inhibitors of endocytosis  
(such as dynasore) and phagocytosis (such as cytocalasin D).   
Interestingly, Cai and colleagues recently reported the induction of ATF3 by 
apilimod, a PIKfyve inhibitor (167).  PIKfyve, a class III lipid kinase, 
phosphorylates endosomal phosphatidylinositol 3-phosphate (P1(3)P) to yield 
phosphatidylinositol 3,5-bisphosphate (PI(3,5)P2). The authors suggest that 
apilimod induces ATF3 by causing an imbalance of PI(3)P/PI(3,5)P2 in endo-
lysosmal membranes, which is sensed by an unknown lipid sensor in the 
endo-lysosome (167). Whether HDL is also sensed from the endo-lysosome 
to induce ATF3 remains to be determined.   
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HDL and its phospholipids. 
 
Several studies in endothelial cells suggest that HDL is anti-inflammatory via 
its phospholipid components, such as lysosphingolipids (104). While the rHDL 
used in this study contains phosphatidylcholine (PC), rather than the complex 
mix of phospholipids likely found in native HDL, it is conceivable that the PC is 
mediating much of the anti-inflammatory effect of HDL, as PC has been 
reported to be anti-inflammatory in ulcerative colitis (185), though this is likely 
due to effects on mucosal membranes (186). ApoA1 alone did not show the 
same anti-inflammatory effects as HDL (128), indicating that the PC may 
mediate much of the effect. Whether PC alone is mediating the anti-
inflammatory effects of HDL could be assessed by using PC uni-lamellar 
vesicles and investigating their effect on TLR-mediated macrophage 
activation..  
 
Lipidomics analysis of HDL treated cells confirmed that HDL delivered large 
amounts of PC into the cells. Whether this PC is distributed throughout the 
cell or concentrated in specific membranes is unclear. Further analysis by 
lipidomics suggests that the PC present in HDL could be metabolised further 
to other lipid species. PC can be metabolised into various products, including 
other phospholipids such as PE, PS or PA, or into lyso-phospholipids and 
fatty acids (Figure 5.6). These metabolites could conceivably activate 
signalling pathways to induce ATF3 expression. 
 
One of the key PC metabolites detected in HDL treated cells was lysoPC 
(Figure 5.7). The conversion of PC to lyso PC and Arachadonic Acid is 
mediated by the phospholipase A2 (PLA2) enzyme family (187). This family 
consists of 15 groups of enzymes that can be broadly categorized into 5 
subtypes, the secreted PLA2 enzymes (sPLA2), the cytosolic PLA2 enzymes 
(cPLA2), the Calcium independent PLA2 enzymes (iPLA2), the lysosomal PLA2 
enzymes (lPLA2) and the Platelet - Activating Factor Acetylhydrolases (PAF-
AH) (187). As lyso PC was detected in both HDL treated cells and in HDL 
alone, it is conceivable that Lyso PC could have been converted from HDL 
associated PC either by sPLA2 enzymes present in the serum, or from PLA2 
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enzymes in the cells. Considering the lysosomal localisation of HDL in 
macrophages, perhaps lysosomal PLA2 is a key enzyme required to release 
lysoPC, which could subsequently activate ATF3, as has been reported in an 
earlier study (188). Alternatively, the arachadonic acid released could be 
further metabolised via the cyclo-oxygnase (Cox) enzymes to prostaglandins 
(189).  Indeed, 15-Deoxy-Δ12,14,-prostaglandin J2, an anti-inflammatory 
prostaglandin, can activate the transcription factor Nuclear factor (erythroid-
derived 2)-like 2 (NRF2) to induce anti-inflammatory Heme Oxygenase 1 (HO-
1) signalling (189). HDL has been shown to induce HO-1 in endothelial cells 
(101), and Dr Dominic De Nardo confirmed that NRF2-deficient macrophages 
could no longer induce HO-1 expression in response to HDL, which suggests 
a possible role for arachadonic acid metabolism. However NRF2, which has 
been shown to induce ATF3 in other systems (27), did not appear to mediate 
HDL's induction of ATF3 (Dr Dominic De Nardo, data not shown).  15-Deoxy-
Δ12,14,-prostaglandin J2 is also a ligand for the anti-inflammatory transcription 
factor peroxisome proliferator-activated receptor gamma (PPARγ)(189). 
Whether this pathway influences ATF3 expression has not yet been 
investigated.  
In addition to AA, PC can also be further metabolised into Phosphatidic Acid 
(PA) by the phospholipase D (PLD) enzymes, of which there are two in 
mammals: PLD1 and PLD2 (190). Interestingly, from the lipodomic data 
presented herein, of all the metabolites examined, levels of PA were higher in 
the HDL treated cells than in the supernatant, indicating that perhaps HDL-
derived PC is mainly converted into PA (Figure 5.7). However, PA is unlikely 
to be an intermediate to ATF3 induction by HDL as lysosomal localisation of 
these enzymes is not described (190), and PA treatment of macrophages was 
reported to enhance pro-inflammatory cytokine secretion (191) rather than 
inhibit it. 
Finally, small amounts of Phosphatidylethanolamine (PE) were detected in 
cells treated with HDL. PC can be converted to Phosphatidylserine (PS) by 
the enzyme PS-synthase 1 (PSS1). PS can then be further converted to PE 
by the mitochondrial enzyme PS decarboxylase (PCD). To date, neither PS 
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nor PE has been implicated in anti-inflammatory signalling. However, 
performing an siRNA screen to investigate the importance of some of these 
phospholipases, and therefore of the PC metabolites, in the induction of ATF3 
by HDL could help reveal the underlying mechanism.  
Based on the lysosomal localisation of HDL, plus the requirement of acidic 
pH's for optimal enzymatic activity for various phospholipases (153) I 
hypothesised that lysosomal catabolism of HDL may lead to a signalling 
intermediate that induces ATF3. However, I was unable to infer whether 
lysosomal acidification was necessary for ATF3 induction by HDL, as the 
lysosomal acidification inhibitors used directly induced ATF3. Therefore 
whether lysosomal phospholipase activity is required for HDL-mediated 
induction of ATF3 is still unclear.  
Mechanism of ATF3 induction by HDL 
 
Whether ATF3 is directly induced by HDL or via a secondary mediator is also 
difficult to ascertain. The slow induction of ATF3 by HDL (approximately 6 h) 
suggests that secondary mediator is required. Usually treatment with a protein 
synthesis inhibitor such as cyclohexamide can help distinguish if gene 
expression requires de novo synthesis of an intermediate. However 
cyclohexamide induces ATF3 expression itself, presumably as a cell stress 
response, which therefore excludes the use of this reagent. Whether any of 
the transcription factors induced by HDL, as identified in the transcriptome 
analysis, could bind to the ATF3 promoter could provide a starting point for 
potential intermediates.  
 
HDL has been shown to induce TGFβ expression (103), which could 
potentially act in an autocrine manner to induce ATF3 via SMAD3 (182). 
TGFβ induction by HDL was shown to be PI3K/Akt-dependent in endothelial 
cells (103) while ATF3 induction by TGFβ was shown in epithelial cells (182).  
HDL certainly activated Akt in macrophages, however whether this results in 
subsequent TGFβ-mediated ATF3 induction remains to be determined. The  
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Figure 6.4
Potential mechanisms for HDL induction of ATF3
A) SCAP/SREBP sensing of HDL mediated cholesterol depletion could activate SREBP 
to induce ATF3. B) Phosphatidylcholine metabolism in the endo-lysosome is sensed by 
an unknown sensor that leads to ATF3 induction. Alternatively, signalling lipids released, 
such as prostaglandins, activate transcription factors like PPARγ to induce ATF3. C) HDL 
induces TGFβ in a PI3K/Akt dependent manner, which subsequently acts on the cell in 
an autocrine manner to induce ATF3 via SMAD3
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involvement of TGFβ could also be investigated using an siRNA knockdown 
approach or in KO mice.  
 
Finally, another systematic approach could be used to investigate the HDL-
mediated induction of ATF3. Biotinylated fragments of the ATF3 promoter 
could be incubated with nuclear extracts from HDL treated cells, and used as 
bait to isolate any bound TFs. The TFs could then be identified by mass 
spectrometry, and compared to non-treated cells as a control. This approach 
has been used by other to identified both known and novel TFs binding to the 
human metastasis associated 1 family, member 2 (MTA2) gene promoter 
(192). The mechanism of induction could then be inferred from the 
transcription factor bound to the ATF3 promoter under HDL treatment alone.  
A summary of hypothesised mechanisms for ATF3 induction by HDL is given 
in Figure 6.4.  
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Atherosclerosis, HDL and ATF3 	  
HDL is primarily known for its protective function in atherosclerosis and in 
particular for its cholesterol efflux effects via RCT. While the contribution of 
inflammation to atherosclerosis is widely acknowledged, the relative 
importance HDL's anti-inflammatory effects compared to its cholesterol efflux, 
anti-oxidant and anti thrombotic effects is difficult to quantify. Indeed, it is 
possible that all of these actions are inextricably linked, and that the anti-
inflammatory effect of HDL is a result of its RCT function. Therefore, it is 
difficult to establish the importance of ATF3 to HDL's protective effects in 
atherosclerosis in vivo.  
When fed on a high fat diet, ATF3- and ApoE- double deficient mice develop 
increased atherosclerosis compared to ApoE- deficient mice alone, due to 
increased 25-Hydroxycholesterol induced lipid body formation in 
macrophages (137). Whether infusions of recombinant human HDL (such as 
the HDL used in this study) are protective in mouse models of atherosclerosis 
(e.g. over the course of the 8 week high fat diet) are difficult to assess, as 
these infusions are likely to induce an adaptive immune response against the 
human ApoA1 component of the HDL. For this reason, all in vivo HDL 
treatments in De Nardo and Labzin et al (128) were acute, and HDL treatment 
in a mouse model of atherosclerosis was not investigated. To investigate 
ATF3's role in long-term HDL treatment of murine atherosclerosis, ApoE/Atf3 
dKO mice that do not recognize human ApoA1 (such as ApoE/Atf3 dKO mice 
expressing the human ApoA1 transgene) would be required. 
However, there is evidence to suggest that ATF3 mediates at least some of 
HDL's protective effects in atherosclerosis. HDL injection in atherosclerotic 
ApoE- deficient mice led to an increase in hepatic Atf3 mRNA, which 
correlated with a decrease in hepatic Il6, Il12b and Ch25h mRNA (Figure 
4.7B). Furthermore, it appeared that HDL increased Atf3 mRNA expression in 
the hepatic macrophage population, Kupffer cells, rather than in the 
hepatocytes or other non-parenchymal cells, in keeping with the role of ATF3 
as a negative regulator of inflammation. Obviously more pertinent to 
atherosclerosis would be the induction of ATF3 by HDL in plaque-associated 
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macrophages. No difference in Atf3 or cytokine expression was seen in HDL 
treated aortic roots containing atherosclerotic plaques (Figure 4.7 A), however 
it is possible that the other cell types present in the aortic sections muted the 
macrophage signal. To overcome this, laser capture of plaque macrophages 
as performed by Feig et al (108) could also be performed on HDL treated 
atherosclerotic mice, and Atf3 mRNA levels assessed. Alternatively single cell 
sequencing of plaques could determine whether HDL specifically induces 
ATF3 in plaque macrophages or other cell types. Finally, as these studies 
were done exclusively in normo-cholesterolemic macrophages, it would be 
interesting to investigate whether foam cells also induce ATF3 in response to 
HDL. Therefore, initially, in vitro derived foam cells could be analysed for 
ATF3 induction by HDL, and should this occur, whether ATF3 is also required 
for HDL's anti-inflammatory effects in foam cells could be investigated using 
ATF3-deficient cells.  
HDL is also likely to have many anti-inflammatory effects that are independent 
of ATF3. HDL changed the expression of multiple transcription factors other 
than ATF3 in BMDMs, and these TFs may also modulate macrophage 
activation (Figure 4.3 A). Analysis of the HDL-modulated genes between 
ATF3-/- and WT BMDMs showed that HDL induced the genes involved in 
cholesterol biosynthesis independently of ATF3 (128). This suggests that RCT 
is an ATF3-independent mechanism. Furthermore, HDL's anti-thrombotic 
effects on platelet activation (193) are likely to be ATF3-independent as 
platelets don't contain nuclei. Moreover, HDL prevention of LDL-oxidation 
likely occurs extra-cellularly (79) and therefore independently of ATF3. 
Interestingly, CD36, a scavenger receptor involved in the uptake of oxLDL into 
macrophages and a mediator of sterile inflammation (43), may be an ATF3 
target gene, based on new hits from the ATF3 ChIP Sequencing experiment 
performed as part of this study (Krebs et al, Manuscript in submission to 
Nucleic Acids Research, April 2014). Therefore, whether HDL pre-treatment 
also affects the uptake of atherosclerotic DAMP by down-regulating CD36 
expression via ATF3 could also be investigated.  
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The finding that HDL is anti-inflammatory via ATF3 in normo-cholesterolemic 
macrophages also extends the potential for HDL-based therapy beyond CVD 
towards other inflammatory diseases. It remains to be seen whether ATF3 is 
responsible for much of the protective effect of HDL in models of rheumatoid 
athritis (96). The protective effect of ATF3 in various murine disease models 
(as listed in Table 6.1) also suggests potential diseases where HDL could be 
protective. Ultimately, these findings suggest that both HDL and other 
inducers of ATF3 represent viable therapeutic targets for treating 
atherosclerosis and other inflammatory diseases.  
 
Conclusion: 
 
HDL is well established as the 'good cholesterol', with protective effects in a 
host of inflammatory diseases, and especially in cardiovascular disease. In 
particular, HDL is highly anti-inflammatory, and acts on various immune cells 
to dampen inflammation. The molecular mechanisms of HDL's anti-
inflammatory effects, especially in macrophages, were poorly characterised. 
This study has investigated the effect of HDL on TLR-mediated macrophage 
activation. HDL inhibited TLR-induced pro-inflammatory cytokine release in 
response to diverse TLR ligands, and across numerous pro-inflammatory 
cytokines in both human and mouse cells. This inhibition was mediated at the 
level of transcription, with early TLR signalling remaining intact following HDL 
treatment. The transcriptional repressor ATF3, which is induced both in vitro 
and in vivo upon HDL treatment, mediated HDL’s effects. In this way, pre-
treatment of macrophages with HDL induced a negative regulator of pro-
inflammatory gene expression and thereby inhibited macrophage activation. 
This study confirms the potential for HDL as an anti-inflammatory therapeutic, 
identifies a new biology for HDL in modulating the inflammatory response, and 
highlights the importance and relevance of ATF3 as a potential drug target.  	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8. Abbreviations 
AA:   Arachadonic Acid  
ABCA1:  ATP-binding cassette transporter 1 
ABCG1:  ATP-binding cassette sub-family G member 1 
ADP:   Adenisine Diphosphate  
Akt:   Protein Kinase B 
ANOVA:  Analysis of Variance 
AP-1:   Activator Protein 1 
APC:   Allophycocyanin 
ApoE:  Apolipoprotein E 
ASC:   Apoptosis-associated Speck -like protein containing a CARD 
ATF:   Activating Transcription Factor 
BCA:   Bicinchoninic Acid 
BMDM:  Bone Marrow Derived Macrophages 
BSA:   Bovine Serum Albumin 
c/EBPβ: CCAAT/Enhancer-Binding Protein Beta 
C/EBPδ:  CCAAT/Enhancer-Binding Protein Delta 
cAMP:  cyclic adenosine monophosphate 
cAMP:  cyclic AMP 
CANTOS:  Canakinumab Anti-inflammatory Thrombosis Outcomes Study 
CAPS: Cryopyrin Associated Periodic Syndrome 
CBP:   CREB Binding Protein 
CCL2:  C-C motif ligand 2  
CCR2:  CC Chemokine Receptor 2  
CD:   Cyclodextrin 
CD14:  Cluster of Differentiation 14 
cDNA:  complementary DNA 
CETP:  Cholesterol Ester Transfer Protein 
CFP:   Cyan Fluorescent Protein 
CH25H:  Cholesterol-25-Hydroxylase 
ChIP:   Chromatin Immunoprecipitiation  
CMA:   10-carboxymethyl-9-acridanone  
CO2:   Carbon dioxide 
Cox:   Cyclo-oxygenase  
CREB:  (cAMP) Responsive Element Proteins 
cRNA:  complementary RNA 
CSF1:  Colony Stimulating Factor 1 
CSF1R:  Colony Stimulating Factor 1 Receptor 
CTB:   CellTiter-Blue 
CVD:   Cardio-Vascular Disease 
DAMP:  Danger Associated Molecular Pattern 
DCs:   Dendritic Cells 
DMEM:  Dulbecco's Modified Eagle's Medium 
DNA:   Deoxyribonucleic Acid 
dNTP:  deoxyribonucleotide 
DRM:   Detergent Resistant Membrane 
DTT:   Dithiothreitol 
ECM:   Extracellular Matrix 
EDTA:  Ethylenediaminetetra-acetic acid 
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EGR-1:  Early Growth Response -1 
EGTA:  Ethylene Glycol Tetraacetic Acid 
ELISA:  Enzyme Linked Immunosorbent Assay 
EMSA:  Electromobility Shift Assay  
eNOS:  Endothelial Nitric Oxide Synthase 
ER:   Endoplasmic Reticulum 
ERK:   Extra-cellular Regulated Kinase 
FACS:  Fluorescence Activated Cell Signalling 
FC/FC:  Fold Change/Fold Change 
FCS:   Fetal Calf Serum  
FITC:   Fluorescein isothiocyanate 
fMLP:   N-formyl-methionyl-leucyl-phenylalanine 
FPLC:  Fast Performance Liquid Chromatography 
GM-CSF:  Granulocyte Macrophage Colony Stimulating Factor 
GO:   Gene Ontology 
GOEA:  Gene Ontology Enrichment Analysis 
GPI:   Glycosyl-Phosphatidyl-Inositol  
HAT:   Histone Acetyl Transferase 
HDAC:  Histone De-acetylase 
HDL:   High Density Lipoprotein 
HEK:   Human Embryonic Kidney  
HEPES:  4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HKSC:  Heat-killed Saccharomyces cerevisiae 
HMDM:  Human Monocyte Derived Macrophages 
HMGB1:  High Mobility Group Protein B1 
HO-1:  Heme Oxygenase 1 
HPRT:  Hypoxanthine-guanine phosphoribosyltransferase 
HRP:   Horse Radish Peroxidase 
HSF1:  Heat Shock Transcription Factor 1 
HSP:   Heat Shock Protein 
HSPC:  Haematopoietic Stem/Progenitor Cell  
HUVEC:  Human Umbilical Vein Endothelial Cells 
ICAM1:  Intracellular Cell Adhesion Molecule 1  
IFN:   Interferon 
IKK:   Inhibitors of NFκB  (IκB) kinases 
IL-1R:  IL-1β Receptor 
IL-1R:  Interleukin 1 Receptor 
IL:   Interleukin 
IL2ra:   Interleukin 2 Receptor alpha 
IMMEI:  Institute for Molecular Medicine and Experimental Immunology 
INSIG:  Insulin Induced Gene 1 
IRF:   Interferon Regulatory Factor 
ISG:   Interferon Stimulated Genes 
ISRE:   Interferon Stimulated Response Element 
IκB:   Inhibitors of NFκB 
JAK2:  Janus Kinase 2 
JDP2:  Jun-Dimerizing Protein 2 
JNK:   c-Jun N-terminal Kinases 
KCl:    Potassium Choloride 
KLF7:  Kruppel-Like Factor 7 
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LCAT:  Lecithin Cholesterol Acetyl Transferase  
LDL:   Low Density Lipoprotein 
LDLR:  Low-Density Lipoprotein Receptor 
LIMES:  Life and Medical Sciences Institute 
LOOH:  Lipid Hydroperoxides 
LPS:   Lipopolysaccharide 
LRR:   Leucine Rich Repeat 
LSS1:  Lanosterol Synthase 1 
LTA:   Lipoteichoich Acid 
LXR:   Liver X Receptors  
LysoPC:  Lysophosphatidylcholine  
MACS:  Magnetic Cell Separation 
MAL:   MyD88 Adaptor-Like protein  
MAPK:  Mitogen Activated Protein Kinases  
MCD:   Methyl-β-Cyclodextrin  
MCP-1:  Monocyte Chemotactic Protein -1  
MD2:   (also known as Lymphocyte Antigen 96) 
MDM2:  Mouse Double Minute homolog 2  
MEFs:  Mouse Embryonic Fibroblasts 
MES:   2-(N-morpholino)ethanesulfonic acid 
MIP-1:  Macrophage Inhibitory Protein 1  
miRNA:  micro RNA 
MOPS:  3-(N-morpholino)propanesulfonic acid 
MTA2:  Metastasis Associated 1 family, member 2  
MyD88:  Myeloid Differentiation primary response protein 88  
NFkB:  Nuclear Factor kappa B 
NH4Cl:  Ammonium Chloride 
NK:   Natural Killer (cells) 
NLRP3:  Nod-Like Receptor 3 
NMR:   Nuclear Magnetic Resonance 
NO:   Nitric Oxide 
NRF2:  Nuclear Factor Erythroid Derived 2 (NE) Related Factor 2 
NSAID:  Non-steroidal anti-inflammatory drugs 
P3CSK4:  Pam3CSK4 
PA:   Phosphatidic Acid 
PAF-AH:  Platelet Activating Factor-Acetylhydrolases 
PAMP:  Pathogen Associated Molecular Pattern 
PARP:  Poly (ADP-ribose) Polymerase 
PBMC:  Peripheral Blood Mononuclear Cells 
PBS:   Phosphate Buffered Saline 
PC:   Phosphatidylcholine  
PCD:   Phosphatidylserine decarboxylase 
PCR:   Polymerase Chain Reaction 
pDC:   Plasmacytoid DC 
PE:   Phosphatidylethalanomine 
PI3K:   Phosphoinosotide 3 kinase 
PIKfyve:  FYVE finger-containing phosphoinositide kinase 
PKC:   Protein Kinase C 
PLA2:   Phospholipase A2 
PLD:   Phospholipase D 
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PMA:   Phorbol 12-Myristate 13-Acetate 
PMSF:  Phenyl-Methane-Sulfonyl-Fluoride 
PMT:   Photo-Multiplier Tube 
PON1:  Paraoxygenase 1 
PPARγ:  Peroxisome Proliferator Activated Receptor Gamma 
PRR:   Pattern Recognition Receptor 
PS:   Phosphatidylserine 
PSS1:  Phosphatidyl-Serine Synthase 1 
PTM:   Post Translational Modification 
PVDF:  Polyvinylidene fluoride 
qPCR:  Quantitative PCR 
RA:   Rheumatoid Athritis 
RANTES:  Regulated on Activation, Normal T cell Expressed and Secreted 
RCT:   Reverse Cholesterol Transport 
RIPA:   Radio-Immuno-Precipitation Assay buffer 
RNA:   Ribonucleic Acid 
ROS:   Reactive Oxygen Species  
RPMI:  Roswell Park Memorial Institute (RPMI) 1640 Medium 
S.E.M:  Standard Error of the Mean 
S1P1R:  Sphingosine 1- Phosphate Receptor  
SAIS:   Sepsis-Associated Immunosuppression  
SDS-PAGE:  SDS-Polyacrylamide Gel Electrophoresis 
SDS:   Sodium Dodecyl Sulfate 
siRNA:  Small Interfering RNA 
SLE:   Systemic Lupus Erythamatosus 
SMAD3:  Mothers against decapentaplegic homolog 3  
SNP:   Single Nucleotide Polymorphism 
SR-B1:  Scavenger Receptor class B member 1 
SRE:   Sterol Response Element 
SREBP:  Sterol Response Element Binding Protein  
STAT6:  Signal Transducer and Activator of Transcription 6 
STING:  Stimulator of Interferon Genes 
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